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SUMMARY 
The three isoforms of nitric oxide synthase (NOS) are classified based on their mode 
of regulation by calmodulin (CaM). The "calcium-independent" inducible isoform 
(iNOS) contains tightly-bound CaM and is active at all levels of intracellular calcium. 
In contrast, the two calcium-dependent isoforms (neuronal, nNOS and endothelial 
eNOS) are activated by CaM-binding following stimulus-evoked increases in 
intracellular calcium. However, both the structural basis for these differences in 
regulation and the molecular basis for CaM-induced cNOS activation remained 
unclear. Given that the regulation of calmodulin regulated enzyme systems often 
involves the displacement of an intrinsic autoinhibitory domain, we attempted to 
identify regions of eNOS which may fulfill this autoinhibory function. Herein, I 
describe the identification of two autoinhibitory control elements (ACEs) in eNOS, 
one within the FMN binding domain (ACE-I) and one located at the C-terminus 
(ACE-2). Together with CaM, these form a tripartite system for the regulation of 
eNOS. ACE-lIACE-2 exerting negative effects to attenuate catalytic activity, which 
are overcome by the conformational changes induced by CaM-binding. The 
mechanism of ACE-lIACE-2-mediated inhibition and the alleviation of this inhibition 
were investigated. 
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1.1 Historical Perspective 
Chapter 1 
General Introduction 
Although it was known since the late 1970's that nitric oxide (NO) is among the 
ligands that can activate soluble guanylate cyclase and cause vascular relaxation 
(Arnold et al., 1977; Craven & De Rubertis, 1978; Gruetter et aI., 1979), the molecule 
was generally regarded as an environmental pollutant. It was not until a decade later 
that NO was recognized as an endogenous vasodilator. 
The concept of NO as a biological messenger was first proposed by 
investigators studying a labile substance released from the vascular endothelium in 
response to acetylcholine and other agonists. In a landmark study it was demonstrated 
that the relaxation of blood vessels by acetylcholine required an intact endothelium 
(Furchgott & Zawadzki, 1980). They proposed that the stimulation of muscarinic 
receptors on the endothelium stimulated the release of a labile substance from the 
endothelium causing the relaxation of the vascular smooth muscle. This labile 
substance was termed endothelium-derived relaxing factor (EDRF) and was found to 
increase cGMP in vascular smooth muscle (Holzmann, 1982), activate soluble 
guanylate cyclase (Forstermann et al., 1986) and inhibit platelet aggregation (Azuma 
et al., 1986). 
In 1986, at the Fourth Symposium on Mechanisms of Vasodilation, R.F. 
Furchgott and L.J. Ignarro noted the similarities between NO and EDRF, in that they 
both relax vascular smooth muscle and are similarly quenched by hemoglobin and 
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superoxide. They proposed that EDRF is either NO or a labile compound capable of 
releasing NO (Furchgott, 1988; Ignarro, 1988). It was later demonstrated 
experimentally that the release of NO or an NO precursor accounted for the biological 
activities of EDRF (Ignarro et al., 1987; Palmer et al., 1987). This identification was 
based on the accumulation of nitrite in bioassays, and the similarities' in 
pharmacological and biochemical properties of NO and EDRF (Ignarro, 1989). 
The general acceptance of this hypothesis was hindered by the lack of an 
identifiable enzymatic pathway for the synthesis of NO in mammals. It had been 
suggested that humans could synthesize nitrogen oxides from early nutritional studies 
by Mitchell in 1916 (Mitchell et al., 1916), but it was generally believed that 
mammalian excretion of nitrate and nitrite was due to denitrification reactions by 
enteric bacteria. Interest in the origin of excreted nitrite intensified, based on concerns 
that nitrite may serve as a precursor to the carcinogenic N-nitroso compounds 
(Bogovski & Bogovskl, 1981) and therefore involved in the etiology of cancers. 
Further evidence that humans could endogenously produce nitrogen oxides was 
obtained from studies of nitrate metabolism; fed a low protein diet, humans were 
found to produce more nitrate and nitrite than they ingested (Green et al., 1981; 
Tannenbaum et al., 1978). The involvement of enteric micro flora in nitrate production 
was precluded by studies using germ-free rats (Green et al., , 1981). It was 
additionally noted that one human subject developed a fever during which excreted 
levels of nitrate were significantly increased. Subsequent studies showed that urinary 
nitrate excretion was increased in rats following challenge with bacterial endotoxin 
(Wagner et al., 1983) and suggesting the involvement of the reticuloendothelial 
system. Later, in vitro studies identified macrophages as a source of urinary nitrate in 
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bacterial lipopolysaccharide (LPS) treated mice and of endogenously synthesized 
nitrogen oxides (Stuehr & MarIetta, 1985). 
Cytotoxic activated macrophages caused the metabolic inhibition of tumor 
target cells involving the inhibition of mitochondrial respiration, aconitase, DNA 
synthesis and the loss of intracellular iron. This pattern of metabolic inhibition was 
found to stereospecifically require L-arginine and was paralleled by increases in 
nitrate and nitrite (Hibbs et al., 1987). Isotope studies using 15N_ and 14C-Iabelling 
showed that the nitrogen atom of the nitrogen oxides was derived from one of the 
guanido nitrogens of L-arginine and revealed citrulline to be a co-product (Iyengar et 
al., 1987). Further evidence was provided by the fact that secondary amines, such as 
morpholine can be nitrosylated by immunostimulated macrophages and that this 
process was dependent on L-arginine (Miwa et aI., 1987). Since this nitrosylation 
reaction could not be carried out by either nitrate or nitrite, it was concluded that a 
more reactive nitrogen species must be formed from L-arginine as a reaction 
intermediate in the synthesis of nitrate and nitrite. 
The discovery of this novel macrophage pathway indicated a possible method 
for the synthesis of nitric oxide in endothelium. In 1988 several groups demonstrated 
that L-arginine was the precursor of EDRFINO (Palmer et al., 1988; Sakuma et ai., 
1988). The pathway in endothelial cells was also found to be dependent on L-arginine 
and inhibited by N-guanido substituted arginine based compounds, such as NG_ 
methyl-L-arginine (L-NMA) (Palmer et al., 1988; Schmidt et ai., 1988; Schmidt et 
al., 1988). At around the same time, the cytotoxic effector produced by activated 
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macrophages was identified as nitric oxide (Hibbs et al .• 1988; MarIetta et al .• 1988; 
Stuehr et al .• 1989; Stuehr & Nathan. 1989). 
The idea of a widespread distribution and a variety of functions for this novel 
pathway came from research carried out in another seemingly unrelated area of study. 
the central nervous system (CNS). It was observed that cGMP levels were elevated 
following activation of NMDA receptors. The increase in cGMP levels was found not 
in the cells which received the initial stimulus, but in those nearby. This implied the 
existence of an intercellular signaling system . Earlier studies on rat forebrain 
identified arginine as the endogenous activator of guanylate cyclase (Deguchi & 
Yoshioka. 1982). Further investigation led to the observation that cerebellar cells 
released an activator of guanylate cyclase with similar stability to EDRFINO 
(Garthwaite et al .• 1988). The synthesis of nitric oxide has since been demonstrated in 
a variety of cell types in addition to those mentioned earlier. These include cytokine 
activated hepatocytes (Billiar et al .• 1990; Curran et al .• 1989; Nussler et al .• 1992). 
neutrophils (Rimele et al., 1988; Wright et al., 1989), hepatic Kupffer cells (Billiar et 
al.. 1989). vascular smooth muscle (Marsden & Ballermann. 1990), chondrocytes 
(Stadler et al., 1991). endothelial cells (Gross et al., 1991; Kilbourn & Belloni, 1990). 
adrenal glands (Palacios et al., 1989), and platelets (Radomski et al .• 1990). 
Hence in a little over a decade, research in the fields of physiology, 
immunology and neuroscience converged to study a common pathway and nitric 
oxide emerged as a unique biological messenger molecule regulating cellular 
function. The importance of this field was recognized recently by the award of the 
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1998 Nobel Prize for medicine to Drs. Ignarro, Furchgott and Murad, pioneers of NO 
biology. 
1.2 Nitric Oxide Chemistry and Bioloeical Functions 
NO is a lipophilic, highly reactive, free radical gas with diverse biomessenger 
functions. Evidence reveals an involvement of NO in a remarkable array of key 
physiological processes, including regulation of vascular tone (Furchgott, 1988; 
Ignarro, 1988; Ignarro et al., 1987; Palmer et al., 1987), platelet aggregation, (Azuma 
et al., 1986) host-defense (Hibbs et al., 1987; Hibbs et al., 1987; Iyengar et ai., 1987; 
Marietta et al., 1988), inflammation (Harbrecht et al., 1995; Tiao et ai., 1994), 
neurotransmission (Bredt et al., 1990), learning and memory (Bohme et al., 1993; 
Chen et al., 1997; Holscher & Rose, 1992; Kendrick et al., 1997; Prickaerts et al., 
1997; Rickard et al., 1998; Yamada, 1998), penile erection (Argiolas, 1994; Burnett et 
al., 1992; Hellstrom et al., 1994; Jung et al., 1997; Melis & Argiolas, 1995; Trigo-
Rocha et al., 1993), gastric emptying (Konturek et al., 1995; Orihata & Sarna, 1994; 
Plourde et al., 1994; Takakura et ai., 1997) , hormone release (McCann et al., 1997; 
Rettori et al., 1993; Seilicovich et al., 1995), cell differentiation (Morbidelli et al., 
1996; Peunova & Enikolopov, 1995), cell migration (MacIntyre et al., 1991; Noiri et 
al., 1996) and apoptosis (Albina et al., 1993; Beauvais et al., 1995; Chun et al., 1995; 
Mannick et al., 1994; Messmer et al., 1996; Sarih et al., 1993). These biological 
actions of NO result from covalent modification of numerous enzymes, receptors, 
structural proteins and transcription factors (see Table 1.1). Whether the net effects of 
NO on a given cell are either beneficial or deleterious will be determined by the NO 
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concentration obtained, duration of production and composition of the surrounding 
microenvironment. 
Appreciation of the role of nitric oxide (NO) in mammalian cell biology has 
toppled the paradigm that biological signaling is initiated exclusively by non-
covalent, lock-and-key type interactions with receptor proteins. Remarkably, nitric 
oxide is a free-radical that signals by chemical reaction with its protein targets, 
resulting in covalent modifications and often a stable alteration in protein structure 
and function. While most proteins may be coerced to react with NO in vitro, the 
specific proteins that are functionally modified by NO within cells will depend upon 
the concentration of NO and the composition of the intracellular milieu. A further 
level of complexity is introduced into NO signaling by the fact that reactions can 
occur with NO directly, or secondarily with NO-derived species. Much to the 
surprise of those who thought that reactive molecules are generated and act only . 
under pathophysiological conditions (e.g., ischaemia-reperfusion injury), NO has 
emerged as a prototype molecule that signals by chemistry in normal physiology. 
1.2.1 Reactivity of NO 
In pure aqueous solution, nanomolar concentrations of NO have been reported 
to survive with a half-life of 500 seconds or longer (Wink et ai., 1993). In contrast, a 
measured half-life of only 5 seconds has been reported for endogenously produced 
NO in a physiological milieu (Lancaster, 1994). The rapid physiological inactivation 
of NO is attributed to reaction with components of physiological fluids and buffers. 
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Therefore, critical to our understanding of the signaling capabilities of NO, a 
relatively stable free radical gas, is an appreciation of the range of possible and 
dominant reactions of NO in biological systems. The most preferred chemical targets 
of NO include reactive oxygen species, other free radicals, transition metals, thiols 
and molecular oxygen. Along with NO itself, the products of these reactions, 
peroxynitrite (ONOO), metal-nitrosyl adducts (M-NO), S-nitroso products, higher 
nitrogen oxides (NOx) and other derived species, contribute to the biological actions 
of arginine-derived NO. Th~s, the consequences of NO synthesis, beneficial or 
deleterious, will dependent on the species and concentration of intermediates formed 
and the nature and complexity of available targets for reaction (Stamler, 1994). To 
understand the biological chemistry of NO, it may be useful to consider NO and 
derived species as existing in a redox array (NO·, NO- and NO+) of interconvertable 
species with distinct chemical characters and reactivities (for review see Stamler et 
al., 1992). 
In addition to being mediators of the biological effects of NO, it has been 
suggested that S-nitrosothiols can act as NO reservoirs or NO substitutes (Gaston et 
al., 1994; Stamler et al., 1992). It should be noted however that NO does not react 
directly with thiols to form S-nitrosothiols; redox activation of either the thiol to thiyl, 
or NO to a species capable of nitrosation (NO+, N20 3) appears to be necessary. NO 
reacts with O2- and transition metals to form ONOO· (Beckman et a/., 1990) and a 
species with nitrosonium character (NOn (Ischiropoulos et al., 1992). These species 
are each capable of supporting additional nitrosative reactions at nucleophillic centers 
in tyrosine residues and thiol groups, resulting in the formation of nitrotyrosine and S-
nitrosothiols. A nitrosating species can also arise from the reaction between NO and 
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ferro-heme in hemoproteins, such as hemoglobin and myoglobin. In this reaction 
ferric iron is reduced to the ferrous form, resulting in the formation of an adduct with 
nitrosonium character (NO+) that can react to produce S-nitrosothiols. It should be 
appreciated that reaction of NO with ferri-heme is much slower than that with ferro-
heme; the latter reaction occurs at a near diffusion-limited rate. Only at relatively 
high levels of biologically-derived NO may molecular oxygen become a significant 
target, resulting in the production of the very potent nitrosating species, NOt. 
As noted above, a preferred reaction of NO is with superoxide anion (0;), to 
form peroxynitrite (ONOO"). This reaction may be most important under biological 
conditions where abundant NO and superoxide are simultaneously produced, such as 
during inflammation, endotoxemia and ischaemia/reperfusion. The resulting 
peroxynitrite is a much stronger oxidant than either the NO or superoxide, and 
appears to be a key bacteriocidal product of immunostimulant-activated macrophages 
(Zhu et at., 1992). Under physiological conditions peroxynitrite is sufficiently stable 
to diffuse some distance before reacting with target molecules such as membrane 
lipids (Radi et ai., 1991), protein sulfhydryl groups (Radi et al., 1991), DNA (Inoue & 
Kawanishi, 1995; Wink et at., 1991), and antioxidants (Hogg et aI., 1994). 
Peroxynitrite, when produced by endothelial cells, is thought to contribute to 
endothelial injury via modification of the low density lipoprotein within the arterial 
wall (White et at., 1994), a process which may contribute to formation of the fatty 
streak and plaque that are characteristic of the atherosclerotic lesion (Beckman et at., 
1990; White et ai., 1994). Peroxynitrite also has been implicated in the nitration of 
tyrosine residues in histone, lysozyme, and superoxide dismutase (Ischiropoulos et 
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al., 1992). However, more recent evidence suggests that another species, possibly 
-N02, is most responsible for tyrosine nitration in vivo (Pfeiffer & Mayer, 1998). 
Regardless of the mediator responsible, tyrosine nitration has been identified 
in several pathological conditions. There are several possible ways in which tyrosine 
nitration could influence cellular signaling. While nitration may inhibit tyrosine 
phosphorylation and associated signal transduction (Martin et al., 1990), it may also 
mimic the effects of tyrosine phosphorylation (Berlett et al., 1996). Nitration may also 
alter protein function/activity by inducing distinct conformational changes (Deckers-
Hebestreit et al., 1987; Lundblad et al., 1988) or cause proteins to be targeted for 
proteolysis. Nitrated tyro sines structurally resemble dinitrophenol, a strongly 
antigenic compound, and have therefore been implicated in the initiation of 
autoimmune responses (Cross et al., 1997; van der Veen et al., 1997). Nitrated 
tyrosines have also been implicated in systems essential to the survival of motor 
neurons (Nixon, 1993). 
In addition to causing tyrosine nitration, peroxynitrite can also interact directly 
with iron-sulfur clusters and zinc-thiolate centers contained in many enzymes and 
transcription factors (Drapier et al., 1993; Hibbs et al., 1990; Kroncke et al., 1994; 
Pantopou!os & Hentze, 1995; Stuehr & Nathan, 1989; Weiss et ai., 1993; Zeng et al., 
1991). By this route, peroxynitrite may have effects on metabolic pathways, DNA 
repair, gene expression and various other cellular effects attributed to NO. 
Nitric oxide also undergoes rapid reaction with other biological free radicals. 
In conditions such as inflammation or oxidative stress, hydroxyl radical (OH-) and 
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lipid species such as peroxyl (LOO-) and alkoxyl (LO-) radicals, are generated by the 
fenton reaction and lipid peroxidation. As NO- reacts with these radicals at near 
diffusion-limited rates, it can act as a potent scavenger of OH- (Rubbo et al., 1994) 
and hence inhibit the radical-induced chain propagation reaction in lipid peroxidation 
(Padmaja & Huie, 1993). Also, because of its high lipophilicity, NO concentrates in 
membranes and can act as a vitamin E-like antioxidant in oxidant-mediated lipid 
peroxidation. During bacterial infection, phagocytes are rapidly activated to produce 
cytotoxic reactive oxygen species (ROS) and subsequently become activated to 
produce NO. In addition to the desirable bacteriocidal effects of ROS, these species 
can damage host cells by initiating lipid peroxidation, as noted above. The delayed 
production of NO may serve to terminate lipid radical-induced chain propagation and 
hence limit host cell damage. NO can also react with highly oxidized iron, Fe(IV)=O, 
a potent oxidizing species produced by reaction with hemoproteins, and inhibit lipid 
peroxidation of LDL. 
1.2.2 Biological Targets of NO 
The biological activities of NO can be attenuated by competing targets, such 
as superoxide anion, ferro-hemoproteins, and thiol-containing compounds. Thus, 
actual reactions of NO obtained with potential biological targets will be dependent on 
the local NO concentration as well as the specific components of the surrounding 
microenvironment (e.g. availability of alternate targets and intracellular redox 
potential). It should be considered that the concentration of NO required to elicit a 
given biological response will vary from target to target, with some reactions 
occurring at low physiologically-occurring concentrations of NO (e.g. activation of 
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guanylate cyclase) and others requiring pathophysiological concentrations of NO (e.g. 
inhibition of cytochrome P450). Key reactions of NO with potentially important 
biological targets are outlined below and summarized in Table 1.1. 
1,2.2,1 Nitric Oxide Synthases 
Due to the role of ferro-heme in NOS catalysis, and the high affinity of NO for heme, 
NOS is a most obvious target for NO. Indeed it has been shown that NO can inhibit 
its own biosynthesis by heme binding in NOS (Abu-Soud et al., 1995; Buga et al., 
1993; Griscavage et aI" 1993). This feedback inhibition may serve to regulate 
neurotransmitter release, blood vessel relaxation and NO-mediated cytotoxicity. 
1.2.2.2 Guanylate Cyclase 
Guanylate cyclase is an important hemo-protein target for NO, binding of NO alters 
the conformation of the heme moiety and causes activation of the enzyme. The 
subsequent rise in cGMP levels causes the activation of cGMP-dependent kinases, 
which mediate smooth muscle relaxation, platelet adhesion and aggregation, and 
contribute to neuron signaling, cGMP elevation may also cause the phosphorylation 
of synaptic vesicle proteins associated with the release of neurotransmitters 
(Montague et ai" 1994), open 
cGMP-gated ion channels to increase intracellular Ca2+ levels, and modulate the 
activity of phosphodiesterase isoforms to control intracellular cAMP levels (Schmidt 
et al., 1993). 
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Table 1.1 Biological Targets of NO Signaling 
Tart:et Int~ril~tion Action (refs) 
{ifkm!wnl 
Signal Transd]J!;;tion 
Nitric oxide synthase Heme Inhibition (Buga et al., 1993; Abu-Soud 
et at., 1995; Griscavage et al., 1993) 
Guanylate cyclase Heme Activation (Arnold et at., 1977; Craven 
et at., 1978; Gruetter et aI., 1979) 
Cyclooxygenase Heme ActivationlInhibition (Corbett et al., 
1993; Salvemini et al., 1993) 
12-lipoxygenase Heme Inhibition (Nakatsuka et aI., 1994) 
Cytochrome P450 Heme Inhibition (Khatsenko et aZ., 1993) 
Receptors 
NMDA receptor Sulhydryl Desensitization (Lei et aZ., 1992; Lipton 
et aZ., 1993) 
TPA receptor Activation (Stamler, 1994) 
Ang II receptor (Katoh et aZ., 1998) 
Adenosine A2/ Al (Lawrence et al., 1997) 
Signal AmplificatiQn 
G-proteins Sulfhydryl Activation (Lander et al., 1995) 
P-21ra5 Sulfhydryl Activation (Lander et al., 1995) 
PKC Sulfhydryl Inhibition (Gopalakrishna et aZ., 1993) 
Adenylate cyclase Sulfhydryl Inhibition (Duhe et al., 1994) 
Src family PTK P56lck Activation (Lander et aI., 1993) 
Tyrosine phosphatases Inhibition (Lander et aI., 1993) 
Ca2+ -dependent K+ channel Sulfuydryl Activation (Bolotina et aZ., 1994) 
Voltage Gated Ca2+ channel Sulfhydryl Activation (White and Marletta, 1992) 
Ryanodine receptors Sulfhydryl Activation (Stoyanovsky et al., 1997; Xu 
et aZ., 1998) 
Energ~ Metabolism 
cis-aconitase Iron-sulfur Inhibition (Stuehr et al.,1989; Hibbs et 
a1.,1990) 
Mitochondrial complex I and II Iron-sulfur Inhibition (Stuehr et al.,1989; Hibbs et 
al.,1990) 
GAPDH Sulfhydryl Inhibition (Mohr et aI., 1994; Molina y 
Vedia et al., 1992) 
PARP DNA Activation (Zhang et al., 1994) 
DNA Synthesis 
Ribonucleotide reductase Iron-sulfur Inhibition (Hibbs et aZ., 1990; Kwon et 
Transcription factors Zinc-sulfur 
aZ., 1991; Lepoivre et al., 1990) 
Inhibition (O'Halloran, 1993; Kadonga et 
aZ., 1987) 
Sulhydryl Inhibition (de la Torre et al., 1998) 
Iron Metabolism 
IRFllRE Iron-sulfur Activation (Drapier et aZ., 1993; Weiss et 
al .• 1993; Pantopoulos et aI., 1995) 
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Apoptosis 
DNA Amines Strand breaks (Inoue et al., 1995, Nguyen 
et al., 1992) 
Caspases Sulhydryl Inhibition (Dimmeler et al., 1997; Li et 
al., 1997) . 
Direct C~totoxicitt 
Glutathione Sulfbydryl Redox signaling (Walker et al., 1995; 
Nikitovic et al., 1996; Hou et al., 1996) 
MnlFe SOD Tyrosine Inhibition (Ischiropoulos et al., 1992) 
Glutathione reductase Sulhydryl Inhibition (Wharton et aI., 1988) 
Catalase Heme Inhibition (Brown et aI., 1995) 
Other 
Methionine adenosyltransferase Sulfbydryl Inhibition (Ruiz et al., 1998) 
Alcohol dehydrogenase Sulfbydryl Inhibition (Gegel et aI., 1996) 
Caeruloplasmin Copp_er Inhibition (Swain v 1994) 
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1.2.2.3 Enzymes Involved in Arachidonate Metabolism 
The metabolism of arachidonic acid results in the production of various biologically 
active lipid mediators. Cyclooxygenase is the rate-limiting enzyme in the synthesis of 
arachidonate-derived prostaglandins, thromboxane A2 and prostacyclins. There is 
evidence for both activation (Corbett et ai., 1993; Salvemini et al., 1993) and 
inhibition (Kanner et al., 1992) of this process by NO interaction with the heme group 
of both cyclooxygenase types I and II. Other hemo-proteins involved in arachidonate 
metabolism, including the 12-lipoxygenase in platelets (Nakatsuka & asawa, 1994) 
and cytochromes P450 (Khatsenko et al., 1993; Stadler et al., 1994) are inhibited by 
NO and nitro vasodilator drugs. Hence it would seem that NO has the capability to 
modulate the production of prostaglandins and other bioactive metabolites of 
arachidonate, as well as the metabolism of numerous endogenous and exogenous 
compounds by cytochromes P450. 
1.2.2.4 Receptors 
Stimulation of N-methyl-D-aspartate (NMDA) receptors results in the production of 
NO, and overstimulation may result in neurotoxicity due to reactions of NO with O2" 
to form ONOO- (Lei et al., 1992; Lipton et al., 1993). However, nitrosation of a 
critical thiol on the NMDA receptor by an NO derived species, leads to receptor 
desensitization and neuroprotection. This desensitization seems to result from the 
subsequent formation of an intramolecular protein disulphide bond (Lei et al., 1992; 
Lipton et al., 1993). Hence, it seems that although contributing to the toxicity caused 
by overstimulation by NMDA, NO can also protect against this amino acid 
excitotoxicity by desensitization of NMDA receptors. The activation of tissue specific 
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plasminogen activator receptors also seems to occur by the post-translational 
modification of a single thiol (Stamler et al., 1992). 
More recently, chronic inhibition of NO production has been demonstrated to 
cause an upregulation of angiotensin II (An gIl) receptors in a rat model (Katoh et al., 
1998) and NO has been suggested to interact with the adenosine A2A and Al 
receptors in rat vagal afferent neurons (Lawrence et al., 1997). However, the 
physiological relevance and effects of these interactions remain to be assessed. 
1.2.2.5 Signal Amplification Systems ' 
NO has been reported to activate pertussis toxin-sensitive G-proteins and 
p21ras (Lander et al., 1995) by S-nitrosylation. This same modification causes the 
inhibition of activity for both protein kinase C and type I adenylate cyclase (Duhe et 
al., 1994; Gopalakrishna et al., 1993). Studies using NO donor compounds in human 
peripheral blood mononuclear cells indicate that NO activates the src family protein 
tyrosine kinase p56lck and inhibits tyrosine phosphatase activity (Lander et al., 1993). 
Also NO has been shown to activate the calcium-dependent potassium channel in 
smooth muscle, activation of this channel occurs by a conformational change induced 
by S-nitrosylation (Bolotin a et al., 1994). Similar results have been found for the 
voltage-gated calcium channels in vascular smooth muscle (Xu et al., 1998). More 
recently, poly-S-nitrosylation has been identified as a mechanism for the activation of 
cardiac and skeletal muscle calcium release channels (ryanodine receptors) 
(Stoyanovsky et al., 1997; Xu et al., 1998). 
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1.2.2.6 Energy Metabolism 
Early studies on macrophage-induced injury of neoplastic cells (Granger & 
Lehninger, 1982; Granger et at., 1980) suggested that endogenously produced NO 
was a potent inhibitor of mitochondrial respiration and energy metabolism (Hibbs et 
at., 1990; Stuehr & Nathan, 1989). It is now known that NO is capable of inhibiting 
mitochondrial cis-aconitase, and complexes I and II of the electron transport chain 
(Hibbs et ai., 1990; Stuehr & Nathan, 1989), although there is some controversy as to 
whether peroxynitrite is the actual modifying species. These enzymes all contain iron-
sulphur clusters and the method of inhibition seems to be the displacement of iron 
from these centers. This process has been shown to be readily reversible by the 
addition of iron salts (Hibbs et ai., 1990) and hence would be suited to a role in 
physiological regulation controlling oxygen utilization. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) is an important enzyme in the glycolysis pathway and has 
been shown to be inhibited by NO in rat liver (Mohr et ai., 1994; Molina y Vedia et 
ai., 1992). The inhibition appears to be by direct S-nitrosation and would predictably 
suppress anaerobic ATP generation. NO has also been shown to stimulate the 
apparent ADP-ribosylation of GAPDH in the presence of NAD+ or NADH. This is an 
inductive automodification, independent of endogenous ADP-ribosyltransferase, and 
involves an active site cysteine (Dimmeler & Brune, 1992). S-nitrosylation of this 
residue leads to ADP-ribosylation-induced inhibition of catalytic activity and the 
depression of glycolysis and gluconeogenesis. This active site thiol of GAPDH is 
readily oxidized under oxidative stress conditions (H20 2) leading to irreversible 
inhibition by disulphide generation or oxidant-specific S-thiolation (Schuppe-
Koistinen et at., 1994). Therefore, S-nitrosylation may represent a mechanism to 
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protect GAPDH from irreversible inhibition in this manner, perhaps regulating 
glucose metabolism (Mohr et at., 1996). 
Intracellular energy stores can also be depleted by the enzyme poly-ADP 
ribosyl transferase (PARP) in a process activated by DNA strand breaks. PARP 
catalyzes the addition of long chains of NAD to the DNA strand break ends and hence 
depletes intracellular NADH stores. NADH would normally be used to generate ATP 
by oxidative phosphorylation and this process leads to cell death by energy store 
depletion. NO has been shown to activate P ARP and to contribute to neurotoxicity in 
vitro (Zhang et at., 1994). 
1.2.2.7 Transcription Factors and DNA Synthesis 
NO has been shown to inhibit cell proliferation (Hibbs et al., 1990; Stuehr & 
Nathan, 1989) and this could be due to the previously discussed effects on energy 
metabolism and ATP synthesis. However, the anti-proliferative effect occurs prior to 
inhibition of ATP synthesis and most likely occurs by an alternate mechanism (Hibbs 
et at., 1990). The rate-limiting process for cell division is the synthesis of 
deoxyribonucleotides from ribonucleotides, a reaction catalyzed by ribonucleotide 
reductase. It has been demonstrated that NO can interact with the iron-sulphur cluster 
of this enzyme and this may be a possible method of enzyme inactivation. Studies 
show that the inhibition of DNA synthesis occurs simultaneously with NO production 
and this inhibition can be prevented by selective NOS inhibitors (Kwon et al., 1991). 
Also, adenocarcinoma cells overexpressing ribonucleotide reductase have been shown 
to be much less sensitive to NO-mediated cytotoxicity than wild-type cells (Lepoivre 
et al., 1990). 
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In addition to these more general effects on DNA synthesis, NO can influence 
gene expression by interaction with transcription factors. Many transcription factors 
contain zinc fingers, zinc complexed with thiol ligands of cysteine and/or imidazole 
nitrogen atoms of histidine. Redox sensitive transcription factors, including Sp 1 and 
Egr-l (O'Halloran, 1993), bind specific DNA sites via three zinc fingers of the 
Cys2His2 type (Kadonaga et al., 1987). Zinc is easily displaced from this structure by 
redox reactions or intracellular thiol compounds (Zeng et al., 1991). NO can also 
interact with Zn-sulfur clusters in transcription factors, such as the LAC9-containing 
Cys6Zn(II)-type cluster (Kroncke et al., 1994). It has also been demonstrated that NO 
can modulate the DNA-binding capabilities of other transcription factors by S-
nitrosylation, these include NF-KB p50 and c-jun (del a Torre et al., 1998). These 
findings reveal that NO may be capable of altering the structural integrity of 
transcription factors and thereby influence the expression of specific genes. 
1.2.2.8 Iron Metabolism 
Iron release has been shown to be an important effector of tumor cell 
cytotoxicity by activated rodent macrophages (Hibbs et al., 1990) and limitation of 
cell growth by iron availability is ubiquitous in nature. High concentrations of NO, 
especially in the presence of superoxide, can profoundly disturb iron metabolism, 
leading to a substantial loss of intracellular iron (Hibbs et al., 1990). Free intracellular 
iron contributes to cell toxicity via the formation of highly reactive oxygen species by 
the fenton reaction (Gutteridge, 1989) and NO may contribute to this by causing the 
release of iron from ferritin, an iron storage protein (Reif & Simmons, 1990). 
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More recently NO has been shown to influence intracellular iron metabolism 
at the post-transcriptional level by direct interaction with cytosolic aconitase (also 
referred to as the iron-regulatory factor, IRF). NO disrupts the conformation of the 
iron-sulfur cluster at the catalytic site of the enzyme and increases the binding of IRF 
to a specific mRNA structure (the iron-responsive element, IRE) (Drapier et a/., 1993; 
Pantopoulos & Hentze, 1995; Weiss et al., 1993). This element is present in mRNA 
transcripts of numerous proteins involved in iron homeostasis. These include ferritin, 
transferrin receptor, erythroid 5-aminolevulinate synthase and mitochondrial 
aconitase. Binding of IRF to the IRE of ferritin mRNA inhibits ribosomal binding and 
represses protein expression. In the case of transferrin receptor mRNA, the same 
process protects the transcript from RNAse digestion and increases mRNA half-life, 
resulting in increased protein synthesis. Hence the interaction between NO and iron 
may regulate cellular iron by direct interaction with storage proteins and by 
translational control of the various proteins involved in iron homeostasis. NO may 
also contribute to cellular toxicity by its effects on iron metabolism (Drapier & Hibbs, 
1988; Hibbs et ai., 1988; Schwarz et ai., 1995).· 
1.2.2.9 Apoptosis 
Apoptosis, the process of cell suicide, is conserved in all animal species and 
represents a critical feature of the regulated development of multicellular organisms. 
Apoptotic cell death is characterized by a distinct set of cellular changes, including 
cell shrinkage, DNA fragmentation, chromatin condensation and membrane blebbing 
(Cohen, 1993). Apoptosis can result from the developmentally controlled activation 
of endogenous execution programs (Ellis et al., 1991) or from the transduction of 
death signals triggered by a variety of exogenous stimuli (Steller, 1995). The process 
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is regulated by various "death genes", including the Bcl-2-like proteins and the 
caspase family of proteases. The role of NO in this process is controversial, with it 
being implicated in both induction and suppression of apoptosis (for review see 
Dimmeler & Zeiher, 1997). 
NO can induce the biochemical features of apoptosis in a variety of cells, 
including macrophages (Albina et al., 1993; Messmer et al., 1996; Sarih et al., 1993), 
pancreatic ~-cells (Ankarcrona et al., 1994; Kaneto et al., 1995)and thymocytes 
(Fehsel et al., 1995). Also, transfection of the iNOS gene has been demonstrated to 
cause apoptosis in vascular smooth muscle cells (Iwashina et al., 1998). The 
proapoptotic effects of NO seem to be mediated in a guanylate cyclase-independent 
manner (Brune et al., 1996). NO may act directly to damage DNA by deamination 
reactions (Inoue & Kawanishi, 1995; Nguyen et al., 1992), and hence induce 
apoptosis (Nguyen et al., 1992). Also, accumulation of the cell death gene product, 
P53, has been described as an early indicator of NO-induced apoptosis (Messmer et 
al., 1994). Subsequent activation of caspases leads to the proteolysis, and activation 
of P ARP (Messmer et al., 1996). This is supported by the finding that overexpression 
of Bcl-2 (Messmer et al., 1996) or HSP70 (Bellmann et al., 1996) abrogates NO-
induced apoptosis and PARP cleavage, but not p53 accumulation. There may also be 
p53-independent pathways (Messmer & Brune, 1996) for the activation of apoptosis 
by NO and this indicates that the proapoptotic signal transduction by NO may be 
more much more complex than suggested above. 
The precise NO species involved in the induction of apoptosis remains 
unclear. Studies have indicated that the proapoptotic effects of NO are due to the 
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formation of peroxynitrite and this· species has been shown to induce apoptosis in 
thymocytes (Salgo et al., 1995), neuronal cells, and HL-60 cells (Estevez et al., 1995; 
Lin et al., 1995) . However, studies using physiological concentrations of 
peroxynitrite found no evidence of the induction of apoptosis in endothelial or 
mononuclear cells (Lin et al., 1995). Also, the simultaneous production of oxygen 
radicals and NO, conditions ideal for the production of peroxynitrite, had less of an 
apoptotic effect than NO alone (Brune et al., 1997; Sandau et al., 1997). Hence it 
seems most likely that NO and not peroxynitrite is the effective compound which 
induces DNA damage by deamination of DNA. 
There are several ways in which NO has been shown to inhibit apoptosis. The 
precise mechanisms are unclear, but a number of molecular targets have been 
identified. One key action of NO may be to increase cGMP levels, via activation of 
guanylate cyclase. However, the role of cGMP in the control of apoptotic signals is 
still controversial. Some studies demonstrated that NO could prevent apoptosis in 
human eosinophils during cytokine deprivation (Beauvais et al., 1995) and that these 
effects could be mimicked by stable cGMP analogues (Beauvais et al., 1995; Chun et 
al., 1995; Mannick et al., 1994). Conversely, other studies did not reveal any 
protective effect of cGMP analogues (Dimmeler et al., 1997; Genaro et al., 1995; 
Kim et al., 1997). Since NO-induced cGMP elevation is short lived, an interference 
with apoptosis signal transduction, requiring at least 3-24 hours, appears to be highly 
unlikely under normal physiological conditions. Further research in this area is 
required to resolve this controversy. 
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NO has also been shown to have a direct inhibitory effect on the caspase 
cascade, the activation of caspases by proteolysis of inactive precursors into active 
subunits. It has recently been shown that endothelial-derived NO, and low micromolar 
concentrations of exogenous NO donors, can inhibit TNF-a.-induced caspase 
activation in endothelial cells (Dimrneler et al., 1997). Inhibition of a specific caspase 
family member, caspase-3, has been shown to be due to specific S-nitrosylation of 
Cys 163, a functionally essential amino acid which is conserved throughout the 
caspase protein family (Dimrneler et al., 1997). Indeed NO has been shown to inhibit 
at least seven members of the caspase family in vitro, probably by S-nitrosylation (Li 
et al., 1997). In addition to the role of caspases in TNF-a. and FAS/APO-l induced 
apoptosis, they also tum out to be of general importance in the apoptotic signaling 
cascade (Enari et al., 1996; Los et aI., 1995; Nicholson et al., 1995). Low level NO 
may serve to modulate caspase activity and may control the responses of cells to 
death signals. 
NO has also been implicated in the control of Bcl-2, expression of this 
antiapoptotic protein has been shown to be enhanced by NO in B-cells (Genaro et al., 
1995). More recent experiments have demonstrated a role for NO in the post-
translational regulation of Bcl-2 by inhibition of TNF-a.-induced proteolysis 
(Dimmeler et al., 1998). This could lead to sustained levels of Bcl-2 and a reduction 
in sensitivity to apoptotic signals. NO may also induce the expression of other 
antiapoptotic proteins, such as heat shock proteins. It has been reported that NO can 
induce the expression of HSP32 and HSP70, thereby preventing TNF-a.lactinomycin 
D induced apoptosis in hepatocytes (Xu et a., 1998; Rettori et al., 1993). However, 
the mechanism of this protective effect of HSPs is unclear. It is clear from the above 
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that NO and/or NO-derived species, can either elicit or suppress apoptosis depending 
on concentration, the biological redox environment, the induction of intracellular 
defense mechanisms, the apoptotic stimulus and the cell type involved. 
1.2.2.10 Direct Cytotoxicity and Cell Defense Mechanisms 
Sensitivity toward the cytotoxic action of NO varies greatly in different 
mammalian cell types and cell lines (Kroncke et al., 1993). Islet cells (Kroncke et al., 
1991) and neurons are extremely sensitive to the toxic actions of macrophage derived 
NO and NO-donor compounds (Boje & Arora, 1992; Chao et al., 1992). Other cell 
types, such as human keratinocytes and rat aorta endothelial cells are much less 
sensitive (Kroncke et al., 1993). Differences in sensitivity may be due to differing 
capacities of cells for NO scavenging, detoxification, the efficiency of anaerobic 
respiration and the efficacy of DNA repair mechanisms. Glutathione is the most 
dominant cellular antioxidant; and reacts with NO to form S-nitrosoglutathione 
(Clancy et al., 1994). Depletion of glutathione stores has been shown to dramatically 
enhance NO-mediated cytotoxicity, indicating an important NO-scavenging role of 
this compound (Walker et al., 1995). However, the S-nitrosoglutathione is rapidly 
broken down, by the intracellular thioredoxin system (Nikitovic & Holmgren, 1996) 
and glutathione peroxidase (Hou et ai., 1996), to release NO. Hence it is more likely 
that NO sensitivity is dependent upon the relative activity of the broader cellular 
antioxidant system. This consists of catalase, superoxide dismutases (SODs), 
glutathione reductase, glutathione peroxidase, thioredoxin, thioredoxin reductase and 
the capacity to supply reduction equivalents via the hexose monophosphate shunt 
(Clancy et al., 1994). Expression of some of these proteins can be influenced by NO 
at the transcriptional level. NO has been shown to induce the expression of Mn-SOD 
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(Sano et at., 1996), heme oxygenase (Motterlini et at., 1996), and stress activated 
protein kinases (Pfeilschifter & Huwiler, 1996). In addition, a cell line that 
overexpresses metallothionein was found to be relatively resistant to NO cytotoxicity 
(Schwarz et al., 1995). 
Macrophage-derived NO has been shown to be a cytotoxic effector against 
tumor cells by the previously discussed effects on intracellular iron, DNA synthesis 
and energy metabolism (Drapier & Hibbs, 1988; Wharton et al., 1988). NO and 
derived species can also contribute to it's own toxicity by incapacitating some of the 
defense mechanisms discussed above. Thus peroxynitrite has been shown to interact 
with the transition metal in the active site of (SOD) giving rise to a nitronium ion. 
This results in self-nitration of tyrosine residues and inactivation of both the Mn- and 
Fe-SOD, but not CuIZn-SOD (Ischiropoulos et a/., 1992). NO can also inhibit 
glutathione reductase by nitrosylation of cysteines located in the active site of this 
enzyme (Wharton et at., 1988). NO has also been shown to inhibit metallothionein by 
interaction with the iron-sulfur (Kennedy et at., 1993; Schwarz. et at., 1995) and 
catalase by interaction with the heme group (Brown, 1995). 
1.2.2.11 Other Targets 
NO has also been demonstrated to have a modulating effect on methionine 
metabolism in rats by inhibition of hepatic methionine adenosyltransferase via S-
nitrosylation (Ruiz et al., 1998). Alcohol metabolism has been shown to be 
modulated by NO via S-nitrosylation-dependent inhibition of alcohol dehydrogenase 
(Gergel & Cederbaum, 1996). Caeruloplasmin is a copper containing protein in the 
24 
plasma with ferroxidase activity. Peroxynitrite interacts with this protein resulting in 
copper release and the loss of ferroxidase activity (Swain et al., 1994). 
1.2.3 Summary 
NO is simultaneously involved in signaling, cytotoxicity, and cytoprotection 
by interaction with a variety of molecules present in the intracellular environment. 
The resulting redox family of NO-derived compounds with their range of reactivity 
and diversity of intracellular targets account for the broad biological actions of NO. 
Such complexity makes the therapeutic remediation of conditions that arise from 
excess or insufficient NO a great challenge, but one with the potential for even greater 
rewards. 
1.3 Nitric Oxide Synthases 
Mammalian nitric oxide synthases (NOSs) have been characterized from 
various cell types and found to comprise three distinct isoforms that are 50 - 60% 
homologous and distinguished by their histological expression, susceptibility to 
arginine-based inhibitors, intracellular localization, NO output and mode of regulation 
(for review see Sessa, 1994). Within each isoform group there is a high degree of 
conservation of amino acid sequence (80-94%) across species, demonstrating that 
these differences are species-related (orthologous) and not due to the existence of 
different genes. These isoforms are products of three distinct genes (Chartrain et al., 
1994; Hall et al., 1994; Kishimoto et al., 1992; Marsden et al., 1994; Marsden et al., 
1993; Robinson et al., 1994; Xu et al., 1994; Xu et al., 1993) and are functionally 
categorized as to whether their expression is constitutive or inducible (see tables 1.2 
and 1.3). 
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Two isoforms, approximately 60% homologous, are constitutively expressed 
in specific cell types where activity is regulated by changing levels of intracellular 
Ca2+ (cNOSs). The two cNOSs are termed neuronal NOS (nNOS =160 kDa) and 
endothelial NOS (eNOS =130 kDa), named for the tissues from which they were 
initially isolated. These cNOSs are transiently activated by agonist-induced elevations 
in intracellular calcium, resulting in the evanescent binding of Ca2+/calmodulin. This 
pulsatile activation is ideally suited to a regulatory role by puffs of NO in cells and 
tissues. 
The remaining isoform, iNOS (=130 kDa), can be induced by 
immunostimulants in most cell types; activity is continuous, high output and Ca2+_ 
independent. iNOS was originally isolated from murine macrophages as an enzyme 
that contains tightly-bound calmodulin (Cho et al., 1992) and accordingly, it is fully 
active at resting low levels of intracellular calcium. iNOS produces a large 
continuous flux of NO which may be limited only by substrate availability. 
Transcriptional upregulation of the iNOS gene occurs in response to various 
inflammatory cytokines (e.g. IL-I, TNFa) or immunostimulants such as bacterial 
lipopolysaccharide (LPS), by a mechanism that is syn~rgistic with interferon-y (for 
review see Nathan & Xie, 1994). While the high-output of NO that derives from 
iNOS plays an important role in host-defense against intracellular parasitism (Green 
et al., 1990; Hayashi et al., 1996), it can also be toxic to the host, contributing to 
inflammatory dysfunctions and potentially lethal hypotension (Kilbourn et al., 1990; 
Kilbourn et al., 1992; Kilbourn et ai., 1994; Lin et al., 1994; Liu et al., 1997; Petros 
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et al., 1991). Evidence suggests that iNOS may be expressed in some tissues under 
normal conditions; these include fetal and adult lung (Kobzik et al., 1993) and kidney. 
This possibility challenges the common view that iNOS is exclusively inducible. An 
overall comparison of the NOS isoforms is shown in Fig. 1.1 
1.4. Nitric Oxide Synthase; Gene Structure. Re&ulation and Expression 
Three distinct genes encoding the family of human NOS proteins have been 
identified and characterized. Analysis of these complex loci reveals that the control of 
mRNA expression is unique for each of the different NOS isoform genes. The NOS 
genes are not clustered in one part of the genome, but are spread out on separate 
chromosomes. Analysis of the genomic organization and exon/intron structure 
indicates a remarkably high degree of similarity between the three genes. This is 
especially evident in the two Ca2+/calmodulin-dependent NOSs (Hall et al., 1994; 
Marsden et al., 1993). The high degree of conservation between the NOS isoforms 
may be due to evolutionary events such as gene duplication and chromosome 
transposition. 
The three genes share several striking features, they all display the same exon 
structure, discounting the first exons, which supports the theory that the three genes 
are probably derived from a common ancestral gene. Most of the exon sizes are 
similar and the position of the introns within interrupted codons are always the same. 
However, there are two important differences between the eNOS genes and the iNOS 
gene. Firstly, nNOS exon 15 and eNOS exon 17 have no counterpart in iNOS. 
Secondly, iNOS exon 12 corresponds to two exons in both nNOS (exons 12 and 13) 
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Table 1.2 Purified Nitric Oxide Synthases 
Species and Tissue Classification Co-factor Mr(KOa) Specific Activity Reference 
additions required 
for activity 
Rat Cerebellum Constitutive Ca2+ ICaM,' 150 960 nMol citrulline Bredt and Snyder, 1990 
Soluble NADPH lmin/mg protein 
Rat Cerebellum Constitutive Ca2+ ICaM, 155 107 nMol citrulline Schmidt et ai, 1991 
Soluble NAOPH lmin/mg protein 
Rat Cerebellum Constitutive Ca2+ ICaM, 150 20 nMol citrulline Hiki et ai, 1992 
Particulate NADPH,FAO, lmin/mg protein 
BH4 
Porcine Cerebellum Constitutive Ca2+ ICaM, 160 730 nMol citrulline Mayer et ai, 1990 
Soluble NAOPH,BH4 lmin/mg protein 
Human cerebellum Constitutive Ca2+ ICaM, 160 74.3 nMol citrulline Schmidt and Murad, 1991 
Soluble NAOPH,BH4 lmin/mg protein 
Bovine Brain Constitutive Ca2+ ICaM, 150 115 nMol citrulline Ohshima et aI, 1992 
" Soluble NAOPH,BH4 lmin/mg protein 
Bovine aortic Constitutive Ca2+ ICaM, 135 15.3 nMol citrulline Pollock et aI, 1991 
endothelial cells Particulate NADPH,BH4 lmin/mg protein 
Rat macrophage Inducible NADPH,BH4, 150 1052 nMol citrulline Yui et aI, 1991 
Soluble OTT lmin/mg protein 
--_ .. _----
Mouse Macrophage Inducible NADPH,BH4, 130 0.96nmol Hevel et ai, 1991 
Soluble FAD citrullinelhr 
Mouse Macrophage Inducible NADPH,BH4, 125-135 1313 nmol NOx Stuehr et ai, 1991 
Soluble· FAD, thiol lminlmgprotein 
Rat Liver Inducible CaM, BH4, FAD, 135 462 nMol citrulline Evans et ai, 1992 
Soluble FMN lmin/mg protein 
Rat Inducible Ca2+ , NADPH, 150 122nmolNOx Yui et ai, 1991 
polymorphonuclear Soluble FAD, BH4 lmin/mg protein 
neutrophils 
Table 1.3. Cloned Nitric Oxide Synthase Isoforms 
NOS Isoform Species Cell Type Protein Mr Ca2+ _ Reference 
(Deduced) dependent 
Neuronal Human Cerebellum 161037 Da Yes Nakane et al., 1993 
(NOS 1) Rat Cerebellum 160458 Yes Bredt et al., 1991 
Inducible Human Hepatocyte 131000 No Gellar et aZ., 1993 
(NOS 2) Rat Hepatocyte 130653 No Wood et aZ., 1993 
Rat Vascular Smooth 131000 No Nunokawa et al., 1993 
Muscle 
Murine Macrophage 130556 No Lowenstein et al., 1992 , 
Endothelial Human Aortic endothelium 133000 Yes Janssens et aZ., 1992 
(NOS 3) Marsden et aZ., 1992 
Bovine Aortic endothelium 133286 Yes Lamas et al., 1992 
Nishida et aZ., 1992 
Sessa et al., 1992 . 
--
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Fig 1.1 Overview and Comparison of the Modular Structure of Nitric Oxide 
Synthase Isoforms 
The diagram shows the division of NOSs into distinct reductase and oxygenase 
domains. Special note should be made of the lack of homology in the N-terminal 
regions, with nNOS and eNOS containing important po ttranslational modification 
si tes within this area. nNOS contains a GLGF repeat and eNOS contains acylation 
sites which are important in the subcellular localization of the proteins necessary for 
efficient in vivo function of the enzymes. 
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and eNOS (exons 10 and 11). This region corresponds to the calcium/calmodulin 
binding domain and this region in cNOSs is split by an intron. 
1.4.1 iNOS 
The iNOS gene is located on mouse chromosome 11 (Jenkins et ai., 1994) and on 
human chromosome 17ql1.2-qI2 (Chartrain et ai., 1994; Marsden et ai., 1994; Xu et 
ai., 1994). However, it is unknown whether there are other iNOS-like sequences in 
the genome, such sequences have been found in the pericentric region of chromosome 
17p11-q11 and on chromosome 14 (Xu et ai., 1995; Xu et aI., 1994). However, it is 
not known whether these regions are transcriptionally active or are pseudogenes. 
The human iNOS gene comprises 26 exons covering 37 kb and the protein is 
encoded by exons 2-26. The full length open reading frame is 3459 bp and encodes 
for a protein of 1153 amino acids (130 kDa). A transcription initiation site 30 
nucleotides downstream of a TAT A box has been identified in studies using 
cytokineILPS-stimulated human hepatocytes (Chartrain et ai., 1994). Analysis of the 
5' -flanking region shows several consensus sequences that are implicated in cytokine-
modulated gene expression. These include NF-KB, NF-interleukin-6 (IL-6), y-IRE, a 
palindromic TNF-RE-like site, and a liver-specific transcription factor consensus 
sequence, AABS (Chartrain et ai., 1994; Nunokawa et ai., 1994). 
The expression of iNOS can be induced in almost every tissue and nucleated 
cell type tested thus far. The induction of iNOS expression in these varied cell types 
appears to be predominantly under transcriptional regulation. Although there is a low 
basal level of expression, this is markedly enhanced by treatment of cells with LPS or 
32 
cytokines. Maximal promoter activation occurs with synergistic combinations of 
inflammatory cytokines (TNF-a, IL-l~, IFN-l') and LPS. What constitutes an 
effective combination varies depending on cell-type and species (Beasley & Eldridge, 
1994; Geller et aI., 1993; Lorsbach et al., 1993; MacNaul & Hutchinson, 1993; 
Markewitz etal., 1993; Sherman etal., 1993; Sirsjo etal., 1994; Suschek etaZ., 1993; 
Wood et al., 1993; Yamada et al., 1993). Activation of protein kinase A (PKA), 
protein kinase C (PKC) and protein tyrosine kinase signaling pathways have been 
implicated in a modulatory role in some cell types (Gilbert & Herschman, 1993). 
Characterization of the murine iNOS promoter indicates that distinct areas of the 5'-
flanking regions of the gene participate in the transcriptional response to the different 
exogenous stimuli (Lowenstein et aZ., 1993; Xie et al., 1994; Xie et al., 1993). There 
is a proximal region of the promoter (-85/-76) which interacts with the NF-KB trans-
acting factor. NF-KB resides in the cytosol of quiescent cells as an inactive complex, 
bound to an inhibitory protein, I-KB. Following activation of cells by a number of 
agents, I-KB becomes phosphorylated, dissociates and is degraded by the proteosome. 
This allows NF-KB to translocate to the nucleus, where it binds to the cis-regulatory 
regions of the iNOS promoter (Grilli et al., 1993; Xie et ai., 1994). This proximal NF-
KB binding site has been shown to be critical for the induction of the iNOS gene by 
LPS (Lowenstein et al., 1993; Xie et al., 1993). Promoter/reporter construct studies 
indicate that the more distal regions of the promoter are involved in IFN-l'-stimulated 
changes in iNOS mRNA expression (Lowenstein et al., 1993; Xie et al., 1993). An 
IRF-l cis-regulatory DNA region is implicated in this response and this is supported 
by in vivo evidence demonstrating that homozygous IRF-l (-/-) mice do not exhibit 
an iNOS response following stimulation by cytokines or viruses (Kamijo et al., 1994). 
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1.4.2 nNOS 
The nNOS gene is present as a single copy in the haploid human genome and is 
located on human chromosome 12q24.2-24.31 (Kishimoto et ai., 1992; Marsden et 
ai., 1994; Xu et al., 1993). The gene comprises 28 codons, 2-29 coding for the protein 
and spanning over 200 kb. The nNOS gene yields an mRNA with an open reading 
frame of 4302 bp that encodes a protein of 1434 amino acids with a predicted 
molecular weight of 160.8 kDa. Homologous genes of mouse and rat have been 
assigned to chromosome 5 (Lee et al., 1995) and chromosome 12 (Deng et al., 1995), 
respectively. The genomic structure for human brain nNOS is well documented (Hall 
et al., 1994; Marsden et al., 1994). More recently sequence data for the rat nNOS 
transcriptional cluster expressed in yeast artificial chromosome has been published 
(Lee et al., 1997). Also nNOS cDNAs have been isolated for both rat and mouse 
homologues (Bredt et aI., 1991; Ogura et al., 1993), and the coding sequences show 
86-88% homology to the human gene at the nucleotide level. 
Consensus sequences coding for the various functional domains of the protein 
are localized to distinct exons or groups of exons. Although considered to be 
constitutively expressed, nNOS may also be transcriptionally regulated. This is based 
on the fact that the 5' -flanking region of the human nNOS exon 1 contains putative 
transcription factor binding sites for AP-2, TEF-IIMCBF, CREB/ATF/c-fos, NRF-l. 
Ets, NF-l, and NF-KB-like sequences (Hall et al., 1994). However, these sites have 
not been proven to have functional activity with transcription factors. In addition, a 
variety of cis-regulatory elements implicated in testis-specific transcription are 
evident including the transcription factor GATA and GATA-like sites, p53 half-
element, an Ets binding site, Pu box, polyomavirus enhancer activator 3 (PEA3) 
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sequences, myocyte-specific enhancer factor 2 motif, and an insulin response site. 
Again the functionality of these sites has not been proven. The transcription initiation 
sites in brain nNOS mRNA has been determined via primer extension analysis and 
RNAse protection, revealing a major start site 28 nuc1eotides downstream of a TAT A 
box. 
Cloning and characterization of nNOS cDNAs from both human and rodent 
tissues reveals structural and alleic mRNA diversity. Various broadly distributed, 
tissue-specific, or developmentally regulated mRNA transcripts have been reported. 
These arise from combinations of two or three of the following mechanisms. Initiation 
by different transcriptional units containing alternative promoters, cassette exon 
deletions or insertions, and the use of polyadenylation signals. The usage of 
alternative promoters seems to be one of the main mechanisms involved in controlling 
nNOS gene expression, in a tissue specific manner. For the human gene two major 
transcriptional clusters have been identified, neuronal- and testis-specific. The 
neuronal cluster is located upstream from exon two. At least eight different first exons 
and the corresponding 5' -flanking promoter regions have been detected within the 
200 kb gene sequence. Major transcription sites were found located at ~25 kb 
upstream from exon 2 (Hall et al., 1994; Wang & Marsden, 1995; Xie et al., 1995; 
Young et al., 1995). The different first exons appear to splice to the common exon 2, 
which contains the initiator ATG codon. Hence, the protein encoded by the different 
mRNA species is the same, full-length, wild type nNOS protein. However, the use of 
alternative promoters is a versatile mechanism which can influence gene expression 
(Ayoubi & Van De Ven, 1996). These influences of different leader exons influence 
mRNA processing, localization, translation efficiency, and longevity. The 
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various promoters have distinct tissue specificities and developmental regulation and 
may respond differently to stimuli. This is supported by in situ hybridization studies 
using antisense cRNAs which localized the different exon 1 variants to distinct cell 
populations. Results suggest that cell type-specific transcription or splicing factors 
may control the levels of nNOS expression (Wang & Marsden, 1995). 
Multiple first exons have also been reported for the mouse nNOS gene, 
cDNA sequencing reveals at least five distinct mRNA transcripts (Brenman et al., 
1997) in the rat nNOS gene, with at least three distinct mRNA transcripts arising from 
alternative splicing (Lee et al., 1997). In normal human testis, transcription can 
initiate from a region located within intron 3 (Wang et al., 1997). A novel nNOS 
mRNA transcript with a 5' terminus encoded by two new exons (Tex 1 and Tex 2) 
spliced to exon 4 of full length nNOS. This appears to be expressed at a comparable 
level in the testis to that of full length nNOS. Also a minor transcript containing a 
unique 95bp exon Tex Ib5' of exon 2 was detected. The two mRNAs predicted the 
translation to occur at an ATG within exon 5, giving rise to a protein (TnNOS) with a 
calculated molecular mass of 125 kDa (1098 amino acids). This represents an N-
terminal truncation of the full length nNOS and lacks the PDZlGLGF domain. An 
analogue of TnNOS is found in mice, nNOS-y, which is produced by a different 
molecular mechanism to TnNOS. In nNOSMa mice with a targeted deletion of exon 
2 (Huang et al., 1993), two NOS transcripts (~+y) are found at very low levels. These 
use alternative first exons, la in the case of nNOS-~ and lb in the case of nNOS-y, 
spliced to a common exon 3 (Brenman et al., 1997). Translation of nNOS-y is 
initiated at the same ATG within exon 5 as the human TnNOS and gives rise to a 
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similar 125 kDa protein. The nNOS-~ transcript is initiated at an ATG codon within 
exonla, generating a 136 kDa NOS protein with six new N-terminal amino acids. 
Different nNOS transcripts can also arise via cassette exon deletions or 
insertions. Cassette deletions of ex on 10 and exons 9/10 have been detected in human 
nNOS mRNA transcripts (Hall et ai., 1994). The deletion of exon 10 introduces a stop 
codon 16 bp downstream of the splice junction. This could potentially lead to the 
production of a novel truncated 560 amino acid protein. Excision of exons 9/10 
results in a 315 bp frame deletion possibly resulting in the production of a protein 
lacking 105 amino acids. Low expression of this protein has been shown in various 
human brain tissues, mouse brain tissues and neuroblastoma cell lines (Fujisawa et 
ai., 1994; Ogura et ai., 1993). It remains to be established that these variants are 
relevant in vivo, although it is likely since the nNOS-related dNOS cloned from 
Drosophila exhibits the same 315 bp deletion and is fully active (Regulski & Tully, 
1995). 
Cassette exon insertions have also been reported to give rise to novel variants 
of nNOS. In the rat, a fully active muscle nNOS (IlNOS) has been reported to be 
derived from a 102 bp insertion between exons 16 and 17, resulting in the addition of 
34 amino acids (Magee et ai., 1996; Silvagno et ai., 1996). This is expressed in rat 
skeletal muscle, heart, penis, urethra and prostate (Magee et ai., 1996). In muscle, 
most of IlNOS is found associated with dystrophin at the sarcolemma (Chao et ai., 
1997). Also a cassette insertion of exon Tex 2 between exons 3 and 4 of the full 
length nNOS has been shown from screening of a human testis cDNA library and was 
subsequently found in other tissues (Wang et ai., 1997). The insertion of 56 bp leads 
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to a frame shift, which introduces a stop codon 371 bp downstream of the splice 
junction within exon 6. The production of the resulting C-terminal truncated, 407 
amino acid protein has not been shown to be translated in vivo. 
The last source of variation in the nNOS gene is the presence of three potential 
polyadenylation signals within exon 29. These sites are present over a 200 bp region 
with a predominant site located at 6449 bp downstream of the initiator methionine 
(Hall et al., 1994). Exon 29 also contains a (CA)n repeat sequence and genotypic 
analysis of normal individuals showed multiple alleles of various sizes, depending on 
the number of (CA)n repeats. The effects of these 3' -untranslated end variations on 
mRNA transcription efficiency, processing, stability, or subcellular targeting is 
unknown at present. 
1.4.3 eNOS 
The human eNOS mRNA is encoded by a unique gene consisting of 26 exons 
spanning 21-22 kb of DNA (Marsden et ai .• 1993; Miyahara et ai., 1994). The human 
gene has been mapped to the 7q35-7q36 region of chromosome 7 (Marsden et ai .• 
1993). The bovine eNOS gene also contains 26 exons and spans 20 kb of DNA. Two 
transcription start sites are located 170 and 240 bps upstream of the methionine 
translation initiation codon (Venema et ai., 1994). Full length eNOS cDNAs have 
been isolated from human (Marsden et al .• 1992) (Janssens et ai., 1992), murine 
(Gnanapandithen et aI, 1996), bovine (Lamas et ai., 1992; Nishida et ai., 1992; Sessa 
et ai., 1992) and porcine (Zhang et ai., 1997) endothelial cells . 
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The 5' -flanking region of the bovine eNOS gene indicates that the promoter 
has no TATA motif and exhibits Spl and GATA motifs, elements consistent with a 
constitutively expressed gene in endothelial cells (Zhang et al., 1995). Analysis of the 
human eNOS gene promoter reveals consensus sequences for the binding of 
transcription factors AP-1, AP-2, NF-l, nuclear factor, IL-6, NF-KB and PEA3. Also 
CACCC-, CCAAT-, heavy metal-, acute-phase response-, shear stress-, cAMP-
response-, retinoblastoma control-, INF-y-response-, and sterol-regulatory cis 
elements appear to be present. Incomplete sites for estrogen response elements have 
also been identified. So far, a functional response has been shown for only a few of 
these binding sites and deletion/mutation studies reveal an essential role for the Sp-l 
binding site at position -103 (Zhang et al., 1995). Stimulation of the eNOS promoter 
in the human E.A.hy 926 endothelial cell line has been shown in 'response to estrogen 
(Kleinert et ai., 1998), and in human umbilical vein endothelial cells (HUVECs) in 
response to lysophosphatidy1choline (Cieslik et ai., 1998); these responses may result 
from enhanced binding of Sp-1. Mutation of the GAT A site at position -230 caused a 
30% reduction in eNOS promoter activity (Zhang et ai., 1995) and mutation of the 
PEA3 binding site at position -26 caused a 50% reduction in activity. An 
upregulation of bovine eNOS promoter activity in response to hypoxia has been 
demonstrated (Amet et ai., 1996), but the human eNOS promoter does not contain 
any identifiable sites with homology to the hypoxia inducible factor-l (HIF-l) 
consensus sequence. A possible role for PKC in the induction of promoter activity 
has been demonstrated in human endothelial cells transfected with a human eNOS 
promoter-Iuciferase construct (Li et aI., 1998). However, the mechanism and 
transcription factors involved remain to be elucidated. 
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The bovine gene 5' -flanking region, or the known 2.9 kb of sequence, also 
lacks a typical TAT A box and contains numerous putative transcription factor binding 
sites. Comparison of the first 1.6 kb of the 5'-flanking regions of human and bovine 
eNOS genes reveals 75% sequence identity (Venema et al., 1994). Reporter gene 
assays using a fragment of the bovine promoter (positions -1548 to +240) in 
transfected BAEC showed a significant basal activity. A smaller fragment (-1548 to 
+192) which lacks two putative Sp-l binding sites in the 5'-VTR, lost nearly all its 
promoter activity in the same system. This suggests that transcription factor Sp-l is 
important for bovine, as well as human eNOS transcription • Reports of an 
upregulation of eNOS mRNA in response to TGF-~l in BAEC are likely to be due to 
enhanced activity of the bovine promoter due to an increased binding of transcription 
factor NF-l (Inoue et al., 1995). 
1.5 NOS Structure 
Nitric oxide synthases, like many other enzymes, have evolved to function in an 
oligomeric form. They are only active as dimers comprised of identical subunits. The 
homodimers are formed by two NOS subunits aligned in a head-to-head fashion, with 
the oxygenase domains of each subunit interacting functionally with the reductase 
domain of the companion subunit (see Fig.1.2). The structure of NOS monomers and 
dimers are discussed below. 
Sequence analysis of all three NOS isoforms identified consensus binding 
sequences for reduced nicotinamide adenine dinucleotide phosphate (NADPH), flavin 
adenine dinucleotide (FAD), flavin mononucleotide (FMN) and CaM (Bredt et al., 
1991; Lamas et al., 1992; Lyons et al., 1992; Xie et ai., 1992), concurring with 
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Fig 1.2 Formation of the NOS Dimer 
The NOS dimeric structure is formed by a "head-to-head" association between the 
oxygenase domains of the two subunits with the reductase domains attached as 
independent extensions. 
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previous data from purification studies that showed NOSs were NADPH dependent 
flavoproteins containing FMN and FAD, and capable of binding CaM. (Hevel et al., 
1991; Mayer et al., 1991; Schmidt et al., 1992; Stuehr et al., 1991). The locality of 
these binding sites indicated a bidomain structure with a C-terminal reductase domain 
and a N terminal oxygenase domain, linked by a canonical CaM binding domain (see 
Fig.l.!). 
The NOS reductase domain (C-terminal half) contains the NADPH, FAD and 
FMN binding domains and, taken on its own, displays ... 40% sequence homology to 
mammalian NADPH-cytochrome P450 reductase, the flavo-protein subunit of sulfite 
reductase and the reductase portion of the bacterial cytochrome P450 (Porter, 1991). 
As all of these enzymes transfer electrons from NADPH onto an endogenous or 
associated heme group; it was appreciated early that the role of the C-terminal region 
of NOS is to transfer electrons from NADPH onto a redox component in another 
region of the enzyme. The redox component in question has since been identified as 
iron protoporphyrin IX (heme) (Klatt et al., 1992; McMillan et al., 1992; Stuehr & 
Ikeda-Saito, 1992; White & MarIetta, 1992) which was found to be bound within the 
N-terminal oxygenase domain of NOS. 
Limited proteolysis studies of nNOS (Ghosh & Stuehr, 1995; Sheta et al., 
1994) and expression of individual domains (Chen et al., 1996; Gachhui et al., 1996; 
McMillan & Masters, 1995; Salerno et al., 1996), allowed the positive assignment of 
the CaM-, flavin- and NADPH-binding sites to the reductase domain and the heme-, 
tetrahydrobiopterin- (BH4), and L-arginine-binding sites to the oxygenase domain. 
Point and deletion mutation studies of iNOS confirmed the involvement of residues 
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1121-1144 in the reductase domain to be involved in NADPH binding (Xie et ai., 
1994). Peptides synthesized to correspond to the putative CaM binding domains have 
been shown to bind CaM with similar affinities to those demonstrated for the intact 
enzymes (Anagli et ai., 1995; Persechini et ai., 1996; Persechini et ai., 1996; Stevens-
Truss & MarIetta, 1995; Venema et ai., 1996; Vorherr et ai., 1993; Zoche et ai., 
1996). This confirms a role for the sequence in binding CaM. Nonetheless, studies 
using chimeric NOS constructs containing the CaM binding region of another isoform 
indicate that other areas of NOS may also contribute to CaM binding (Venema et ai., 
1996). 
The heme iron group is axially coordinated in NOS by a Cys thiolate (Klatt et 
ai., 1992; McMillan et ai., 1992; Salerno et ai., 1996; Stuehr & Ikeda-Saito, 1992; 
Wang et ai., 1993; White & MarIetta, 1992). Sequence and structural comparison of 
NOS with other thiolate-ligated hemoproteins such as cytochrome P450 have 
suggested that the coordinating Cys residue is located within the oxygenase domain at 
positions iNOS-194 (murine), nNOS-415 (rat) and eNOS-184 (bovine) (McMillan et 
ai., 1992; Renaud et aI., 1993). Point mutation studies involving these residues 
resulted in either the loss of heme binding (Chen et ai., 1994; Richards et at., 1996; 
Xie et ai., 1996) or the formation of an unstable heme containing species (McMillan 
& Masters, 1995). 
Specific BH4 or L-arginine binding amino acids or regions within the 
oxygenase domain are poorly defined. Based on homology matching with other 
pterin-binding enzymes, three sites have been proposed, all are located C-terminally 
with respect to the heme-binding Cys residue. One of these sites can be discounted as 
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it lies within the reductase domain and, as discussed earlier, BH4 has been shown to 
bind to the oxygenase domain (Chen et ai., 1996; Gachhui et ai., 1996; Ghosh & 
Stuehr, 1995; McMillan & Masters, 1995; Salerno et ai., 1996; Sheta et ai., 1994). A 
region in the oxygenase domain, iNOS residues 448-480, was noted to be similar to 
the BH4 binding sites in the aromatic amino acid hydroxylases (Cho et al., 1995). 
Point mutations in this region of iNOS led to a loss of both BH4 binding and dimeric 
structure, but retained heme binding capability. Given this result, the role of dimer 
destabilization in the prevention of BH4 binding can not be ruled out, especially since 
it has been shown that monomeric iNOS and nNOS do not stably bind BH4 (Baek et 
al., 1993; Klatt et al., 1996). The third site (iNOS residues 340-494) shows some 
sequence homology to the dihydrofolate reductase pterin-binding domain (Nishimura 
et al., 1995), but studies using GST-fusion peptides corresponding to this region 
suggest that it cannot bind BH4. However such peptides were shown to be capable of 
binding radio-labeled nitroarginine, suggesting a role in L-arginine binding. Point 
mutagenesis of residues in the oxygenase domain N-terminal to the heme-binding site 
(e99) resulted in NOS with decreased BH4 affinity, but normal characteristics for L-
arginine binding, activity and dimer formation. This suggested a possible role for 
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C99 in modulating BH4 binding (Chen et al., 1994). Residues involved in BH4 and L-
arginine binding are present in the oxygenase domain and may be distributed on 
opposite, or possibly both sides of the heme binding domain. 
The effects of arginine and BH4 on the oxygenase domain active site, and the 
heme-iron contained within, have been investigated using both the isolated oxygenase 
domain and the full length enzymes. It has been shown that the ferric heme-iron of 
NOS is predominately six-coordinate and low-spin in the absence of both BH4and L-
44 
arginine (Fossetta et ai., 1996; Martasek et ai., 1996; Rodriguez-Crespo et aI., 1996; 
Roman et ai., 1995; Wu et ai., 1996). Binding of BH4 and L-arginine favors a shift to 
a five-coordinate high-spin state, BH4 binding causes a mixture of the two spin states 
and arginine causing an almost complete shift to the high spin state. Binding studies 
using L-arginine or L-arginine analogues with BH4-containing ferric NOS, suggest 
that the binding of substrate can occur in several different modes with respect to the 
heme environment (Garvey et ai., 1994; Salerno et ai., 1995; Salerno et ai.; 1996). 
Inhibitor studies indicate that the NOS isoforms differ in the geometry of their 
substrate binding pockets (For review see Griffith & Stuehr, 1995; Gross, 1995). It 
appears that BH4 and arginine both bind near the distal side of the heme group and can 
influence each other's binding, as well as the binding of heme-ligands, such as NO, 
CO, CN- and imidazole (Chabin et al., 1996; Wang et al., 1993). These effects were 
to be expected from L-arginine based on mechanistic considerations, but were 
surprising for BH4 and suggest a new role for this molecule in hemoproteins 
(discussed later in Mechanism section). 
The oxygenase and reductase domains of iNOS or nNOS can be separated by 
trypsinolysis and purified by 5'-ADP sepharose chromatography (Ghosh & Stuehr, 
1995; Sheta et al., 1994). The individual domains seem to remain intact as they are 
unaltered in terms of prosthetic group binding and spectral properties. As predicted, 
neither domain alone was capable of NO formation from L-arginine. The oxygenase 
domains are homodimeric and reductase domains are monomeric. Hence, the 
oxygenase domain would seem to contain the determinants necessary for 
dimerization. This led to a head-to-head model for NOS dimerization with the 
oxygenase domains interacting to form the dimer and the reductase domains attached 
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as independent extensions (Ghosh & Stuehr, 1995). This model is supported by light-
scattering studies which indicate that dimeric NOS has an elongated structure (Klatt et 
al., 1995) (see fig 1.2). However, immunoprecipitation studies using cells that co-
express eNOS and the eNOS reductase domain found that overexpression of the 
reductase domain prevented eNOS homodimer formation. Instead this seemed to 
cause the formation of a non-functional heterodimer comprised of one intact eNOS 
subunit and one eNOS reductase domain. Dimer dissociation studies show that the 
concentration of urea required to dissociate the oxygenase domain dimer is much 
higher than that required to cause the dissociation of the full-length iNOS dimer 
(Ghosh et al., 1996). This would suggest that the attached reductase domains 
destabilize the dimeric interaction between the two oxygenase domains. The role of 
the reductase domain in modulating dimeric interactions and active site structure is 
potentially important, but is as yet undefined .. 
, 
The roles of the various prosthetic groups and substrates in promoting NOS 
dimerization have also been studied in both nNOS and iNOS. NOS monomers will 
not form dimers when incubated together at rnicromolar concentrations in a minimal 
buffer. However, it has been shown that dimerization of iNOS is promoted by the 
presence of L-arginine, BH4, and a stoichiometric amount of heme (Baek et al., 1993). 
The omission of BH4 reduced dimer association and the omission of heme or L-
arginine prevented dimer association. However, dimerization of heme-free nNOS 
monomers can be obtained in the presence of heme alone (Klatt et al., 1996), 
suggesting the role of heme insertion may be the most important factor in promoting 
dimer assembly in nNOS. The heme iron in the reconstituted iNOS dimer was ligated 
to the protein through a cysteine thiolate, and the dimer expressed a specific activity 
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similar to the native dimeric iNOS (Baek et a/., 1993). This would indicate that the 
prosthetic groups are bound properly in the monomers during dimerization. This data 
may suggest a role for heme and possibly BH4 and L-arginine in regulating NOS 
dimeric structure. Substrate or prosthetic groups affecting enzyme subunit assembly is 
not uncommon (for review see Jaenicke, 1996). However, the possible involvement of 
two prosthetic groups, heme and BH4, and substrate, L-arginine, is unusual and 
suggests multiple means by which NOS dimer assembly can be regulated in cells. 
1.6 NOS Mechanism and Possible Roles for Cofactors and Prosthetic Groups 
All three NOS isoforms catalyze a five-electron oxidation of one of the 
equivalent guanido nitrogens of L-arginine to yield one mole each of nitric oxide and 
L-citrulline, at the cost of 1.5 moles of NADPH and 2 moles of dioxygen (see 
Fig.l.3)(for review see Stuehr & Griffith, 1992). The reaction involves two successive 
monooxygenation reactions with NCIl-hydroxy-L-arginine produced as an isolatable 
intermediate (Stuehr & Ikeda-Saito, 1992). Isotopic studies have shown that NOS 
incorporates atoms from molecular oxygen into both citrulline and NO (Kwon et ai., 
1990; Leone et ai., 1991). All NOS isoforms contain four prosthetic groups: FAD, 
FMN, Iron protoporphyrin IX (heme) and BH4. The flavins are involved in electron 
storage and delivery, accepting two electrons from NADPH and then delivering single 
electrons to the heme group within the active site (Bredt et ai., 1991). The heme has 
an established redox role in the activation of molecular oxygen (McMillan et ai., 
1992; Stuehr & Ikeda-Saito, 1992; White & Marietta, 1992). Although essential to 
NO production, the role for BH4 is presently unclear. Based on information that the 
stoichiometry ofNADPH utilization is 1.5 NADPH per NO formed from arginine and 
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0.5 NADPH per NO formed from NHA (Stuehr et al., 1991), several possible 
mechanisms have been proposed for NO production by NOS (Feldman et al., 1993; 
Klatt et al., 1993; Pufahl & Marietta, 1993). In order to simplify these possible 
mechanisms it is first necessary to consider the roles of the individual co-factors. 
1.6.1 NADPH and Oxygen 
In the N-oxidation of L-arginine, NADPH acts as a source of electrons for oxygen 
reduction-activation, as it does in cytochrome P450 (Watanabe et al., 1991). The 
overall reaction for cytochrome P450 can be written as follows: 
One atom of oxygen is incorporated into the substrate (RH) and the other atom is fully 
reduced to water. The initial N-hydroxylation of arginine by NOS to give NHA is 
likely to occur by the same mechanism as depicted for cytochrome P450. However, 
subsequent NOS catalyzed transformation of the NHA intermediate to give citrulline 
and NO cannot be reconciled by cytochrome P450 mechanism as NO production 
constitutes an overall odd-electron oxidation. Consistent with this odd-electron 
oxidation, the conversion of NHA to NO has been found to require 0.5 NADPH per 
NO formed (Stuehr et ai., 1991). 
1.6.2 FAD and FMN 
There are two conceivable roles for the flavins present in NOS. On the one hand they 
have potential to act as the ultimate oxygen activators, forming 4a-hydroperoxyflavin 
and participating directly in the oxidation of the substrate, as they do in the 
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monooxygenases (Ziegler, 1988). The alternative, much more likely role is that they 
act as an electron 
buffer and transfer system. In this they would act as a link to transfer electrons from 
the NADPH onto the heme group, and eventually onto the substrate (see Fig. 1.4). The 
high-degree of sequence homology between the flavin binding domains of NOS and 
cytochrome P450 reductase (Bredt et ai., 1991), would suggest that the roles of the 
flavins in these two systems are identical. The cytochrome P450 system consists of 
two closely related enzymes, the flavin containing cytochrome P450 reductase and the 
heme containing cytochrome P450. In this system the role of the reductase is to bind 
NADPH and to transfer the electrons, via FAD and FMN, to the heme of the 
cytochrome P450. A similar role for the flavins in NOS is supported by the facts that 
both cytochrome P450 reductase and NOS are capable of cytochrome c reduction 
(Klatt et ai., 1992; Mayer et ai., 1992). Also, spectroscopic studies have indicated that 
the redox-active flavins in NOS are capable of interaction with the heme group 
(Stuehr & Ikeda-Saito, 1992) and that a role of calmodulin is to enable this electron 
flux to occur (Abu-Soud & Stuehr, 1993). Hence it is clear that the role of the flavins 
in NOS is to transfer the electrons from NADPH to the heme group for the eventual 
activation of molecular oxygen. 
1.6.3 Heme Group 
Based on the analogy between NOS and cytochrome P450 systems discussed above, it 
is clear the role for the heme in NOS is likely to be to bind, reduce and activate 
molecular oxygen to generate the ultimate oxidant. Also the heme environment in 
NOS appears to be similar to that of cytochrome P450 in that the heme is ligated 
axially by a thiolate (Stuehr & Ikeda-Saito, 1992). Studies showing that carbon 
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monoxide (CO) and other heme-binding agents inhibit arginine oxidation by NOS 
indicate a crucial catalytic role for the heme group (Klatt et al., 1992; McMillan et al., 
1992; Stuehr & Ikeda-Saito, 1992; White & MarIetta, 1992). A role for heme has also 
been established in the oxidation of the biosynthetic intermediate NHA (Pufahl & 
MarIetta, 1993). Hence the heme appears to be involved in the entire, multi-step 
oxidation pathway. 
Both NOS and cytochrome P450 are known to 'uncouple' from substrate 
oxidation to generate reactive oxygen species such as superoxide and hydrogen 
peroxide (Heinzel et al., 1992; Mayer et al., 1992; Pou et al., 1992). In NOS isolated 
from pig brain, the degree of uncoupling appears to be increased at low 
concentrations of arginine (Heinzel et al., 1992). The production of superoxide or 
hydrogen peroxide would appear to occur via a heme-bound dioxygen intermediate. 
1.6.4 Tetrahydrobiopterin CBHJ 
The requirement of BH4 for maximal NOS activity in all NOS isoforms is well 
established (Hevel & MarIetta, 1992; Kwon et al., 1989; Mayer et al., 1991). 
However, of all the co-factors of NOS the role of BH4 is the least well understood and 
most controversial. 
BH4 is known to be a co-factor in only four other enzyme systems, three of 
which are aromatic amino hydroxylases (phenylalanine, tyrosine and tryptophan 
hydroxylase). It is therefore not unreasonable to anticipate that BH4 would serve a 
similar role in NOS, an arginine hydroxylase (Kwon et al., 1989). Aromatic amino 
acid hydroxy lases use BH4 directly for oxygenation of substrate via the formation of 
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e" 
L-Arginine NO -Hydroxy-L-Arginine 
Fig. 1.3 Summary of the Nitric Oxide Synthase Catalyzed Reaction. 
L-Citrulline 
+ 
Nitric Oxide 
Electrons are donated by NADPH at both stages, with 1.5 moles of NADPH required 
for each mole of NO produced. 
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A3ductase Domain Oxygenase Domain 
Fig. 1.4 Schematic Representation of Electron Flux Through NOS 
While a monomer is shown for simplicity, electron transfer actually occurs between 
the reductase domain of one subunit and the oxygenase domain of the companion sub-
unit of the homodimer. 
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4a-hydroperoxybiopterin (Dix et ai., 1987). After donating oxygen, this species 
becomes oxidized to quinoid dihydrobiopterin (BH2-q), which must then be recycled 
by an NADPH -dependent dihydropteridine reductase mediated reaction back to BH4 
for sustained catalytic function (Nichol et ai., 1985). 
A role for BH 4 participating as a direct redox-active agent in NOS catalysis 
has been rejected (Giovanelli et ai., 1991), in favor of an allosteric or membrane 
stabilizing role for BH4. The main evidence against a direct redox role for BH4 
stemmed from the fact that citrulline formation is not stoichiometric with BH4 
consumption. Indeed for every BH4 consumed, more than 15 equivalents of citrulline 
are formed (Giovanelli et ai., 1991). Isotopic studies have shown that the binding of 
BH4 induces conformational effects in NOS which can be detected as an increase in 
affinity for arginine-based ligands (Klatt et ai., 1994; Liu & Gross, 1996). Also 
spectroscopic and electron paramagnetic resonance studies have indicated that BH4 
causes a low-spin to high-spin shift in the state of the NOS-bound heme group. 
It has been established for rat nNOS that citrulline formation is not 
stoichiometric with BH4, BH4 has little effect on initial rate and BH4 is not recycled 
(Giovanelli et ai., 1991). Hence it was suggested that BH4 act as an allosteric 
modulator or may serve a protective role by keeping a crucial catalytic component in 
the reduced form. 
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1.6.5 Overall Mechanism 
NOSs catalyze the five-electron oxidation of one of the chemically equivalent 
guanido nitrogens of L-arginine to form equimolar amounts of nitric oxide and L-
citrulline. This process requires oxygen as a co-substrate and NADPH as an electron 
source. The overall reaction has little or no chemical or biochemical precedent. 
Due to the obvious similarities between NOS and cytochrome P450 reductase, 
it is likely that the two systems will share chemistry and enzymology in the catalysis 
of their respective reactions. However, there are two major differences which are 
immediately obvious. Firstly, cytochrome P450 enzymes typically perform a two 
(even) electron oxidation of its substrate whereas NOS catalyses a five (odd) electron 
step to produce NO. Secondly, cytochrome P450 does not share a requirement for 
BH4 with NOS. Because of these key differences, it is unlikely that the cytochrome 
P450 cycle can be directly applied to all the steps of NO production by NOS. 
The first step in arginine oxidation appears to be N-hydroxylation of a 
terminal guanido nitrogen of L-arginine to give an N-hydroxy-L-arginine (NHA) 
intermediate. This is as simple two-electron oxidation of nitrogen and could be similar 
to other P450-catalyzed oxidations of nitrogen. The mechanism proposed for the 
nitrogen oxidation catalyzed by cytochrome P450 occurs via an initial electron 
transfer from nitrogen to the iron-bound oxygen followed by deprotonation 
(Macdonald et al., 1989; Miwa et al., 1983). Recombination of the subsequent 
radicals then results in a N-hydroxylated species. 
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This first step in NO production, N-hydroxylation of a guanidium nitrogen, is 
not unusual in that N-oxidation is a common step in the biotransformation of many 
organic nitrogen compounds. However, further oxidation of the NHA or related 
compounds has little biochemical precedence. It has been proposed that a related 
compound containing an aromatic aminodoxime functionality could be oxidized by 
cytochrome P450 to give NO (Andronik-Lion et al., 1992). This represents a novel 
cytochrome P450 catalyzed reaction in that an odd electron product, NO, is the 
proposed product. Also peroxidation of NHA by cytochrome P450 and horseradish 
peroxidase to give citrulline has been proposed (Boucher et al., 1992). The chemical 
oxidation of N-hydroxy-guanidines by a variety of mild oxidizing agents has shown 
that HNO and not NO is the preferred nitrogen oxide released under those oxidizing 
conditions (Fukuto et al., 1993). This is not surprising since HNO would be the 
expected two-electron oxidation product from a N-hydroxyguanidine. It is therefore 
possible that NOS catalyzes a reaction in which the four electron oxidation of arginine 
gives rise to HNO, a process which would be entirely consistent with proposed 
cytochrome P450 chemistry. HNO could then be converted to NO by a one-electron 
oxidation, this pathway has been proposed and remains a viable mechanistic 
possibility (Stuehr & Griffith, 1992). HNO has been shown to possess similar 
biological activity to that demonstrated by NO (Fukuto et ai., 1992) and this similarity 
may be due to the conversion of HNO to NO under these oxidizing conditions 
(Fukuto et al., 1993). 
Other mechanistic possibilities for NO generation from NHA all require a one-
electron oxidation step at some point in the catalysis. The donation of an electron 
from the substrate to the enzyme would account for the observed NADPH 
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stoichiometry of 0.5 NADPH (one electron equivalent) per NO formed. It has been 
proposed that NHA acts as a one electron reducing agent for the enzyme and 
subsequent reactions occur in a similar manner to those performed by cytochrome 
P450 aromatase (MarIetta, 1993). A mechanism has also been proposed in which 
enzyme reduction by the NHA intermediate occurs prior to further oxidation via an 
iron-oxo species (Klatt et ai., 1993). 
I.' Relmlation of NOS Actiyity 
Because of the lability and potential toxicity of NO, the activity of the NOSs 
must be tightly regulated to ensure correct physiological functioning. The three 
isoforms are regulated in different ways. Once synthesized, iNOS is constantly active 
and is regulated by substrate/co-factor availability and protein degradation. The 
regulation of cNOSs is more complex with regulation by intermittent binding to 
Ca2+/CaM and various other proteins. 
1.7.1 Trancriptional Re&ulation of iNOS 
iNOS is mainly regulated at the transcriptional level (see Fig. 1.5) and can be 
detected following cytokine or bacterial lipopolysaccharide (LPS) stimulation 
(Nathan & Xie, 1994). Although, there is increasing evidence for "constitutive" 
expression of iNOS in some cell types (airway and renal epithelium, microvascular· 
endothelium, and cell lines including PC-12, T84, AM) (Chu et ai., 1995; Guo et 
ai., 1995). 
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IkB digest ion by 
prot eosome complex 
Ubiquit inylat ion 
Translocat ion to nucleus and DNA binding 
I 
iNOS protein ..... 1-------- mFl'JA 
Fig 1.5 Schematic Representation of iNOS Induction. Stimuli bind to receptors at 
cell surface that initiate a signaling cascade, which leads to activation of 11(B kinases 
and phosphorylation of IKB. Phosphorylation triggers the ubiquitinylation of 11(B, 
tagging the protein for degradation via the proteosome complex. The free NFK:B can 
now translocate to the nucleus and initiate transcription of gene products, including 
iNOS. 
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Pro inflammatory cytokines that increase iNOS transcription are tumor 
necrosis factor-a (TNF-a), interleukin-l (IL-l), IL-2 and interferon-y (IFN-y). The 
efficacy and potency of the various cytokines differ with cell type studied, and 
combinations of cytokines/LPS often exert a synergistic effect. There are also various 
molecules which can either increase or decrease iNOS mRNA and/or protein levels; 
these include inhibitory cytokines (IL-4, IL-8, IL-lO, IL-13), peptides, and growth 
factors (platelet-derived growth factor, transforming growth factor-~, angiotensin II) 
(for review see Forstermann et al., 1995; Morris & Billiar, 1994; Szabo & 
Thiemermann, 1995; Xie & Nathan, 1994). 
Transcriptional control of iNOS is complex with at least 22 potential binding 
sites for transcription factors present in the promoter/enhancer region of the iNOS 
gene (Nathan, 1995). However, it is evident that the NFlCB/rel transcription factor 
plays an important role in the induction of iNOS expression (Goldring et al., 1995). 
NFKB proteins are a heterogeneous group of proteins, and heterodimers containing 
mainly the reI family of proteins appear to be involved in iNOS induction (Nathan & 
Xie, 1994). Under resting conditions, NFlCB is bound to an inhibitory protein (IKB) 
and is present in the cytoplasm in an inactive form. Stimulation of cells results the 
activation of protein kinases, which phosphorylate IKB, causing the ubiquitinylation 
of IlCB and results in the protein being "tagged" for degradation by the proteosome 
complex. NFKB is then free to translocate to the nucleus, where it can initiate gene 
transcription (Chen et aI, 1995) .. The activation of NFKB often relies on the 
production of reactive oxygen species (Kroncke et al., 1995), although, exogenous 
NO has been shown to inhibit LPSrrNF-elicited NFlCB activation (Colasanti et ai., 
1995). NO can also inhibit TNF synthesis in macrophages (Eigler et al., 1995). Hence 
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there are feedback mechanisms whereby high levels of NO inhibit the induction of 
iNOS. 
Expression of maximally active iNOS requires an efficient arginine transport 
system and the availability of cofactors such as BH4 (Morris & Billiar, 1994). Most of 
the proteins responsible for the supply of these substrates/co-factors are co-induced 
with iNOS following cytokine activation of cells. Interference with the induction of 
the Y + transporter (responsible for arginine transport into the cell) or GTP-
cyclohydrolase I (GTPCH I, the rate limiting enzyme in the synthesis of BH4), would 
decrease NO production in cells. The intricacies of iNOS regulation are not fully 
understood and further work in this area is required. 
1.7.2 Regulation of NOS Activity by Calmodulin 
Although the CaM-dependent regulation of enzymes is very common in 
physiology, the NOSs are the first enzymes in which CaM has been shown to regulate 
electron flux (Abu-Soud & Stuehr, 1993). This is assumed to be due to the ability of 
CaM to align the reductase flavin groups with the oxygenase heme groups, leading to 
efficient inter-domain electron transfer. However, CaM has also been shown to 
promote inter-flavin electron flux (Abu-Soud et al., 1994), an effect which involves 
the reductase domains only. Conceivably, the rate-limiting step in electron transfer 
within NOSs (at least eNOS,) (Nishida & Ortiz de Montellano, 1998) is actually 
within the reductase domain and the principal or sole effects of CaM may be at this 
site. Future high resolution crystal structures of CaM-bound and CaM-free eNOS will 
be needed to reconcile these possibilities. 
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Despite the void in direct structural information, a prototypic CaM binding 
site composed of basic and hydrophobic amino acids was clearly recognized in the 
deduced amino acid sequence of the first NOS cDNA to be cloned (residues 725-745 
of rat nNDS) (Bredt et ai., 1991). Subsequent studies of CaM binding to synthetic 
peptides confirmed this identification in nNDS (Vorherr et at., 1993; Zhang et al., 
1995) and the corresponding amino acid sequences in the other NDS isoforms (Anagli 
et al., 1995; Venema et al., 1996). CaM binding by the nNDS-derived peptide was 
demonstrated to have an estimated ~ of 2 nM (Vorherr et al., 1993). Notably, the 
CaM-bound peptide adopted an a-helical conformation (Zhang & Vogel, 1994), a 
structure which was not stable in the absence of bound CaM. NMR studies showed 
that this complex has structural features in common with other complexes of 
Ca2+/CaM and target peptides such as that from myosin light chain kinase (Zhang et 
ai., 1995). The nNOS peptide binds with a C to N orientation to the N- and C-terminal 
domains of CaM and interaction appears to involve methionine-rich hydrophobic 
patches, similar to the interactions of CaM with other well-studied CaM-binding 
peptides (Zhang et aI., 1995). Tryptophan fluorescence quenching studies using 
nNDS holoenzyme indicate a similar Kd (InM) for CaM binding (Sheta et al., 1994). 
In the absence of bound CaM, the N-terminal peptide bond of arginine 728 in the 
CaM-binding sequence of bovine nNOS was shown to be hypersensitive to 
trypsinolysis (Lowe et ai., 1996) and CaM binding prevented trypsinolysis at this site. 
Combined with other findings, these results suggested that in the absence of 
Ca2+/CaM, the CaM binding site is exposed on the surface of nNOS and is rather 
flexible, but adopts a more rigid structure when complexed with Ca2+/CaM. 
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The precise molecular interactions of CaM required for activation of the 
cNOSs has not been elucidated, however, investigations using mutant CaM proteins 
have provided some insights into this process. CaM is a 17 KD protein composed of 
an 8-tum central a-helix, flanked by globular N-terminal and C-terminal Ca2+ -binding 
lobes (Babu et al., 1988). Each lobe consists of two EF-hand motifs that possess the 
capacity for binding a single Ca2+ atom (Persechini et al., 1989). Binding of Ca2+ 
causes a conformational change, exposing hydrophobic and acidic residues which 
engage in binding to the relevant regulatory sites on target proteins (Weinstein & 
Mehler, 1994). Using engineered CaM proteins expressing two C- or two N-terminal 
lobes, each of these lobes have been shown to bind to nNOSs independently 
(Persechini et al., 1994). However, while binding of C-C CaM to nNOS elicited no 
activation, binding of N-N CaM allowed full activation of the enzyme (Persechini et 
al., 1996). Hence, binding of the N-terminallobe of CaM is required for nNOS 
activation. 
Whether or not a given NOS isoform binds CaM in a Ca2+-dependent (cNOSs) 
or Ca2+-independent manner (iNOS) was assumed to be solely a property of the 20-25 
amino acid sequence that comprises the CaM binding site. Thus, it was unexpected 
when eNOS and nNOS chimera, engineered to have their native CaM binding sites 
substituted with a homologous sequence from murine iNOS, were demonstrated to 
retain a Ca2+ -requirement for full activity (Ruan et al., 1996; Venema et al., 1996). 
Studies of NOS chimera suggested the CaM binding site, on its own, is insufficient to 
explain the observed Ca2+-dependence of NOS isoforms. Hence, there must be other, 
as yet unknown, regions within the sequence of the NOSs, that contribute to the 
observed Ca2+-dependence of the NOS isoforms. 
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1.7.3 Intracellular Localization. Protein-Protein Interactions and Posttranslational 
Modification of NOS Isoforms 
Targeting to specific subcellular regions is an important mechanism for the regulation 
of various signaling proteins, including protein kinases, phosphatases, and G-proteins. 
This process of targeting is often under the control of posttranslational modifications 
(phosphorylation, acylation) and interactions between the targeted protein and 
structural proteins in the designated subcellular region (Blenis & Resh, 1993; Resh, 
1994; Resh, 1996). 
Phosphorylation is an important mechanism for the posttranslational 
regulation of several key proteins, including hormone receptors, transcription factors 
and several intracellular effector molecules (Krebs & Beavo, 1979). Phosphorylation 
of NOSs is of particular interest as it would allow cross talk between several different 
signaling pathways. Sequence analyses of NOSs reveal several consensus sequences 
for phosphorylation, including putative sites for cyclic AMP-dependent protein kinase 
(PKA), protein kinase C (PKC), cyclic GMP-dependent protein kinase (PKG), protein 
kinase B (PKB/AKT), casein kinase II and calmodulin-dependent kinase II (CaMKII). 
However, the functional significance of these sites has not been established in most 
cases. Earlier reported studies have been inconclusive and, in some cases, 
contradictory. However, great strides in the understanding of phosphorylation-
mediated regulation of eNOS in particular, has been made during the last year. 
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Due to the labile nature of NO and its important role in signaling, discrete 
subcellular localization of NOS proteins within the cell might be expected. Indeed, all 
three NOS isoforms have been shown to be localized to distinct subcellular regions, 
undergo posttranslational modifications and to interact with various cellular proteins. 
The regulation and functional significance of these processes is discussed in the 
following section. 
1.7.3.1 iNOS 
1.7.3.1.1 Subcellular Localization 
iNOS was originally purified as a soluble cytosolic protein (Stuehr et al., 1991), it 
has since become apparent that this enzyme may undergo tissue specific targeting to 
distinct subcellular organelles, although the evidence is somewhat limited. Inducible 
NOS can be found in the particulate subcellular fraction of freshly isolated tissue 
macrophages (Stuehr, 1997; Vodovotz et al., 1995), to a novel subcellular organelle 
that has been termed the "nitroxysome" (Vodovotz et al., 1995). The nitroxysome 
may serve to facilitate the NO-dependent killing of opsonized intracellular 
microorganisms. Nonetheless, factors which determine cytosolic vs. subcellular 
targeting of iNOS remain to be established. 
1.7.3.1.2 Protein-Protein Interactions 
Until recently it was thought that iNOS activity was regulated purely by 
protein degradation and substrate/co-factor availability. However, recent evidence 
points to the existence of an iNOS-associated regulatory protein. Murine macrophages 
were shown to express a 110 kDa protein (NAP 110), which directly interacts with the 
amino terminus of iNOS and inhibits catalytic activity by preventing the formation of 
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NOS homodimers (Ratovitski et al., 1999). The expression of this protein may be a 
mechanism by which macrophages protect themselves from the production of toxic 
levels of nitric oxide. Additionally, a proposed interaction between iNOS and the Rho 
family GTPase, Rac2 (Kone & Kuncewicz, 1998) has been suggested. This 
interaction was verified by co-immunoprecipitation of iNOS and Rac2 from 
lipopolysaccharide treated macrophages. Overexpression of Rac2 in RAW 264.7 
macrophage cells resulted in increased NO generation and suggested that Rac2 serves 
as an allosteric activator of iNOS. 
1.7.3.1.3 Posttranslational Modifications 
Although phosphorylation of iNOS has been demonstrated in cell culture (Nathan & 
Xie, 1994), the functional or cellular consequences have not yet been established. 
Overall the regulation of iNOS seems to occur mainly at the transcriptional level (See 
gene regulation section) and the evidence for posttranslational regulation is limited. 
1.7.3.2 nNOS 
1.7.3.2.l Subcellular Localization 
Like iNOS, nNOS was also originally purified as a soluble cytosolic protein (Bredt & 
Snyder, 1990), it has since been demonstrated that this enzyme may undergo tissue 
specific targeting to distinct subcellular regions. The regulation of this process is 
discussed below. 
Immunoelectron microscopy has demonstrated nNOS localization to the 
membrane regions of certain neuronal cells and colocalization with NMDA receptors 
(Brenman et al., 1996). A similar situation occurs in skeletal muscle where nNOS is 
also localized to the plasma membrane (Kobzik et al., 1994) and in macula densa 
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cells in the rat kidney where nNOS was specifically localized to the basolateral 
membrane (Tojo et al., 1999). 
1.7.3.2.2 Protein-Protein Interactions 
The localization of nNOS seems to occur by protein-protein interactions associated 
with a specific region of the N-terminal region of nNOS. The N-terminal sequence of 
nNOS is extended in relation to the other isoforms (300 amino acids) and it was noted 
that residues 18-97 (rat nNOS) contained a motif which is termed a "GLGF repeat" or 
"PDZ domain" (Hendriks, 1995). This motif is shared in common with proteins 
which localize to cell-cell junctions (Hendriks, 1995). 
In the case of neuronal cells, nNOS associates with the post synaptic density 
(PSD) proteins, either PSD-95 or PSD-93, depending on location within the brain 
(Brenman et al., 1996; Brenman et al., 1996). These interactions occur via the PDZ 
domain-PDZ domain interactions. These PSDs associate with NMDA receptors and 
the complex of NMDA receptor-PSD-nNOS may ensure that Ca2+ influx through 
NMDA receptors is specifically coupled to nNOS activation. Another nNOS-
associated protein, CAPON, has been identified in neural tissues and is thought to 
function by regulating the interactions of nNOS with PSO-95 (Jaffrey et al .• 1998). In 
the kidney nNOS and PSD-93 were similarly found to co-localize to membrane 
regions of macula densa cells (Tojo et al., 1999). 
nNOS associates via its PDZ motif with the membrane-bound dystrophin 
complex in skeletal muscle; this association is responsible for the localization of 
nNOS to the sarcolemmal membrane (Brenman et al., 1995). In this setting, it was 
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demonstrated that nNOS specifically associates with another PDZ domain containing 
protein, al-syntrophin, a component of the dystrophin complex (Brenman et ai., 
1996). This targeting seems to serve two purposes. Firstly, this localization may 
improve the efficiency of Ca2+ influx-mediated nNOS activation via calmodulin. 
Secondly, NO synthesis at the plasma membrane facilitates delivery of NO to 
surrounding cellular targets such as the vasculature (Bredt, 1998). 
nNOS also seems to interact with another protein, protein inhibitor of nNOS 
(PIN), this 89 amino acid protein inhibits nNOS by destabilizing the active 
homodimer (Jaffrey & Snyder, 1996). The PIN binding domain of nNOS (amino 
acids 161-245) is absent from the other NOS isoforms allowing for specific inhibition 
ofnNOS (Jaffrey & Snyder, 1996). The pattern of expression of PIN and nNOS in the 
different brain regions are nearly parallel, supporting the idea that PIN may function 
as an in vivo regulator of nNOS activity (Greenwood et ai., 1997). A neuroprotective 
role for PIN is also supported by studies which show that PIN is induced in the brain 
following global ischaemia (Gillardon et a1., 1998), defining regions that are resistant 
to ischaemic damage. 
A protein interaction of nNOS which has recently come to light is a proposed 
inhibitory interaction between nNOS and the 4th intracellular domain of the 
bradykinin B2 receptor (B2R) (Golser et ai., 2000). In this study, synthetic peptides 
corresponding to the 4th intracellular loop of this receptor were shown to form a 
complex with nNOS and inhibited NO formation with an ICso of =7 J.lM. These 
studies also demonstrated the coimmunoprecipitation of B2R and nNOS from human 
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embryonic kidney (HEK 293) cells that had been stably transfected with human 
nNOS; results in an in vivo interaction between nNOS and B2R. 
1.7.3.2.3 Posttranslational Modification 
The Regulation of nNOS by phosphorylation is poorly understood. Several studies 
have demonstrated the phosphorylation of nNOS, although the effects upon enzyme 
activity are inconclusive. One laboratory has reported that PKA, CaM Kinase II and 
PKC, can stoichiometrically phosphorylate nNOS in vitro, but only the activation of 
PKC resulted in phosphorylation in vivo (Bredt et al., 1992). The in vitro 
phosphorylation did not modify NOS activity, whereas in vivo phosphorylation by 
PKC resulted in depression of nitrite production, despite constant levels of NOS 
protein. These results would indicate that agonists which activate phospholipase C 
and the phosphoinositide pathway could send signals that both activate and inactivate 
NOS. The IP3-mediated calcium release, which activates NOS and the activation of 
PKC by diacylglycerol leads to the phosphorylation and inactivation of NOS. This 
could serve as a possible regulatory mechanism. However, other in vitro studies have 
demonstrated that only PKA' not PKC or CamKII, phosphorylate nNOS and that this 
PKA-mediated phosphorylation had no effect on activity (Brune & Lapetina, 1991). 
Studies by yet another group demonstrated phosphorylation by PKC and CaMKII 
with an associated increase or decreased in NOS activity, respectively (Nakane et al., 
1991). This was partially contradicted by experiments in which both PKA and c-GMP 
dependent protein kinase (PKG) phosphorylated nNOS and diminished catalytic 
activity in vitro. Cell culture studies using HEK-293 cells stably transfected with 
nNOS, showed phosphorylation of nNOS and a reduction of nitrite release following 
activation of PKG by 8-Bromo-cGMP (Dinerman et al., 1994). It has even been 
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suggested by one group that nNOS is capable of autophosphorylation, although the 
effect on activity was not studied (Watanabe et ai., 1996) and no follow up studies 
have been published. The discrepancies in these studies indicate the obvious need to 
further investigate the extent to which phosphorylation of nNOS occurs, conditions 
that promote phosphorylation, the effect on activity, and the physiological relevance. 
1.7.3.3 eNOS 
1.7.3.3.1 Subcellular Localization 
In contrast to the other two isoforms, the eNOS isoform was originally characterized 
as a membrane-associated protein, purified from a detergent solublized cell fraction 
(Pollock et ai., 1991). However, it has since been observed that eNOS targeting to the 
plasma membrane may be dynamically modulated in a reversible manner, a process 
which makes eNOS unique amongst NOS isoforms. 
eNOS is localized to specific regions of the plasma membrane termed 
caveolae (Shaul et ai., 1996). These are small invaginations in the plasma membrane 
characterized by a distinctive lipid composition and by the presence of the 
transmembrane protein caveolin (For reviews see Anderson, 1998; Anderson, 1993; 
Schlegel et al., 1998). Caveolae are a prominent feature ofthe endothelial cell plasma 
membrane and are also present in cardiac myocytes, adipocytes, and numerous other 
cell types. These caveolae appear to be sites for sequestration of signaling molecules 
such as receptors, G-proteins, protein kinases, as well as eNOS. 
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1.7.3.3.2 Protein-Protein Interactions 
Subsequent to the original observation of the caveolar localization of eNOS (Shaul et 
al., 1996), it was reported that eNOS is quantitatively associated with caveolin in 
endothelial cells and cardiac myocytes (Feron et al., 1996). Further studies revealed 
that this association leads to the inhibition of enzyme activity, and that a protein-
protein interaction takes place between the two proteins (Feron et al., 1998; Garcia-
Cardena et al., 1997; Ju et al., 1997; Michel et ai., 1997; Michel et al., 1997). 
Consensus sequences were identified within both proteins: the scaffolding domain of 
caveolin, a juxtamembranous 20 amino acid sequence in the C-terminal region of 
caveolin (Ju et al., 1997; Michel et al., 1997) and the caveolin binding motif, a 
peptide sequence that is rich in aromatic residues in the oxygenase domain of eNOS 
(Feron et al., 1998; Garcia-Cardena et al., 1997). The caveolin binding motif is shared 
with other caveolae-associated proteins, including H-ras, G-protein-a., the src family 
of proteins, mitogen activated protein kinase, epidermal growth factor receptor and 
protein kinase C, all of which also form inhibitory complexes with caveolin (Okamoto 
T et aI, 1998) (Shaul & Anderson, 1998). However, eNOS also has motifs present in 
the reductase domain which associate with the N-terminal end of caveolin (Ghosh et 
al., 1998; Ju et al., 1997). 
An interesting factor governing the eNOS-caveolin association,· is that CaM 
disrupts the complex in a Ca2+ -dependent fashion and completely reverses the 
inhibitory effect of caveolin (Michel et al., 1997). Caveolin serves as a competitive 
inhibitor of calmodulin-dependent eNOS activation (Michel et aI., 1997). Hence, 
calmodulin binding to the CaM binding sequence of the eNOS reductase domain 
activates the enzyme by promoting inter-domain electron flux, and in the process 
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displaces caveolin, relieving the inhibitory effects (Ghosh et al., 1998; Michel et al., 
1997). This process has also been shown to occur in intact cells with dissociation of 
the eNOS-caveolin complex promoting translocation of eNOS from the caveolae 
(Peron et al., 1998). 
Another protein which has been shown to directly interact with eNOS is heat 
shock protein 90 (HSP90) (Garcia-Cardena et al., 1998). This protein was originally 
termed eNOS-associated protein 1 (ENAP-l) (Venema et al., 1996) and was first 
detected in bradykinin treated endothelial cells. The interaction of eNOS with HSP90 
facilitates eNOS activation in endothelial cells following stimulation with a Ca2+ 
mobilizing agonist or shear stress application (Garcia-Carden a et ai., 1998) (See Ca2+ 
independent activation of eNOS Section). More recent evidence indicates that HSP-90 
(or an associated protein) promotes the calmodulin-dependent displacement of eNOS 
from the eNOS-caveolin complex (Gratton et at., 2000) .. 
The arginine transporter CAT-l represents another protein with which eNOS 
has been shown to interact. Coimmunoprecipitation of eNOS and CAT -1 has been 
demonstrated and both are localized to the membrane caveolae (McDonald et ai., 
1997). This particular interaction may help to explain "the arginine paradox". Simply 
stated, this paradox is that half-saturating arginine concentration for eNOS is < 10 J.1M 
(Liu et al., 1996; Palmer & Moncada, 1989; Pollock et at., 1991), while intracellular 
endothelial arginine concentration is typically millimolar (Block et al., 1995; Hecker 
et al., 1990; Mitchell et at., 1990), yet NO production by endothelial cells is 
dependent upon an adequate and continuing supply of extracellular arginine (Aisaka 
et at., 1989; Cooke et al., 1991; Taylor & Poston, 1994). At these levels of 
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intracellular arginine, eNOS should be saturated and the addition of extracellular 
arginine should not cause an increase in NO synthesis. An association between the 
CAT-l transporter and eNOS, facilitating a direct supply of exogenous arginine to 
eNOS provides explanation of this apparent paradox. 
Other caveolar proteins have also been implicated in interactions with eNOS. 
The bradykinin B2 receptor (B2R) and the angiotensin II type I receptor (AT.) have 
both demonstrated an ability to form an inhibitory complex with eNOS via the 4th 
intracellular loop region (Golser et al., 2000; Ju et al., 1998). In the case of the B2R-
eNOS interaction, a degree of functionality has been demonstrated. In vitro binding 
and co-immunoprecipitation studies demonstrate that the B2R interacts with eNOS in 
a ligand- and Ca2+-dependent manner (Ju et al., 1998). In the resting state, the receptor 
docks with eNOS in the caveolar membrane and participates in its inactivation. 
Activation of endothelial cells by bradykinin or Ca2+ ionophore promotes the 
dissociation of the eNOS-B2R complex coincident with the activation of eNOS (Ju et 
al., 1998). The site of binding to eNOS and the mechanism by which the B2R exerts 
this inhibition seems to be distinct from those by which caveolin-l interacts with, and 
inhibits eNOS. A similar in vitro interaction has been demonstrated between eNOS 
and ATt-glutathione-s-transferase fusion protein (Iu et al., 1998), however, no 
stimulus-dependent dissociation of the complex was demonstrated. If physiological, 
this process of effector activation by agonist-induced receptor-effector complex 
dissociation, represents a novel mechanism of receptor-dependent effector activation. 
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1.7.3.3.3 Posttranslational Modification 
eNOS is regulated by a complex pattern of covalent modification, including 
phosphorylation (Michel et al., 1993), myristoylation (Busconi & Michel, 1993; Liu 
& Sessa, 1994; Pollock et al., 1992), and palmitoylation (Robinson et al., 1995; 
Robinson & Michel, 1995). All of these covalent modifications have an impact on the 
subcellular targeting of eNOS, the effects of the individual modifications are 
considered below. 
1.7.3.3.3.1 Phosphorylation 
The phosphorylation of eNOS has been demonstrated in several studies and 
was, until recently, a very controversial area of eNOS regulation. Older studies using 
cell culture of metabolically 32P-Iabelled bovine arterial endothelial cells (BAECs) 
showed a several fold increase in basal phosphorylation of eNOS in response to 
bradykinin, ionomycin and the NO donor, sodium nitroprusside (Michel et al., 1993). 
The increase was time dependent and not associated with an increase in de novo 
synthesis of NOS protein. The bradykinin induced phosphorylation was inhibited by 
the calmodulin antagonist, H-7, but was unaffected by inhibitors of PKA, PKC, 
CaMKII or myosin light chain kinase (MLCK). This suggested that either the 
phosphorylation was dependent on the activation of eNOS or the kinase responsible 
was calmodulin-dependent (but not CaMKII). Phosphorylation of eNOS was also 
found to be associated with the translocation of the enzyme from the membrane 
bound to the cytosolic compartment. Under normal conditions, 90-95% of eNOS is 
located in the particulate fraction of endothelial cells. Upon stimulation with 
bradykinin, approximately 50% of total 3SS-methionine labeled enzyme and 85% of 
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the total phosphorylated enzyme was cytosolic. Both the phosphorylation and 
translocation are blocked by H-7. 
Another stimulus that has been demonstrated to cause activation and 
phosphorylation of eNOS is fluid shear-stress; this is caused by increases in blood 
flow through a blood vessel (Fleming et al., 1997). In the case of activation by fluid 
shear-stress, there is also some evidence for intracellular mechanisms which are able 
to influence eNOS activity at basal intracellular calcium levels. In studies using 
cultured endothelial cells, a disparity is apparent in the temporal relationship between 
the duration of the agonist-induced increases in intracellular calcium and the duration 
of activity of eNOS. The duration of the calcium response being significantly shorter 
than the duration of the subsequent period of eNOS activity (Fleming et al.~ 1997; 
Fleming et al., 1994). Studies suggest that this Ca2+-independent pathway for 
activation of eNOS is abrogated by tyrosine kinase inhibitors, such as erbstatin A 
(Ayajiki et al., 1996; Fleming et al., 1997). 
However, the lack of an identified eNOS kinase for either shear-stress or 
mitogenic stimuli was problematic in the interpretation of these results. Recent studies 
by two independent groups cleared up much of the confusion surrounding the 
regulation of eNOS by phosphorylation with their identification of at least one of the 
kinases involved (Dimmeler et al., 1999; Fulton et al., 1999). The relevant kinase 
turned out to be the recently cloned protein kinase B (Masure et al., 1999), also 
known as Akt. This kinase is activated via the phosphatidylinositol 3-kinase (PI-3K) 
pathway, resulting in the production of membrane-restricted second messenger 
molecules (polyphosphatidylinositides containing a 3'-phosphate) (for review see 
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Coffer et ai., 1998; Downward, 1998). Inactive Akt complexes interact with these 3-
phosphorylated inositides via a pleckstrin homology domain. Once targeted to the 
membrane via this motif, Akt becomes phosphorylated at two residues which relieves 
the intermolecular inhibition, allowing the activated complex to dissociate and modify 
its targets, eNOS included. In these studies, it was demonstrated that phosphorylation 
of serine 1179 (bovine sequence, 1177 in the human sequence) is involved in the 
activation of eNOS in response to stimuli including shear-stress and vascular 
endothelial growth factor (VEGF). Furthermore, transfection of a constitutively active 
mutant of Akt increased basal NO release from cultured endothelial cells, conversely 
transfection of an activation-deficient Akt attenuated the NO response to VEGF. 
Serine 1179 was confirmed as the site of phosphorylation by the transfection of a 
serine 1179 phosphorylation mimic (Aspartate 1179) or a mutant incapable of 
phosphorylation of this residue (Alanine 1179) which produced constitutive activity 
or an inability to be activated by the normal stimuli, respectively. Phosphorylation of 
this residue has since been shown to be required for the activation of eNOS in 
response to traditionally Ca2+ -independent stimuli, such as shear-stress, as well as 
Ca2+-dependent stimuli, such as insulin-like growth factor (Michell et ai., 1999), 
acetylcholine (Luo et ai., 2000) and VEGF (Dimmeler et ai., 2000; Fulton et al., 
1999; Michell et al., 1999). Additionally, mass spectrometry identified this site as the 
predominant site of phosphorylation in eNOS in response to shear-stress and that 
L Y294002, an inhibitor of phosphatidylinositol kinase, abrogated this 
phosphorylation by 97% and NO production by 68% (Gallis et ai.,· 1999). 
Interestingly, in cultured human cardiac myocytes, this site has been shown to be a 
target for phosphorylation by PKA (Chen et al., 1999). In vitro studies of a mutant 
eNOS mimicking phosphorylation of this site (aspartate 1179) showed a 2-4 fold 
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increase in the rates of NO production and cytochrome c reduction. This mutant also 
exhibited an increased resistance to inactivation by Ca2+-chelation. These results 
suggest that phosphorylation of this residue increases catalytic activity by increasing 
the rate of electron flux through the reductase domain and attenuating CaM 
dissociation from eNOS at sub-optimal levels of free Ca2+ (McCabe et al., 2000). 
1.7.3.3.3.2 Acylation 
As mentioned earlier, eNOS undergoes another form of posttranslational 
regulation, acylation, a characteristic which makes it unique amongst NOS isoforms. 
eNOS undergoes both myristoylation (Busconi & Michel, 1993; Liu & Sessa, 1994; 
Pollock et al., 1992), and palmitoylation (Robinson et al., 1995; Robinson & Michel, 
1995). Both modifications occur at the N-terminus of the enzyme with palmitoylation 
occurring at glycine 2 (Busconi & Michel, 1993; Sessa et al., 1993) and 
palmitoylation at cysteine residues 15 and 26 (Garcia-Cardena et al., 1996; Liu et al., 
1995). The exact contribution of each of these modifications to eNOS regulation is 
unclear at the present. 
From mutation studies it is known that myristoylation of eNOS is necessary 
for targeting the enzyme to the endothelial plasma membrane (Busconi & Michel, 
1993). However, this cannot control the reversible translocation of eNOS between 
membrane and cytosol, as myristoylation is typically cotranslational and irreversible, 
precluding its dynamic regulation by agonists (Resh, 1994). Also, for other 
myristoylated proteins, additional hydrophobic or electrostatic interactions (in 
addition to those between myristate and membrane lipids) are required for stable 
membrane association. Hence, reversible posttranslational modifications, such as 
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phosphorylation or palmitoylation, often regulate the subcellular localization of 
myristoylated proteins. 
As discussed earlier, it has been shown that eNOS undergoes phosphorylation, 
which is enhanced by agonists that also promote migration of the protein from the 
membrane to the cytosolic fraction (Michel et al., 1993). This raises the possibility 
that phosphorylation of eNOS at the cell membrane triggers its translocation to the 
cytosol. However, a mutant eNOS lacking the myristoylation site, still undergoes 
phosphorylation despite being restricted to the cell cytosol, precluding this as the 
cause of translocation. 
It was subsequently discovered that eNOS underwent reversible 
palmitoylation (Robinson et al., 1995). Due to the reversible nature of this acylation 
(Resh, 1994), it provides a potential mechanism for the regulation of agonist induced 
changes in the subcellular localization of eNOS and agonist induced changes in 
palmitoylation status have previously been described for G-protein-coupled receptors, 
such as the ~-adrenoceptor (O'Dowd et al., 1989). The loss of palmitate often 
correlates with protein redistribution to the cytosolic subcellular fraction, and agonists 
which activate G-protein (Is accelerate depalmitoylation of the protein (Wedegaertner 
& Bourne, 1994; Wedegaertner et al., 1995). There are striking similarities here for 
eNOS: bradykinin has been shown to promote depalmitoylation of eNOS in CH] 
palmitate-labeled endothelial cells (Robinson et al., 1995). The loss of the palmitate, 
and its hydrophobic interactions with the membrane, could be the determining factor 
in the bradykinin-induced translocation of eNOS to the cytosol. However, other 
groups, using a very similar system, have failed to identify this agonist-induced 
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eNOS-depalmitoylation (Liu et al., 1995) and concluded that palmitoylation plays no 
major role in the subcellular targeting of eNOS. 
The exact role of palmitoylation is complicated by the fact that very little is 
known about the systems which regulate the reversible palmitoylation of signaling 
proteins and few of the enzymes are known (Resh, 1996). However, from mutation 
studies it is known that a myristoylation-deficient mutant eNOS does not undergo 
palmitoylation (Robinson & Michel, 1995), possibly because the mutant is not 
targeted to the membrane, the presumed site for protein palmitoylation (Resh, 1994). 
This acylation-deficient mutant eNOS, lacking both myristate and palmitate, is 
entirely cytosolic. A mutant which is deficient in palmitoylation only, has a reduced, 
but not completely abrogated membrane targeting. This indicates that palmitoylation 
is not necessary for eNOS membrane association, but increases the efficiency and 
specificity of the process. 
1.7.3.4 The eNOS-CaveolinlCalmodulin Cycle 
From the data presented above, a model of the regulatory cycle for eNOS may be 
inferred. 
In resting endothelial cells, the association between eNOS and caveolin 
suppresses eNOS activity. After agonist activation, the increase in intracellular Ca2+ 
concentration promotes CaM binding to eNOS and the dissociation of the eNOS-
caveolin complex. The CaM association causes NO production until the intracellular 
Ca2+ levels decrease to a point where CaM dissociates from eNOS and the inhibitory 
eNOS-caveolin complex reforms. The precise details and sequence of events involved 
in the inactivation and recycling of the enzyme are unclear. This working, speculative 
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model has depalmitoylation of eNOS, after prolonged agonist activation, trigger the 
translocation of eNOS out of the caveolae. In this non-caveolar compartment, the 
enzyme undergoes phosphorylation, retargeting back to the caveolae, followed by 
dephosphorylation and palmitoylation. This leads to the inhibitory eNOS-caveolin 
complex reforming and the return to a resting level of NO production (Michel et a/., 
1997; Michel et a/., 1997). 
However, this is an incomplete model, the enzymes involved in the reversible 
palmitoylation of proteins are almost entirely unknown and the protein 
kinases/phosphatases relevant to eNOS regulation are poorly understood. The identity 
of the intracellular compartment to which eNOS trans locates is unknown, although it 
is likely that some depalmitoylated eNOS translocates to non-caveolar regions of the 
plasma membrane (Shaul et a/., 1996). Other plausible locales include the trans-golgi 
system, intracellular vesicles derived from caveolae, or a possible interaction with 
HSP90 (Garcia-Cardena et a/., 1998) . The interaction between eNOS and caveolin is 
facilitated by, but not dependent upon, eNOS acylation (Feron et al., 1998). 
Therefore, agonist-promoted depalmitoylation is unlikely to relieve the tonic 
inhibition of eNOS activity by caveolin and so it is suggested that palmitoylation may 
serve to stabilize eNOS on its return to caveolae, promoting the reformation of the 
eNOS-caveolin complex. 
The interactions of eNOS with CaM versus caveolin provide a novel example 
of the reciprocal regulation of enzyme activity by competing-allosteric protein-protein 
interactions. This extra level of control of enzyme activity may be particularly 
important for eNOS in caveolae, where CaM is abundant (Shaul et ai., 1996) and 
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where even small increases in intracellular Ca2+ could lead to eNOS activation if the 
eNOS-caveolin complex were not keeping the enzyme in check. Overall, the 
association between eNOS and caveolin is somewhat of a paradox, providing tonic 
inhibition of eNOS activity, and yet being required for the efficient activation of 
eNOS. 
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AIMS 
The molecular processes involved in the regulation of eNOS by Ca2+/CaM remain 
largely unknown. Inasmuch as Ca2+/CaM-dependent regulation remains intact in 
isolated NOS reductase domains, we looked for regions of eNOS for which there was 
no conserved structure in the highly homologous, yet CaM-independent, mammalian 
cytochrome P450 reductase (CPR). Sequence alignments reveal three major areas of 
eNOS for which there is no homologue in CPR: 
1) The 25-30 amino acid CaM-binding site (analogous to the transmembrane region 
of CPR). 
2) A peptide insertion of approximately 40 amino acids in length within the FMN-
binding domain. 
3) An extension of the C-terminus of approximately 40 amino acids in length. 
As these regions are not essential for the CPR-like reactions of the reductase domain, 
we hypothesized that they functioned in a coordinated manner with Ca2+/CaM to 
facilitate eNOS regulation. Herein we present studies to investigate the possible 
regulatory roles of the aforementioned regions of eNOS. 
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Chapter 2 
Materials and methods 
2.1 Materials 
Calmodulin was obtained from Calbiochem (La Jolla, CA) and (6R)-5,6,7,8 
tetrahydrobiopterin from Schirks laboratories (Jon a, Switzerland). [l125]CaM and 
[ 32Pl-Iabeled ATP were purchased from New England Nuclear (Boston, MA). 
Terrific broth, isopropyl-~-D-thiogalactopyranoside (lPTG) and chloramphenicol 
were purchased from Gibco BRL Products (Gaithersburg, MD). 2'5'-ADP-sepharose 
4B was purchased from Pharmacia Biotech (Piscataway, NJ) and GFB membrane-
clad 96-well microfiltration plates were from Millipore (Bedford, MA). Engineered 
calmodulin proteins and recombinant HSP90 were kind gifts from Dr. A. Persechini 
and Dr. N. Pavletich, respectively. Bovine heart cytochrome c, ~-lactoglobulin and all 
other chemicals were purchased from Sigma and of the best grade available (St. 
Louis, MO). 
2.2 Mutagenesis of wildtype eNOS 
Mutagenesis of wild type bovine eNOS cDNA was performed using the PCR-based 
QuiKChange™ site-directed mutagenesis kit (Stratagene; La Jolla, CA). Briefly, the 
mutagenesis of eNOS cDNA was carried out in the pCW-eNOS expression vector 
using two synthetic oligonucleotide primers (forward and reverse) to introduce the 
desired mutation into wildtype eNOS cDNA. The oligonucleotide primers, each 
complimentary to opposite strands of the vector, extend during cycling by means of 
. . 
Pfu DNA polymerase. On incorporation of the oligonucleotide primers, a mut~ted 
plasmid containing staggered nicks is generated. Following temperature cycling, the 
product is treated with endonuclease Dpn I (target sequence: 5'-Gm6ATC-3'). This 
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endonuclease is specific for methylated or hemimethylated DNA and is used to digest 
the parental DNA template, selecting for the mutation-containing synthesized DNA 
(DNA isolated from most E. coli strains is methylated and therefore susceptible to 
Dpn I digestion). The nicked vector DNA, containing the mutation, is then ligated and 
transformed into competent DH5cx E. coli. Introduction of the desired stop codon was 
confirmed by dideoxynucleotide sequencing, performed by the Cornell University 
DNA Sequencing Facility. The sequence of the specific primer pairs for each 
individual mutation are shown in table 2.1. 
2.3 eNOS expression and purification 
Bovine endothelial NOS (eNOS) was purified from Escherichia coli harboring 
pGroELS and pCW-eNOS expression vectors (Martasek et al., 1996). An overnight 
culture of pCW-eNOS/pGroELS was used to inoculate 0.5 liter volumes of terrific 
broth containing ampicillin (50 Jlg/ml) and chloramphenicol (35 Jlg/ml) in 2.8 L 
Fembach flasks. Cultures were grown to an OD600 of 0.8 at 37°C with shaking at 250-
300 rpm. To enhance heme biosynthesis, o-aminolevulinic acid was added (0.5 mM 
final) and cultures grown for another hour. Riboflavin (3 JlM final) and ATP (1 roM 
final) were then added to the cultures and eNOS expression was induced with IPTG 
(0.5 mM final). Cultures were then grown in the dark at 25°C and bacteria were 
harvested after 48 hours by centrifugation. Pellets were stored at -70°C until eNOS 
purification. Purification of eNOS was accomplished by a modification of the method 
of Martasek et al.(Martasek et al., 1996). Briefly, eNOS pellets were resuspended in 
ice-cold buffer A (100 mM Tris-HCI, pH 7.6, 1 mM EDTA, 1 mM DTT, 10% 
glycerol, 100 mM NaCI, 1 roM phenylmethylsulfonyl fluoride,S Jlglrnl pepstatin A, 5 
Jlg/mlleupeptin and 20 roM CHAPS), lysed by pulsed sonication, and then 
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eNOS 
Mutant 
Cd27 
RRKRKdel 
RRKRKsub 
Ala 635/636 
Ala 494 
Sequence of Primers 
(f) 5'-CTCCTGCAGGGAAAATCACGGGTACGTATACG-3' 
(r) 5'-CGTATACGTACC CAGTGATTTICCCTGCAGGAG-3' 
(f) 5' -CAGACCCGCTGGTGTCCTCCTGGGAGTCCAGCAACACAGACAGTG-3' 
(r) 5' -CACTGTCTGTGTIGCTGGACTCCCAGGAGGACACCAGCGGGTCTG-3' 
(f) 5' -TGGTGTCCTCCTGGGCGGCGGCGGCAGCGGAGTCCAGCAACAC-3' 
(r) 5' -GTGTIGCTGGACTCCGCTGCCGCCGCCGCCCAGGAGGACACCA-3' 
(f) 5' -GGAAGAGAAAGGAGGCCGCCAACACAGACAGCGC-3' 
(r) 5' -GCGCTGTCTGTGTIGGCGGCCTCCTTICTCTICC-3' 
(f) 5' -GGCATCACCAGGAAGAAGGCCTTT AAGGAAGTGGCCAAC-3' 
(r) 5' -GTIGGCCACTICCTI AAAGGCCTTCTTCCTGGTGAT -3' 
Ala 635 I (f) 5'-GGAAGAGAAAGGAGGCCAGCAACACAGACAGCGC-3' 
(r) 5' -GGAAGAGAAAGGAGGAGGAAAGCAACACAGACAGCGC-3' 
Glu 635 I (f) 5' -GGAAGAGAAAGGAGCAAAGCAACACAGACAGCGC-3' 
(r) 5' -CACTGTCTGTGTIGCTGGACTCCCAGGAGGACACCAGCGGGTCTG-3' 
Table. 2.1. Sequences of primer pairs for individual eNOS mutations. (f = forward, r = reverse). 
centrifuged to sediment cell debris (120,000 x g, for one hour). The supernatant was 
applied to a 2'5'-ADP sepharose 4B column that had been pre-equilibrated in buffer 
B (100 mM Tris-HCI, pH 7.6, 0.1 mM EDTA, 1 mM DTT, 10% glycerol, 100 mM 
NaCI). The column was washed with 20 column volumes of buffer B and again with 
20 column volumes of buffer B containing high salt (600 mM NaCl). eNOS Protein 
was eluted with high salt buffer B that additionally contained 10 mM NADPH. The 
NADPH eluate was diluted to 100 mM NaCl concentration in buffer B by repeated 
concentration/dilution using a centrifugal filter device (Biomax-100K, Millipore). The 
concentrated and desalted NADPH eluate was further purified by affinity 
chromatography on a calmodulin-sepharose column as previously described (Black & 
Ortiz de Montellano, 1995). Purification of nNOS was achieved by an identical 
method using pCW-nNOS/pGroELS transformed BL21 E. coli. iNOS was prepared 
using BL21 E. coli containing pCW/iNOS and an additional calmodulin expression 
vector (Xia et al., 1998). Due to the cotranslational incorporation of calmodulin, 
purification of iNOS was performed using the 2'5' -ADP-sepharose step only. Protein 
purity was assessed by SDS-polyacrylamide gel electrophoresis using Coomassie 
staining. Quantification of NOS protein was determined spectrophotometric ally, 
based on an extinction coefficient of 74 mmor1cm-1 for A444-ASSO of the dithionite-
reduced CO-bound eNOS heme-chromophore (Adak et ai., 1999). 
2.4 SDS-PAGE 
SDS-PAGE was carried out using precast 8-16% polyacrylamide gels (Novex, 
San Diego. CA) and were stained with Coomassie blue. Samples were prepared in gel 
loading buffer (63 mM Tris-HCI, 10 % glycerol, 2% SDS, 0.0025% bromophenol 
blue, pH 6.8) and denatured by boiling (95°C, 15 min). Electrophoresis was 
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performed in SDS running buffer (25 mM Tris-HCI, 192 mM glycine, 0.1% SDS, pH 
8.3) at a constant amperage of 30 rnA. 
When NOS dimer stability was assessed by low-temperature SDS-PAGE, 
samples were prepared in gel loading buffer, but were not denatured by boiling. 
Electrophoresis was performed in SDS running buffer and the electrophoresis tank 
was placed in an ice-bath. Separation was performed at a constant voltage of 185 V. 
2.5 Spectrophotometry of the CO-bound heme chromophore 
Spectral data were recorded on a Beckman DU-7500 spectrophotometer. 
Scans of dithionite-reduced CO-bound proteins were taken in CO-saturated buffer (40 
mM HEPES, pH 7.6, containing 10% glycerol, 1 mM DTT and 100 mM N aCI). The 
ferrous-CO adduct absorbing at 444 nm was used to quantitate the hemoprotein 
content using an extinction coefficient of 74 mmo}"lcm-1 (A444-Asso) (Adak et al., 
1999). 
2.6. Assays of enzyme activity 
2.6.1 Griess assay 
NO production was deduced from accumulation of the stable oxidation 
product nitrite, as determined using the Griess assay. Assays were carried out in a 96-
well microplate format with 100 J.11 total sample volume. All wells contained L-
arginine (1 mM), calmodulin (100 nM), CaCl2 (100 J.1M), BH4 (10 J.1M), Tris-HCI (50 
mM, pH 7.6) and eNOS at specific concentrations. Reactions were initiated by the 
addition of NADPH (1 mM). After one hour at 3rC, 10 J.11 of lactate dehydrogenase 
was added (20 J.11 LDH slurry in 0.5 ml of 500 mM pyruvate) and samples were 
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incubated at 37°C for 15 min. Griess reagent (freshly made 1: 1 mix of 1 % 
sulfanilamide in 5% phosphoric acid and 0.1 % N-(1-napthyl)-ethylenediamine) was 
then added as a 100 Jll volume and Asso was determined within 10 min. The level of 
nitrite in samples was assessed by comparison with sodium nitrite standards. 
For experiments that assess the Ca2+-dependence of NO synthesis, reactions 
were carried as above, except that reaction buffer was substituted (10 mM MOPS, 100 
mM KCl, pH 7.2), containing varying ratios of EGTA-Ca2+ to give desired Ca2+ 
concentrations (described separately). 
2.6.2 Assay of NOS activity by myoglobin or NADPH oxidation 
NOS activity was measured in 96-well microtiter plates at 37°C based on the 
kinetics of NADPH consumption or the oxidation of Fe2+-myoglobin to Fe3+_ 
myoglobin (Gross, 1996). For NADPH consumption measurements assay mixtures 
contained L-arginine (1 mM), calmodulin (100 nM), CaCl2 (100 JlM), BH4 (10 JlM), 
Tris-HCI (50 mM, pH 7.6) and eNOS at specific concentrations. Reactions were 
initiated by the addition of 20 pmole of nNOS, 10 pmole of eNOS, or 15 Jlg of rat 
iNOS-rich cytosol. NADPH consumption was determined from the rate of decrease in 
A340, measured at 15 second intervals for a period of 30 min in a kinetic microplate 
spectrophotometer (Molecular Devices; Menlo Park, CA). The rate of decline in A340 
measured when NOS was omitted from incubates was subtracted from all values. 
Samples in which iNOS activity was measured based Fe2+-myoglobin oxidation were 
prepared as above, but additionally contained 15 Jlg of iNOS-rich cytosol and Fe2+_ 
myoglobin (40 JlM). Fe2+-myoglobin oxidation was determined by monitoring the 
change in A420 in a kinetic 96-well microplate spectrophotometer. Preparation of Fe2+_ 
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myoglobin was attained by treatment with sodium dithionite and purification by size 
exclusion chromatography using a 0-25 column (Pharmacia). 
2.6.3 Reduction of cytochrome c and ferricyanide 
Assays of eNOS reductase domain activity were carried out in 96-well plate 
format with a total reaction volume of 100 ~l. Reaction progress was monitored 
continually at IS-sec intervals at Asso and A4os, for cytochrome c and ferricyanide 
reduction, respectively. Assay buffer was added to wells (40 roM HEPES, pH 7.6, 0.1 
mg/ml bovine serum albumin, 250 nM CaM, 0.6roM EDT A, 10 units/ml superoxide 
dismutase, and 10 units/ml catalase) and either 100 ~M bovine heart cytochrome c or 
1 roM potassium ferricyanide. To assess the dependence on CaM binding, maximum 
CaM binding was elicited by addition of 0.83 roM Ca2+ to relevant samples. 
Following addition of the desired quantity of eNOS, substrate reduction was initiated 
by addition of NADPH (100 ~M final concentration). 
2.6.4 Calcineurin Activity Measurement 
Activity of the CaM-dependent phosphatase, ca1cineurin (protein phosphatase 
2B) was monitored in a 96-well kinetic microplate spectrophotometer at 37°C, based 
on the rate of hydrolysis of the artificial substrate p-nitrophenyl phosphate (pNPP). 
Incubation mixtures contained Tris-HCI (50 roM, pH 7.6), CaCl2 (100 ~M), CaM 
(100 nM), 2-mercaptoethanol (0.1 %) and pNPP (40 roM) in a 100 ~l reaction 
volume. Reactions were initiated by the addition of calcineurin (40 pmole), and 
activity was monitored kinetically at A405 for 60 min at 15 second intervals. Assay 
blanks additionally contained EOT A (10 mM), resulting in >90 % inhibition of 
activity. 
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2.7 Assays of NOS-ligand binding 
2.7.1 Assay of [12sIJ-Calmodulin Binding to NOS 
CaM binding to eNOS was analyzed in 96-well microfiltration plates 
containing GFB membranes that had been prewashed with binding buffer (10 mM 
MOPS, 100 mM KCI, 100J.1M CaC12, and ~-lactoglobulin 0.5%, pH 7.2). Incubations 
contained binding buffer, BH4 (10 JlM) and DTT (1 mM) supplemented with desired 
concentrations of [l2SIl-CaM in a total volume of 100 Jll. In some cases, Ca2+ -buffer 
solutions were additionally added. Binding reactions were initiated by the addition of 
eNOS at specific concentrations and proceeded for 20 minutes at 25°C. Binding was 
terminated by vacuum filtration and filters were washed twice with 100 Jll of ice-cold 
assay buffer. Filtration plates were air-dried under vacuum and 25 III of scintillation 
cocktail was added to each well (Optiphase Supermix, Wallac). Bound radioactivity 
was determined in a Microbeta Plus 96-well liquid scintillation counter (Wallac). 
Specific binding of CaM was defined as the component of total binding, which was 
lost when samples were co-incubated with excess calcium-chelator (5 mM EGT A) or 
IOOO-fold molar excess of unlabeled CaM. 
2.7.2 [mIl-CaM association and dissociation rate measurement 
Association of CaM to NOS was detennined as described above. except that 
incubations were terminated after the desired interval by rapid filtration. For the 
estimation of dissociation rates, NOS was pre-incubated (15 min) with [12SIl-CaM, 
prior to addition of a 3000-fold molar excess of unlabeled CaM, to initiate 
dissociation. The reaction was terminated after the desired interval by rapid filtration. 
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2.7.3 Assay of [3Hl-N~itro-L-Arginine binding 
Assays of [3H]NGNitro-L-arginine binding were performed in 96-well 
polyvinylidene difluoride microfiltration plates (Millipore, Bedford, MA) in a similar 
manner to that described for [125I]_CaM. Reaction mixture was identical to that used 
for [125I]_CaM, except [3H]NGNitro-L-arginine was substituted for [125I]_CaM. 
Subsequent equilibration and washing steps were performed as decribed. 
2.7.4 Preparation of Calcium Solutions 
Stock solutions of "zero" free Ca2+ (10 mM MOPS, 100 mM KCI, 10 mM 
EGTA, pH 7.2) and 40 J.1M free Ca2+ (10 mM MOPS, 100 mM KCI, 10 mM EGTA, 
10 mM CaCI2, pH 7.2) were prepared. Solutions of defined free Ca2+ (0-40 J.1M) were 
then prepared by mixing varying ratios of the two solutions (Fabiato & Fabiato, 
1979). The free-Ca2+ concentration was quantified by ratiometric fluorometry using 
fura-2. 
2.8 PKA-mediated phosphOlylation of eNOS 
NOS (lOpmoles) was incubated at 25°C for the indicated time period in PKA 
phosphorylation buffer (2mM MgCI2, 100J.1M CaCI2, 50mM Tris-HCI, pH 7.6) 
containing CaM (lOOnM), BH4 (lOJ.1M), PKA (5units) and "(- labeled 32 P-ATP 
(lOOJ.1M) in a final reaction volume of lOOIl!. At relevant time points, aliquots (20IlI) 
were removed, mixed 1:1 with SDS-gelloading buffer and heated (95°C, 10 mins) to 
stop the reaction. Samples were then run on 8-16% SDS polyacrylamide gels a~d 
coomassie stained. Autoradiography was performed on dried gels to assess 32 P 
incorporation into eNOS and appropriate gel slices were excised for quantification by 
liquid scintillation counting. 
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For studies assessing the effect of phosphorylation on eNOS activities, 
phosphorylated eNOS was prepared in 400 pmole quantities (1 pmole/Jll) and then 
frozen for subsequent use in NOS assays. Phosphorylation was confirmed by 
phosphate incorporation using 32P-labeled ATP in a scaled down sample, under 
identical conditions. 
2.9 Limited proteolysis of NOS proteins 
Limited proteolysis was performed on incubates containing 40 pmol of 
recombinant NOS purified from E. Coli. Samples were preincubated at room 
temperature for 15 min in a 100 J.11 volume containing: 50 mM Tris, pH 7.6, 1 mM 
DDT, 10 J.lM CaM, 100 J.lM CaCI2, with or without 10 mM EGTA. Proteolysis was 
initiated by the addition of 20 microunits of L-I-tosyl-amido-2-phenylethyl 
chloromethyl ketone-immobilized trypsin (Sigma) per pmol of NOS. Samples 25 J.lI 
were collected after 0, 5, 10 and 20 min, and proteolysis was terminated by boiling 
with an equal volume of 2X SDS gel-loading buffer. Peptide products were resolved 
by gradient SDS-polyacrylamide gel electrophoresis and visualized by staining with 
Coomassie Blue. Accurate molecular mass determination of tryptic fragments was 
performed by mass spectrometry at the Weill Medical College Mass Spectrometry 
Core Facility by matrix-assisted laser desorption ionization time of flight (MALDI-
TOF) mass spectrometry. 
2.10 Protein modeling 
Molecular modeling of the FMN binding module of nitric oxide synthase 
isoforms was done using the Insight II, Homology and Discover programs from 
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Biosym (BIOSYMlMolecular Simulations, San Diego, CA) running on a Silicon 
Graphics Indigo 2 workstation. After alignment of NOS sequences with homologous 
FMN binding proteins of known structure, structurally conserved region (SCR) boxes 
were created, corresponding to conserved regions of secondary structure and regions 
directly involved in FMN binding. These regions were characterized by high positive 
scores as evaluated by Dayhoffs mutation matrix (Dayhoff et al., 1983). After 
assignment of coordinates in the SCR regions, the loop regions between the SCR 
boxes were modeled by searching the Brookhaven protein database. The crude model 
structure was relaxed to a sterically and energetically reasonable state using the 
Discover program (BIOSYMlMolecular Simulations) for molecular mechanics and 
dynamics calculations. This includes splice repair to remove unrealistic structural 
features at SCR-Ioop junctions and N-terminal extensions, and structural optimization 
to remove steric overlaps. Energy minimizations were begun using the steepest 
descent method; this was replaced by the conjugate gradient method as convergence 
was approached. 
2.11 Peptide synthesis 
Synthetic peptides were obtained from SynPep (Dublin, CA) and other 
commercial suppliers. Purity was assessed to exceed 80% as evaluated by high 
performance liquid chromatography and mass spectrometry. Predominant impurities 
differed from the desired product by one amino acid residue, the result of 
incompletely coupled synthesis. 
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2.12 Electrospray Ionization Mass Spectrometry 
Electrospray ionization mass spectrometry using selected ion recording (SIR-
, 
MS) was performed at the biopolymer mass spectrometry research core facility at 
Weill Medical College. Analysis was performed using a Quatro II (Micromass, U.K.) 
ESI- mass spectrometer 
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Cbapter3 
IDENTIFICATION AND CHARACTERIZATION OF AN 
• AUTOINHIBITORY CONTROL ELEMENT WITHIN THE FMN-BINDING 
DOMAIN OF CALCIUM-REGULATED ISOFORMS OF NITRIC OXIDE 
SYNTHASE 
3.1 Introduction 
Nitric oxide synthases (NOSs) comprise a family of three calmodulin-
dependent isoforms that are functionally distinguished by their modes of regulation. 
The two constitutively expressed isoforms of NOS (cNOSs), originally purified from 
neuronal (nNOS) and endothelial cells (eNOS), remain dormant until 
calcium/calmodulin (Ca2+/CaM) . binding is elicited by transient elevations in 
intracellular Ca2+ (Nathan & Xie, 1994; Sessa, 1994). This Ca2+-dependent mode of 
regulation provides pulses of NO for the moment-to-moment modulation of vascular 
tone/neurosignaling. In contrast, the activity of the imunostimulant-induced isoform 
of NOS (iNOS) is Ca2+-independent, providing continuous high-output NO generation 
for the purpose of host defense. This Ca2+ -independence is due to the remarkably high 
affinity CaM-binding exhibited by iNOS, indeed, extreme conditions (boiling in 1 % 
sodium dodecyl sulphate) are required to cause the dissociation of CaM from iNOS 
(Cho et al., 1992). 
Whether a given isoform binds CaM in a Ca2+-dependent or -independent 
manner has been assumed to be solely due to inter-isoform differences in the amino 
acid sequence of the 20-25 amino acid CaM-binding site. However, this view has 
proven to be restrictive, given that chimeric eNOS and nNOS which have been 
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engineered to contain the CaM-binding site of iNOS, still require Ca2+ for full activity 
(Ruan et al., 1996; Venema et al., 1996). Therefore regions other than the CaM-
binding site must contribute, at least in part, to the Ca2+-dependence exhibited by the 
various NOS isoforms. Because regulation of enzyme systems by Ca2+/CaM typically 
involves the displacement of an intrinsic autoinhibitory polypeptide (Jarrett & 
Madhavan, 1991), we hypothesized that the binding of Ca2+/CaM to cNOSs may 
similarly trigger activation by displacing an autoinhibitory control element. This 
chapter describes studies in which we identify a 40-45 amino acid insertion peptide 
within the FMN-binding domain of cNOSs, and investigate its role in enzyme 
regulation. 
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3.2 Results 
3.2.1 Expression. purification and characterization of eNOS. nNOS and iNOS 
3.2.1.1 Expression and Purification 
In order to investigate the regulation of the NOS family of proteins it was first 
necessary to express and purify the various NOS isoforms for in in vitro 
characterization. Expression and purification were accomplished using an established 
E. coli based expression system (Martasek et al., 1996; Roman et al., 1995) and 
purification was accomplished using two sequential chromatography separation 
steps, as described in methods. Proteins were purified to ... 90% homogeneity, as 
assessed by SOS-polyacrylamide gel electrophoresis (SOS-PAGE) (Fig. 3.1) and 
were of the predicted molecular weights for iNOS (130 kOa), nNOS (160 kDa) and 
eNOS (135 kDa) (Sessa, 1994). 
3.2.1.2 Characterization 
These purified NOSs were then characterized in order to assess functionality. 
As all NOS proteins are obligate homodimers, the ability of the purified proteins to 
form stable dimers was assessed using low temperature SOS-PAGE. As is shown in 
Fig. 3.2, each of the expressed NOS isoforms existed predominantly in homodimeric 
form. Functional NOS proteins contain a heme-group (protoporphyrin IX) held in 
place by planar linkages to four pyrole nitrogens and a conserved cysteine residue in 
the oxygenase domain (penta-coordinate). Ouring NO catalysis ferrous iron binds 
molecular oxygen as the sixth axial ligand. Functional incorporation of heme into 
NOS proteins can be assessed by spectrophotometry using the ability of CO-bound 
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reduced heme to produce a cytochrome P450-like absorption peak at 446 nm (Fig 3.3, 
panels A, Band C, for iNOS, nNOS and eNOS, respectively). All of the purified 
proteins exhibited a P450-like spectrum, indicative of functional heme incorporation. 
To assess the extent to which recombinant NOSs could in fact synthesize NO, 
specific activity of the proteins was measured using the Griess assay for nitrite/nitrate 
accumulation. Determinations were based upon the average of at least two 
preparations of each isoform, assayed in triplicate. The NOSs displayed specific 
activity values of 660 ± 53, 516 ± 83 and 135 ± 17 nmoles/minlmg NOS protein for 
iNOS, nNOS and eNOS, respectively (Fig. 3.4). These specific activities compare 
well with the optimal values from the literature (Martasek et ai., 1996; Roman et ai., 
1995; Stuehr et ai., 1991; Wu et ai., 1996). Due to the differences in regulation by 
Ca2+/CaM, an important functional test was to establish the Ca2+-dependence for 
activation by CaM of the three NOS isoforms. As shown in Fig. 3.5, iNOS displayed 
full activity at all levels of free Ca2+ tested. In contrast, activity of cNOSs were 
dependent upon elevated levels of free Ca2+, ECso values for eNOS and nNOS were 
460 nM and 410 nM, respectively (Fig. 3.5). 
The above studies confirmed that purified NOS proteins were dimeric, 
contained heme in the correct orientation, produced NO and were regulated by Ca2+-
levels in the predicted fashion. These findings demonstrated the suitability of purified 
recombinant NOS isoforms for subsequent investigations of enzymatic regulation. 
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Fig. 3.1. SDS-polyacrylamide gel electrophoresis of purified recombinant 
NOSs. Recombinant NOS proteins were all purified to > 90% homogeneity and 
showed approximate molecular weights of 135 kDa (eNOS), 160 kDa (nNOS) and 
130 kDa (iNOS). 
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Fig. 3.2. Stability of NOS homodimer by low-temperature SDS-
polyacrylamide gel electrophoresis. Low temp SDS-PAGE was 
performed as described in Methods. The apparent molecular weight of > 
200 kDa indicated the formation of stable NOS homodimers for all three 
isoforms. 
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Fig. 3.3. P450 spectra of eNOS, nNOS and iNOS. The CO-bound, dithionite 
reduced spectra of eNOS (panel A), nNOS (panel B) and iNOS (panel C) were 
obtained as described in methods. 
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Fig. 3.4. Rates of NO synthesis of the three NOS isoforms. All experiments 
were carried out using 8 pmoles of NOS, 250 nM CaM and an optimal Ca2+ 
concentration (l00 J.lM). CaM-free measurements of activity were obtained in the 
presence of 5 mM EGT A and rates are the mean of two separate preparations of 
each enzyme assayed in triplicate ± SEM. 
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Fig. 3.5. Ca2+ -dependence of the three isoforms of NOS. NOS (8 pmoJes) in 
the presence of 100 nM CaM was incubated in a range of Ca2+ concentrations, 
as described in Methods . NO ynthesis was a e sed using the Grie as ay and 
blank activ ity was determined in the presence of 10 mM EGT A. Activity i 
expressed as a percentage of the maximum activity obtained at the highe t 
Ca2+-concentration used (::::: 1.8 11M). Value shown are the mean of two 
separate preparations a sayed in triplicate ± SEM. 
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3.2.2 Identification and Characterization of the Autoinhibitory Control Element of 
cNOSs 
It is evident that the large multidomain NOSs evolved from a series of gene 
duplication, fusion and rearrangement events; this process allowed the incorporation 
of functional modules into NOSs from apparent ancestral proteins (Liu & Gross, 
1996; Masters et ai., 1996). The overall structure of NOS can be grossly divided into 
an N-terminal oxygenase domain and a C-terminal reductase domain, bridged by a 
20-30 amino acid CaM-binding domain (Sheta et ai., 1994) (see Fig. 1.1). The 
oxygenase domain has binding sites for arginine, heme and BH4• The C-terminal 
reductase domain of NOSs shows a good degree of homology to NADPH-cytochrome 
P450 reductase (CPR), noting conserved regions corresponding to the binding sites 
for FAD, FMN and NADPH (Bredt et al., 1991). Structural homologues of the FMN-
binding modules of both NOSs and CPR can be found in the bacterial flavodoxins, 
small FMN-binding proteins that function as electron carriers (Porter, 1991). 
Similarly, homologies for the FAD and NADPH binding domains can be found in 
chloroplast ferredoxin-NADP+ reductase and other related FAD-containing proteins. 
3.2.2.1 Sequence Alignments 
High resolution crystal structures of at least five flavodoxins have been solved 
by X-ray diffraction (Watenpaugh et ai., 1973), revealing three distinct regions that 
are involved in binding of the FMN moiety. Although only one of these regions was 
initially identified in nNOS (Bredt et ai., 1991), each has a corresponding homologue 
in NOSs. Homology-based alignments of the FMN-binding domains of NOSs and 
flavodoxins performed by Dr. J.C. Salerno (Salerno et al., 1997) identified these 
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regions in each NOS isoform. This was followed by the identification of conserved 
secondary structural elements in NOS that correspond to elements present in the 
flavodoxins, primarily by their homology based on mutational matrix criteria 
(Dayhoff et al., 1983). 
Fig. 3.6 (Panel A) shows the structurally based alignment of representative 
members of the NOSs, bacterial flavodoxins and CPRs, indicating the conserved 
regions that participate in the binding of FMN. Despite conspicuous sequence 
homology, it is obvious that a major insertion of approximately 45 amino acids is 
uniquely present within the mammalian cNOSs. Inspection of the protein database 
reveals that this insertion is conserved in the FMN-binding domains of all reported 
cNOSs of both mammalian and invertebrate origin (Fig. 3.6, panel B). The insertions 
present in the FMN-binding domains of the cloned insect cNOSs from Rhodnius 
prolixus (Yuda et al., 1996) and Drosophila melanogaster (Regulski & Tully, 1995) 
are somewhat larger than their mammalian counterparts (54-63 amino acids), but the 
sequences still share regions of conservation with the smaller mammalian insertion. 
Expanding the alignment to include the dozens of known related FMN-binding 
proteins reveals that only cNOSs contain such an insertion (alignments not shown). 
Furthermore, like the cNOSs, the FMN-binding domain of the Ca2+-independent 
iNOS shows marked homology to the FMN-binding motifs of the related proteins, but 
lacks the peptide insertion present within the cNOSs. Hence, the insert correlates with 
Ca2+/CaM control and represents the single most prominent difference between cNOS 
and iNOS amino acid sequences, when considered over their entire length. 
104 
3.2.2.2 Structural Modelin~ 
The lack of structural information concerning the reductase domain of any of 
the NOS isoforms is a hindrance to the elucidation of the function of this peptide 
insertion. However, the availability of solved X-ray structures for flavodoxins allows 
us to position the insertion in three-dimensions relative to the CaM-binding site. 
Homology-based molecular models have been constructed for the FMN-binding 
domains of cNOSs, iNOS, and CPR (for which a crystal structure has now been 
solved), which could be relaxed to a sterically and energetically reasonable state. 
After relaxation of these FMN-binding domain models, no steric overlaps were 
evident, and energies were approximately -300 kcal, comparable or lower than that of 
the reference flavodoxin crystal structure. 
As shown in Fig. 3.7 (panel A), the backbone structure of iNOS and CPR are 
virtually superimposable on the backbone of the solved crystal stqlcture of the closest 
solved structural homologue to the FMN-binding domain of NOSs (Desulfovibrio 
vulgaris flavodoxin). The structure, a Rossmann fold motif (Rossmann et al., 1974), 
is a five stranded parallel ~-sheet with the FMN-binding site along one edge. 
Homology predicts that two aromatic residues in murine iNOS, Phes87 and Tyr62S, are 
stacked above and below the FMN ring system. 
Fig. 3.7 (panel B) shows the corresponding backbone structure of eNOS 
(nNOS is extremely similar, but is not shown); the eNOS backbone is essentially 
superimposable over the homologues shown in the previous panel. However, the 
insertion, having no structural homologue, is shown projecting from the upper edge of 
the sheet opposite the FMN-binding site. Structurally, it corresponds to the 
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replacement of a tight 5-10 residue (l~ ~ loop with a 45 amino acid structure, the 
insertion being approximately one third of the overall size of the FMN-binding 
module. Unfortunately, no conformation can be assigned to the insertion region due to 
the lack of a resolved homologue; the mock structure shown is provided merely to 
demonstrate relative position and size. 
The CaM-binding site is immediately N-terminal to the FMN-binding domain 
(this location is tipped white in panel A). In the CaM-bound conformation, the CaM-
binding site would predictably adopt a helical conformation (O'Neil & De Grado, 
1990; Vorherr et ai., 1993) and steric constraints suggest that it extends almost 
directly away from the FMN-binding module. Fig. 3.8 shows models of the FMN-
binding domains of iNOS (panel A) and eNOS (panel B) with CaM (yellow ribbon, 
derived from the structure of Vorherr et ai. (Vorherr et ai., 1993» positioned above 
the N-terminal strand of the FMN-binding domain. There are 7-8 residues between 
the end of the CaM recognition site proper and the start of the initial ~-sheet; 2-3 
residues at each end of this short linker sequence are needed to clear the van de Waals 
surfaces of CaM and the FMN-binding domain. This leaves 2-3 residues that are 
conformationally unrestricted, and hence, there are uncertainties about the exact 
position above the ~-sheet of CaM and the orientation of the axis of the CaM-
recognition site. The position of CaM relative to the FMN-binding domain is 
unspecified with respect to rotations about the y-axis of Fig. 3.8 by available 
information (corresponding to the axis of the CaM-binding helix of Fig. 3.8). 
Although the insertion is midway through the sequence of the FMN-binding module, 
in three dimensions the model predicts it to be directly adjacent to the CaM-binding 
site. The model also predicts that CaM-binding would be sterically hindered by the 
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insertion, suggesting that the insertion can exist in more than one physiologically 
relevant confonnation. 
The structural model strongly suggests that the insertion can function as a 
control element. Firstly, the presence of the insertion correlates with Ca2+/CaM· 
dependent regulation. Secondly, the close proximity of the insertion with the CaM· 
binding domain would likely engineer steric hindrance of CaM·binding. Hence, we 
proposed a role for the peptide insertion within the FMN·binding domain of cNOSs as 
an autoinhibitory control element (ACE). 
3.2.2.3 Synthetic Polypeptide Effects on Activity 
The possible functional significance of the putative ACE of cNOSs was 
evaluated using a series of synthetic polypeptide fragments corresponding to various 
regions of the ACE·derived sequence from nNOS and eNOS. If the insertion served 
an autoinhibitory function, peptides derived from this region might be expected to 
interfere with CaM·binding to, and activation of eNOS. Peptides were synthesized 
that correspond to various regions of the insertion ranging in length from 6 to 33 
residues; specification of polypeptide sequence and origin is provided in Table 3.1. 
Five peptides corresponding to the regions flanking the insertion were also 
synthesized as controls. The effect of one of the insert·derived peptides (eNOS617_639) 
on the activity of nNOS, eNOS and iNOS is shown in Fig. 3.9. At concentrations of 
50.100 J.1M this peptide profoundly inhibits eNOS and nNOS activity, while iNOS is 
essentially unaffected. Several other insertion·derived peptides also elicited profound 
inhibition of eNOS and nNOS activity. Generally, the inhibition profiles for eNOS 
and nNOS were similar, although most peptides inhibited nNOS more potently than 
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Fig. 3.6. Sequence alignment of NOS isoforms and related proteins showing location and 
conservation of the FMN-insertion. Panel A: Structure-based alignments of FMN binding 
domains of NOS isoforms with related bacterial flavoproteins showing location of the FMN-
insertion peptide. Alignments were performed as described in Methods . Proteins represented 
are human NADP+-cytochrome P450 reductase (NCPR_HUMAN), bovine eNO 
(NOSE BOVIN), rat nNOS (NOSB_RAT), murine iNOS (NOSM_MOUSE) and flavodoxins 
from Reali (FLAV _ECOLI) and D. vulgarieus (FLAV _DE ). Panel B: Homology ba ed 
alignments of the FMN-insertion peptides of cNOSs from various species to show regions of 
conservation (shaded). Alignment was performed by the Clustal method using the D A tar 
Megalign, a program in the Lasergene suite of molecular biology tools. 
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Fig. 3.7. Structural models of the FMN binding domains of NOS isoforms and related flavoproteins. Panel 
A (left): Bacterial flavodoxin (silver), CPR (gold) and rat iNOS (blue). Panel B (right) : Bovine eNOS (pink) with 
the insertion peptide (gold) in an arbitrary conformation and bound-FMN in a space filling representation 
(yellow). N-terminal residues of the CaM binding site (white) are directly adjacent to the insertion peptide. 
Models were created as described in Methods using the Discover program (Biosyrn/Molecular Simulations). 
Fig. 3.8. Structural models of the FMN binding domains of eNOS and iNOS with bound-CaM. Panel A 
(left): eNOS FMN binding domain (pink) with the insertion peptide (gold). Panel B (right): iNOS FMN binding 
domain (purple). In bothe cases CaM (yellow) is shown bound to the CaM binding sequence (blue). Models were 
created as described in Methods using the Discover program (Biosym/Molecular Simulations) . 
eNOS. However, inhibition was not observed with peptides derived from the regions 
of cNOS flanking the insertion. Effects of the various ACE-derived peptides are 
summarized in Table 3.2, the most effective polypeptides were derived from the 
eNOS insertion and contained an RRKRK motif. Peptides relating to the nNOS 
insertion weakly inhibited eNOS, but were without effect on nNOS. 
Interestingly, even iNOS activity could be significantly inhibited by some of 
the cNOS insertion-derived peptides. Although all the peptides tested demonstrated a 
reduced efficacy for inhibition of iNOS, significant inhibition of iNOS was observed 
with eNOS601_633 and eNOS607-633' For example, eNOS601_633 inhibited iNOS activity 
., 
with an ICso of more than 1000 Ilg/rnl , while the observed ICso for nNOS was only 
31.0±1.1Ilg/ml. However, due to the extremely high affinity binding of CaM to iNOS 
(Cho et al., 1992), with little CaM dissociation occurring even after boiling in SDS, 
inhibition of iNOS is unlikely to involve the displacement of bound CaM. The 
observed inhibition of iNOS, may indicate the presence of vestigial "docking" sites 
for the insertion. Notably inhibition of iNOS activity by these peptides was rapid and 
apparently complete within one minute of addition (not shown). 
3.2.2.4 Synthetic Polypeptide Effects on CaM-binding 
The molecular model described in Fig. 3.8 suggests that the cNOS insertion 
overlaps the CaM-binding site to a degree, and that the insert may therefore impede 
CaM-binding. If this process involves docking of the insertion with cNOSs, peptide 
effects on CaM-binding to cNOSs may provide insights into the mechanism of 
inhibition of NOS activity described above. The effects of some representative 
peptides on CaM-binding to eNOS (panel A) and nNOS (panel B) are shown in Fig. 
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Fig. 3.9. Inhibitory effect of eNOS617-639 on the activity of the three NOS 
isoforms. The activity of each isoform (10 pmoles) was assessed using the 
Griess assay with 100 nM CaM and optimal levels of Ca2+ (100 J.lM). Activity 
is expressed as a percentage of the control activity in the absence of added 
peptide. Values shown are the mean of triplicates experiments ± SEM. 
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Peptide Derivation Sequence 
b eNOS 628-633 WRRKRK 
b eNOS 626-636 SSWRRKRKESS 
h nNOS 835-845 QEERKSYKVRF 
h eNOS 604-615 RPEQHKSYKIRF 
b eNOS 601-633 SSPRPEQHKSKYKIRFNSVSCSDPL VSSWRRKRK 
b eNOS 607-634 QHKSKYKIRFNSVSCSDPLVSSWRRKRKE 
r nNOS 851-864 SDSRKSSGDGPDLR 
h nNOS 835-864 . QEERKSYKVRFNSVSSYSDSQKSSGDGPDL 
Table 3.1. FMN insert-derived peptide sequence and origin. Species of 
origin is given as human (h), bovine (b) or rat (r). 
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Peptide Conc NOS Activity (% of Control) Ligand Binding to nNOS 
Derivation (f.lM) 
nNOS eNOS iNOS [l2.~I]_CaM CH]-NNA 
eNOS 628-633 107.0 11.0 ± 3.3 24.0±2.8 91.1 ± 5.7 6.7±3.6 91.7 ± 3.6 
eNOS 626-636 71.2 19.1 ±0.9 27.7 ± 2.0 92.1 ± 1.3 0.0±0.5 120.7 ± 12.7 
nNOS 835-845 68.1 102.0 ± 2.1 93.6± 2.3 101.1 ± 3.7 82.7 ± 1.1 118.9 ±4.1 
eNOS 604-615 63.0 54.5 ± 1.8 80.5 ± 2.0 . 99.7±5.7 24.7±2.2 115 ± 8.6 
eNOS 601-633 76.0 30.4 ± 1.7 57.2±7.5 62.2±2.8 0.0±7.4 116.3±1.9·· 
eNOS 607-634 87.7 28.2 ±0.9 40.2±4.0 64.3 ± 3.2 0.0±4.8 122.4 ± 1.0 
nNOS 851-864 72.0 98.4 ± 1.9 102.6±4.1 99.7±2.8 89.2±6.2 119.2 ± 3.4 
nNOS 835-864 84.8 103.0± 1.3 80.2±3.8 84.1 ± 3.5 82.7 ± 1.1 95.7 ± 4.7 
Table 3.2. Summary of the effects of FMN-insert derived peptides on NOS activity and ligand binding. 
NOS activity measurements were based on the rate of NADPH oxidation (for nNOS and eNOS) or myoglobin 
oxidation (iNOS).[125I]-CaM and fH]-Nco-nitro-arginine (fH]-NNA) binding were assessed using microfiltration 
assays as in Methods. All values represent the mean of triplicate determinations ± SEM. 
I 
I 
3.10. Potent inhibition of 12SI-CaM binding to both eNOS and nNOS was observed 
with insert-derived peptides. The relative efficacy of these peptides for inhibition of 
CaM-binding mirrored that observed for inhibition of activity, and is summarized in 
Table 3.2. No inhibition was observed with peptides derived from the insertion-
flanking regions (not shown). For nNOS, ICso values of eNOS-derived peptides 
ranged from 1-10 ).1M, with potency increasing as the RRKRK motif was 
progressively lengthened to include up to 33 residues. 
Conceivably, this inhibition could be due to sequestration of Ca2+ by the 
peptide, however, inhibition of CaM-binding by insert-derived peptides could not be 
overcome by the addition of excess Ca2+ up to 1 mM (Fig. 3.11). 
Inhibition of nNOS activity (Fig. 3.12) and CaM-binding (Fig. 3.13, panel B) 
by insert-derived peptides (in this case, eNOS607-634) was fully reversed by excess 
CaM, indicative of a competitive mode of inhibition. This was supported by double 
reciprocal plots of the saturation [12sI]_CaM binding to nNOS (Fig. 3.13, panel B). 
The fitted lines cross at the Y-axis, suggesting the peptide reduces the affinity of CaM 
binding to nNOS, but does not reduce the available number of sites. This implies that 
competition for binding sites exists between the peptides and CaM. Since the insertion 
peptides have an excess of positively-charged residues, repulsion rather than 
interaction with the similarly positively-charged CaM-binding site is anticipated. It is 
more likely that CaM and the insertion peptide compete by domain overlap, as 
opposed to binding to a common site. Alternatively, using the same logic that 
discounts an interaction between the insertion-peptide and the CaM-binding domain, a 
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direct interaction between the insertion-peptide and acidic (negatively charged) 
regions of CaM is a possibility. 
To ensure that NOS is the actual target for eNOS-derived peptides, the level of 
CaM-binding to the actual peptides was assessed. Direct binding of [125I]_CaM to 
peptide, quantified in the absence of NOS, was undetectable at concentrations that 
inhibited >90% of CaM-binding to nNOS (Fig. 3.14). Additionally, peptides bound 
CaM in the absence or presence of Ca2+ (unlike the Ca2+-dependent CaM binding to 
cNOSs), suggesting that peptides bind to an inactivated form of CaM (Not shown) 
and only at concentrations higher than required for inhibition of cNOS activity. From 
Fig 3.13, it is obvious that the insert-derived peptides have the effect of reducing the 
apparent affinity of nNOS for CaM by competitive inhibition. We therefore 
investigated the effect of these peptides on the rate of dissociation of CaM from pre-
formed CaM-NOS complexes. eNOS607_634 caused a modest increase in the rate of 
dissociation of CaM-eNOS complexes (Fig. 3.15, panel A); this effect was much 
more evident for CaM-nNOS complexes (Fig. 3.15, panel B). The experimental 
design prevented the re-association of [12SI]-CaM-cNOS complexes by the addition of 
a 3000-fold molar excess of unlabelled CaM. For synthetic peptides to displace CaM 
from its binding site on cNOS, it must, at least transiently, form a ternary complex 
with CaM-bound cNOS. 
3.2.2.5 Synthetic Polypeptide Effects on the Activity of Other CaM-dependent 
Enzymes 
The above findings implicate a direct interaction between the peptide and 
eNOS, as the basis for competitive inhibition. However, due to the fact that peptide-
116 
dependent inhibition can be reversed by the addition of excess CaM, it is conceivable 
that the peptides could interact with either the NOS or the CaM. In order to ensure 
that NOS is the actual binding target of eNOS-derived peptides, the effect of these 
peptides on the Ca2+/CaM dependent phosphatase calcineurin (protein phosphatase 
2B, PP2B) was investigated. This proteins were selected due to its high-affinity (Kd 1-
5 nM) (Imparl et ai., 1995) and reversible CaM binding, similar to that of cNOSs 
(Sheta et ai., 1994; Vorherr et ai., 1993). As shown in Fig. 3.16, the same peptides 
that inhibited nNOS and PDE I did not exert any inhibitory effect on PP2B (Fig 3.16, 
panel A and B). The peptide-dependent inhibition of cNOSs must therefore be due to 
an interaction between the peptide and NOS itself. Indeed, as previously shown, at 
concentrations of peptide sufficient to cause >90% inhibition of CaM-binding to 
nNOS, no direct binding of peptide to CaM was detectable (Fig. 3.14). 
~.2.2.6 Effect of Synthetic Polypeptides on Arginine Binding 
Most of the previously established inhibitors of NOS influence the binding of 
1 
substrate in a manner which can be detected as a loss in sites or binding affinity for 
the arginine analog, [3H]-W-nitro-arginine. Thus it is notable that the eNOS-derived 
peptides cause a slight increase, rather than decrease, in CH]-NG-nitro-arginine 
binding (see Table 3.2). This implies that the peptide-dependent inhibition of NOS 
activity is not the result of any reduction in arginine binding and that the substrate 
binding site in the oxygenase domain remains functional when NOS-peptide 
complexes are formed. 
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Fig. 3.10. Effect of eNOS60I.633 and eNOS607.634 on [125Il-CaMbinding to eNOS 
and nNOS. Inhibition of C25I]-CaM binding to eNOS (Panel A) and nNOS (Panel 
B) was assessed as a function of added peptide. [125Il-CaM bindi ng was mea ured 
as described in Methods. Value are corrected for non-specific CaM binding and 
represent the mean of triplicate experiment ± SEM. 
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Fig, 3.11. Effect of Ca1+ concentration on the peptide-dependent inhibition 
of [l2SJ]-CaM binding to nNOS. [l25J]-CaM binding assays were performed in the 
. absence or presence of the indicated concentration of eNOS607_634 as described in 
Methods, the concentration of free Ca2+ was varied from "zero" (10 mM EGT A) to 
100 J.LM. Values shown are the mean of triplicates experiments ± SEM. 
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Fig. 3.12. Peptide-dependent inhibition of nNOS activity is fully reversible by 
the addition of excess calmodulin. The activity of nNOS (10 pmoles) was 
assessed kinetically based on the rate of NADPH oxidation and expre ed a a 
percentage of the maximal rate in the absence of added peptide. The highe t peptide 
concentration shows >80% inhibition of nNOS activity at 100 nM CaM, but 
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Fig. 3.13. Competitive inhibition of [12sI ]_CaM binding to nNOS by 
insertion-derived peptide eNOS607.634' Panel A: [' 25I]_CaM binding assays were 
performed over a range of CaM concentrations, in the absence (control) or pre ence 
of added peptide. Panel B: The results of panel A are shown as a double reciprocal 
replot. Values are corrected for non-specific CaM binding and represent the mean 
of triplicate experiments ± SEM. 
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Fig. 3.15. Acceleration of [I2SI] -CaM dissociation from cNOSs by 
eNOS607.634.The time-dependent dissociation of eNOS-CaM (Panel A) or 
nNOS-CaM (Panel B) complexes in the absence (control) or presence 
(indicated concentration of peptide) was as essed a in Methods. 
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Fig. 3.16. Relative effects of insert-derived peptides on the activity of cNOSs 
and calcineurin. Panel A: Dose-dependent inhibition of nNOS , eNOS and 
calcineurin by eNOS617_639' Panel B: Relative potency of eNOS60I_633 for inhibition 
of nNOS and calcineurin. Activity of cNOSs (10 pmole) was assessed by the Grie s 
assay using 100 nM CaM at optimal concentrations of Ca2+ (100 11M). Calcineurin 
acti vi ty was assessed under the same conditions by a kinetic assay using the 
artific ial substrate p-nitrophenyl pho phate. All activities are expressed as a 
percentage of the maximal activity observed in the absence of peptide. Value 
shown are the mean of triplicate experiments ± SEM. 
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3.2.2.7 An Integrated Model of cNOS Regulation by Ca2+, CaM and the Putative 
Autoinhibitory Control Element 
The data taken together provide support for the proposed role of the FMN-
insertion of cNOSs as an autoinhibitory control element. However, this is unlikely to 
function in the prototypic "flip-flop" model (Jarrett & Madhavan, 1991), accepted for 
other enzymes that express CaM-like autoinhibitory domains. In the "flip-flop" 
model, the CaM-like autoinhibitory domain binds directly to the CaM-binding site 
and is displaced by CaM, as it binds to the same site. The similarly basic composition 
of the putative ACE and CaM binding site of cNOSs, makes a direct interaction 
between the two unlikely. We therefore propose a model in which the putative ACE 
occupies a site, or sites, on the surface of cNOSs that three dimensionally overlaps the 
CaM binding site, preventing CaM binding and causing tonic inhibition. When 
intracellular Ca2+-levels are increased, CaM becomes activated and binds to the CaM-
binding site, sterically displacing the putative ACE from its sites of interaction and 
allowing enzyme activation. The activation of cNOSs in this manner would predict 
that the putative ACE can exist in at least two distinct conformations and that CaM-
binding elicits ACE movement to yield an "active" NOS conformation. We therefore 
investigated the effect of bound CaM upon cNOS ACE conformation. 
3.2.2.8 Effects of CaM on the Exposure of the Insert 
Limited proteolysis of proteins is one of the methods of choice to study 
conformational changes in proteins. A conformational shift in the protein structure 
changes the availability of proteolytic sites to digestion, resulting in a change in the 
pattern of observed cleavage fragments. Displacement of the insert from an 
internalized binding site on cNOSs by CaM-binding would conceivably enhance the 
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exposure of the insert and increase its susceptibility to proteolysis. This hypothesis 
was tested by examining the pattern of peptide accumulation during limited 
trypsinolysis of both nNOS and eNOS, in the absence and presence of bound CaM 
(see Fig. 3.17 and 3.18). 
It had previously been shown that of the possible 165 tryptic cleavage sites in 
rat nNOS, a single preferred cut site is present at Arg727 within the CaM-binding 
region (Sheta et at., 1994). Trypsinolysis of nNOS (see Fig. 3.17, panel A) in the 
absence of bound CaM (due to the chelation of Ca2+), results in the formation of 
fragments consistent with trypsinolysis occurring almost exclusively at this residue 
(Arg727). Accordingly, we found a time-dependent accumulation of fragments with 
apparent molecular masses of 77 and 85 kDa, corresponding to the reductase and 
oxygenase domains, respectively. When nNOS-CaM complexes were permitted to 
form (no chelator present) trypsinolysis yielded fragments of apparent molecular 
masses of 63 and 93 kDa, indicating trypsinolysis at a new site. An accurate 
assessment of these masses was established by matrix-assisted laser desorption 
ionization mass spectrometry (MALDI-MS). The mass of the smaller fragment was 
determined at 64809 ± 324 Da, best explained by cleavage at Arg855 within the insert 
(predicted to yield a C-terminal fragment of 65071 Da). Further confirmation that this 
fragment is derived from a cut site within the reductase domain is provided by 
trypsinolysis of bacterially-expressed reductase (nNOS72J o I429) and oxygenase domains 
(nNOS1072I), the 65071 fragment can only be derived from trypsinolysis of the 
individually expressed reductase domain (Data not shown). Confirmation of this 
cleavage site as Arg8SS is provided by N-terminal sequencing of this fragment, the 
KSSGDGPDLR sequence obtained could only have resulted from trypsinolysis at this 
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site. A cartoon depicting the relative positions of the various trypsinolysis sites is 
shown in Fig. 3.17 (panel B). 
Similar studies using eNOS protein resulted in a slightly more complex (see 
Fig. 3.18, panel A), but analogous pattern of trypsinolysis. Trypsinolysis of CaM-free 
NOS resulted in four principal fragments of approximate molecular masses of 57, 60, 
68, and 77 kDa. This pattern is rationalized by cleavage at ArgS18 within the CaM-
binding region (eNOS1-S18 = 56877 Oa, eNOSSI9-1204 = 76308 Oa) and at a second site, 
likely to be LysS4S within the insert peptide (eNOS1-s4s = 59916 Oa, eNOSs46-1204 = 
73270 Oa). Binding of CaM simplifies this cleavage pattern by providing a single 
dominant cut site, only two strong fragment bands are revealed by gel electrophoresis, 
at 60 and 65 kDa. These are predicted by cleavage of eNOS within the RRKRK motif 
of the insert peptide at Lys632 (with additional cleavage of the N-terminal fragment at 
LysS4S) producing fragments of 59916 Da and 63251 Da. As seen in Fig. 3.6, 
alignment of the peptide inserts of eNOS and nNOS reveals a close correspondence 
between Lys632 of eNOS and Lys8S6 of nNOS, suggesting a similar, CaM-driven 
movement of the peptide insertion in both cNOS isoforms. A cartoon represent~tion 
of eNOS trypsinolysis sites is shown in Fig 3.18 (panel B). 
~.2.3 Function of the Conserved Regions of the AutoinhibitOIY Control Element 
In order to investigate the roles of the various regions of the auto inhibitory control 
element of cNOS, an attempt was made to identify areas of conservation. These 
conserved regions may represent sites required for interaction with a putative docking 
site that confers auto inhibitory function. 
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Fig. 3.17. SDS-polyacrylamide gel electrophoresis showing 
the products of limited tryptic digestion of nNOS. Panel A: 
Trypsinolysis of nNOS was performed for the indicated 
duration in the absence (+EDT A) or presence (-EDT A) of 
bound CaM. Protein bands at 160 and 17 kDa correspond to 
uncut nNOS and CaM, respectively. Results indicate that a 
preferred tryptic cleavage site resides within the CaM binding 
sequence of nNOS, however, when this site is masked by bound 
CaM, a novel tryptic cleavage site is revealed within the FMN-
insertion peptide. Panel B : A representative cartoon of the 
tryptic cleavage sites of CaM-bound and CaM-free nNOS . 
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Fig. 3.18. SDS-polyacrylamide gel electrophoresis showing 
the products of limited tryptic digestion of eNOS. Panel A: 
Trypsinolysis of eNOS was performed for the indicated 
duration in the absence (+EDTA) or presence (-EDTA) of 
bound CaM. Protein bands at 133 and 17 kDa correspond to 
uncut nNOS and CaM, respectively . Results indicate that a 
preferred tryptic cleavage site resides within the CaM binding 
sequence of eNOS, however, when this site is masked by bound 
CaM, a novel tryptic cleavage site is revealed within the FMN-
insertion peptide. Panel B: A representative cartoon of the 
tryptic cleavage site of CaM-bound and CaM-free eNOS. 
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3.2.3.1 Alignment of the auto inhibitory control elements of NOS isofonns 
Sequence alignments of the auto inhibitory control elements of cNOSs reveals 
two major areas of conservation (see Fig. 3.19), an N-terminal region conserved in all 
mammalian cNOSs (shaded red) and a pentabasic motif (RRKRK) present only in 
eNOS isoforms (shaded green). As is shown in Fig. 3.19, a similar motif may be 
present in nNOS isoforms, but in a truncated dibasic form. These conserved regions 
may represent key regulatory sites necessary for auto inhibitory function. Additionally, 
the isoform specific sequence of the ACE, which is the switch for enzyme activation, 
may account for the observed differences in catalytic output between eNOS and 
nNOS. To investigate the role of the RRKRK motif in eNOS regulation, we 
engineered and expressed mutant eNOS proteins in which this region was deleted 
(RRKRK del) or substituted by a string of five alanine residues (RRKRK sub). The 
effect of these mutations on eNOS activation and regulation by Ca2+/CaM was 
assessed. 
3.2.3.2 Expression and purification 
A two-step purification involving sequential affinity chromatographies on 
ADP-sepharose and CaM-sepharose resins resulted in >90% homogeneity for 
wildtype nNOS, wildtype eNOS, RRKRK deletion and RRKRK substitution, as 
estimated from Coomasie-stained SDSIP AGE (Fig. 3.20). Low temperature SDS-gel 
electrophoresis analysis showed that the mutations did not attenuate NOS homodimer 
stability (Fig. 3.21). Overall protein yields ranged from 2-10 mg purified protein per 
liter of bacterial culture. Spectrophotometry demonstrated that the CO-bound spectra 
of dithionite-reduced mutant and wt eNOS were indistinguishable, indicating that 
RRKRK deletion/substitution does not compromise heme-coordination (Fig. 3.22, 
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panels A, B and C). Accordingly, spectral assessment of heme-chromophore was used 
to quantify eNOS protein mass. 
3.2.3.3 Catalytic Activities 
Three catalytic activities of eNOS were analyzed and contrasted for wildtype 
and RRKRK mutant enzymes (Fig. 3.23 and 3.24). These distinct activities were 
determined in the presence or absence of excess Ca2+ and indicate maximal electron 
flux to heme (NO synthesis, 3.23), FAD (ferricyanide reduction, Fig. 3.24, panel A) 
and FMN (cytochrome c reduction, Fig 3.24, panel B), in the absence and presence of 
bound-CaM (Adak et al., 1999). 
As shown in Fig 3.23, neither wt nor mutant eNOS supported detectable levels 
of NO synthesis in the absence of added CaM. Deletion or substitution of the 
RRKRK motif resulted in a 2-3-fold increase in maximal CaM-induced NO synthesis, 
compared to wildtype enzyme (from 136±16 to 450±17 and 504±11 nmol/minlmg, 
respectively). Given that the rate-limiting step for NO synthesis by CaM-bound 
eNOS appears to reside in the reductase domain (Nishida & Ortiz de Montellano, 
1999; Nishida & Ortiz de Montellano, 1998), we monitored the rate that artificial 
electron acceptors could be reduced by electrons derived from reductase domain 
flavins. Although significant basal cytochrome c and ferricyanide reduction was 
observed with both mutant and wildtype eNOS; basal activity was 2-3 fold greater for 
RRKRK del compared to wildtype eNOS (Figs. 3.24, panels A and B). In the case of 
wildtype and RRKRK del eNOS, addition of CaM caused a further 2-3 fold increase 
in the rate of reduction of these electron acceptors. RRKRK sub eNOS exhibited a 
much higher basal rate than either wild type or RRKRK del, the maximal rate in the 
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presence of CaM was, however, comparable to that of the deletion. For both 
cytochrome c and ferricyanide reduction, the CaM-free basal activity of RRKRK 
mutants was comparable to, or higher than, the CaM-bound activities of wildtype 
eNOS. This implies that the reductase function of CaM-bound eNOS is attenuated, 
and that the RRKRK motif is responsible for this attenuation. Hence, it seems that the 
presence of the RRKRK motif in wildtype eNOS causes attenuation of the otherwise 
faster rate of electron flow from NADPH to FAD, and from FAD to FMN. Removal 
of this motif results in an increase in both the CaM-independent and -dependent rates 
of reduction. However, CaM-binding is still required for NO synthesis, presumably 
inducing conformational changes, which align the FMN and heme moieties, required 
for electron transfer to the oxygenase domain. 
3.2.3.4 Ca2+.dependenceofCalmodulin Binding and Activation 
Given the putative role of the auto inhibitory control element in controlling 
CNOS activation by Ca2+/CaM, we investigated the role of the RRKRK motif in the 
control of Ca2+ ·dependent functions of the enzyme. Experiments were performed to 
compare the Ca2+ .dependence for activation of wildtype, RRKRK del, and RRKRK 
sub eNOSs (80 nM) by CaM (100 nM). As shown in Fig. 3.25 (panel A), removal of 
the RRKRK motif ,by deletion or substitution, did not significantly diminish the Ca2+_ 
dependence for activation of eNOS by Ca2+/CaM. On the contrary, a slight increase in 
the levels of Ca2+ required for activation was observed with both the substitution and 
deletion mutants. 
We next compared the Ca2+.dependence for [12SI]_CaM binding to RRKRK 
mutants and wildtype eNOS. Assessment of both [12SI]_CaM binding (Fig. 3.25, panel 
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Fig. 3.19. Regions of conservation within the FMN-inserlions of eNOS and nNOS. 
Alignment of the FMN-insertion regions of representative members of the nNOS and 
eNOS families of proteins. Special note should be made of the RRKRK motif (shaded 
green), perfectly conserved in eNOS proteins, but absent from nNOS. Also a region 
near the N-terrninal end of the insertion (shaded red), which is conserved throughout the 
Ca2+ -dependent isoforms. 
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Fig. 3.20. SDS-polyacrylamide gel electrophoresis of purified recombinant 
RRKRK del and RRKRK sub eNOS. Recombinant NOS proteins were all 
purified to > 90% homogeneity and showed approximate molecular weights of 135 
kDa for both eNOS mutants. 
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Fig. 3.21. Stability of RRKRK mutant eNOS homodimers by low-
temperature SDS-polyacrylamide gel electrophoresis. Low temp SDS-
PAGE was performed as described in Methods. The apparent molecular 
weight of> 200 kDa indicated the formation of stable NOS homodimers for 
both eNOS mutants. 
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Fig. 3.22. P450 spectra of wild type, RRKRK del and RRKRK sub eNOS. The 
CO-bound, dithionite reduced spectra of wild type (panel A), RRKRK del (panel 
B) and RRKRK sub (panel C) were obtained as described in methods. 
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Fig. 3.23. Rates of NO synthesis of wildtype, RRKRK del and RRKRK sub eNOS. 
All experiments were carried out in triplicate using 10 pmoles of NOS, 250 nM CaM 
and optimal Ca2+ concentrations (100 J.1M). CaM-free measurements of activity were 
obtained in the presence of 5 mM EGTA and rates are derived from the mean of two 
separate preparations of each enzyme measured in triplicate 
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Fig. 3.24. Reductase activities of wildtype, RRKRK del and RRKRK sub eNOS. 
All experiments were carried out using 250 nM CaM and optimal calcium 
concentrations (100 JlM). Amounts of NOS added were 1 pmole and 0.1 pmole per well 
for cytochrome c reduction (Panel B) and ferricyanide reduction (Panel A), 
respectively. CaM-free measurements of activity were obtained in the presence of 5 
mM EGTA and rates are derived from the mean of two separate preparations of each 
enzyme assayed in triplicate. 
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B) and eNOS activity (Fig. 3.25, panel A) were performed using an identical array of 
Ca2+ buffer solutions and assay conditions, permitting direct comparison of observed 
Ca2+-dependencies. Assays of CaM-binding to eNOS and RRKRK mutants revealed 
no significant differences in the levels of Ca2+ required to initiate formation of the 
CaM/eNOS protein complex. 
3.2.3.5 Does it Affect the EC50 for Ca2+ if the CaM-eNOS Complexes are Pre-
formed? 
, Experiments described in the previous section only assessed the formation of 
eNOS complexes at defined levels of free Ca2+. Under physiological conditions, 
CaM-binding to eNOS, and hence activation, would occur during the rising phase of a 
spike in intracellular Ca2+. eNOS-CaM complexes would then dissociate, and hence 
inactivate eNOS as intracellular Ca2+ returned to basal levels. We therefore 
investigated any potential difference in the Ca2+-dependence curve for eNOS activity, 
if we looked at activation vs. inactivation. Activities of wildtype and RRKRK del 
eNOS were assessed uniquely under each of two conditions. Firstly, CaM-eNOS 
complexes were allowed to pre-form at maximal levels of Ca2+ (= IJ.lM) prior to 
addition to the Ca2+-chelating buffers. Secondly, eNOS (= 1 JlM Ca2+) was added to 
Ca2+-buffered solutions already containing CaM. For both wildtype and RRKRK sub 
eNOS, the two distinct experimental paradigms did not demonstrate any significant 
alteration in the level offree Ca2+ required for half maximal activity (Fig. 3.26). 
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3.2.3.6 Does "the RRKRK Motif Affect the Rate of Dissociation of CaM-eNOS 
Complexes 
The rate of dissociation of CaM-eNOS complexes was assessed using a [1251]_ 
CaM binding assay, as described in the methods section. The rate of dissociation of 
eNOS-CaM complexes was slightly accelerated in mutants lacking the RRKRK motif 
compared to wildtype eNOS (Fig. 3.27, panels A and B). This may indicate a role for 
this highly basic in the interaction between eNOS and the acidic lobes of compacted 
CaM. Removal of this region might lead to a higher rate of CaM dissociation 
3.2.3.7 The RRKRK Motif and eNOS-HSP90 Association 
HSP90 has been reported to form a complex with eNOS and this is associated 
with a 2 to 3-fold increase in the rate of NO synthesis (Garcia-Cardena et al., 1998). 
As removal of the RRKRK motif results in an enzyme with a comparable increase in 
activity, we investigated a possible role for this motif in the eNOS-HSP90 
association. HSP90 caused a concentration-dependent increase in activity of both 
wildtype and RRKRK mutant eNOS proteins. In both cases, the maximum increase 
was approximately 130% of that demonstrated by eNOS in the absence of HSP90 
(Fig. 3.28). This was much smaller than the published increase and may be due to our 
use of recombinant HSP90, as opposed to the HSP90 purified from rat brain was used 
previously (Garcia-Cardena et al., 1998). 
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Fig, 3.25, Calcium-dependence of NO synthesis and calmodulin-binding for wild 
type and RRKRK mutant eNOSs, Panel A: NO synthesis is shown as a percentage of 
the maximum rate observed in the presence of 1.8 flM Ca2+ for each eNOS protein (8 
pmol). Panel B: Calmodulin binding is depicted as a percentage of complete occupancy, 
where 100% represents a 1: 1 ratio of bound CaM to eNOS (4 pmol). 
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RRKRK del eNOS. C a2+-dependence of eNOS activity was analyzed under 
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Fig. 3.28. Effect of heat shock protein 90 on the activity of wildtype and 
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3.2.4 Phosphorylation of the ACE as a Method of eNOS Regulation 
Although eNOS is normally classified as a Ca2+-dependent isoform, the 
activation by such stimuli as insulin (Scherrer et ai., 1994; Zeng & Quon, 1996) , 
insulin-like growth factor (IGF-l) (Tsukahara et al., 1994), estrogen (Caulin-Glaser et 
al., 1997) and laminar shear (Ayajiki et al., 1996; Kuchan & Frangos, 1994) are 
known to activate eNOS in a "Ca2+-independent" manner. This activation has been 
linked to a possible phosphorylation of eNOS or an associated protein (Ayajiki et al., 
1996; Busse & Fleming, 1998; Fleming et ai., 1997; Fleming et aI., 1996). Given the 
role of the ACE in the control of Ca2 +/CaM-dependent activation of cNOSs, 
functional modification of this region by phosphorylation/dephosphorylation could 
provide a possible mechanism for such Ca2+-independent activators of eNOS. 
J.2.4.1 Putative phosphorylation sites in ACE Regions of cNOSs 
The ACE regions of cNOSs are rich in serine/threonine residues. Comparison 
of the full length sequences of eNOS and nNOS with the Prosite database (Swisprot, 
Expasy) identifies consensus phosphorylation sites for kinases including protein 
kinase A (PKA), CaM-dependent kinase II (CaM KII), casein kinase II (CK II), 
protein kinase C (PKC) and protein kinase B (PKB/Akt). Fig. 3.29 (panel A) shows 
the existence of a PKA site within the ACE of cNOSs, which is conserved across 
species. Another putative PKA phosphorylation site is present within the CaM 
binding domain of cNOSs (eNOS, Threonine494) (Fig. 3.29, panel B). Phosphorylation 
of a ser/thr residue within or near a CaM-binding site or CaM-binding regulation site 
(ACE) is a common mechanism of regulation for many CaM-dependent enzyme 
systems. Nonetheless, the functionality of the two PKA sites remains to be 
established. 
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3.2.4.2 Attenuation of the Inhibitory Potency of eNOSm _639 by Phosphorylation at 
Consensus PKA sites 
To examine the possible functional significance of these two putative 
phosphorylation sites within the ACE of eNOS, synthetic peptides corresponding to 
eNOS617-639 were synthesized in their native form, or phosphorylated at serine63s or 
serine636' The ability of these peptides to inhibit [12sI]_CaM binding to nNOS was 
assessed as described previously. As expected, the native peptide potently inhibited 
CaM-binding to nNOS (ICso 5.56 ± 1.03 JlM) (Fig. 3.30), however, the phospho-
peptides exhibited a substantially reduced ability to inhibit CaM-binding (ICso > 200 
JlM). As these peptides mimic the inhibitory effect of the intrinsic ACE, and 
phosphorylation of the peptide at Ser63S1636 attenuates this inhibitory effect, it is 
conceivable that phosphorylation of the intrinsic ACE may cause a similar loss in 
inhibitory function. We therefore investigated the significance of PKA-mediated 
phosphorylation on eNOS activity in vitro. 
3.2.4.3 In Vitro Phosphorylation of eNOS by PKA 
Although consensus sequences for PKA-mediated phosphorylation can be 
found within the amino acid sequence of eNOS, this does not necessarily mean that 
these sites are available targets of PKA. Hence, the ability of PKA to catalyze the in 
vitro phosphorylation of eNOS was assessed using 32P-Iabeled ATP. PKA-dependent 
phosphorylation of eNOS was demonstrated by a time-dependent incorporation of 
radiolabeled-phosphate into the 130 kDa band on SDS-PAGE gels (Fig. 3.31, panel 
A). Liquid scintillation counting of the excised bands allowed the quantification of 
phosphate incorporation into eNOS and revealed a final stoichiometry of "",I 
phosphate per eNOS monomer (Fig. 3.31, panel B). The stoichiometry and the rate of 
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phosphorylation were unaffected by whether the substrate eNOS was CaM-bound or 
CaM-free. Control experiments demonstrated that omission of PKA from the reaction 
prevented 32P-incorporation into eNOS. 
Although the validity of eNOS as a substrate of PKA was now established, the 
location of the phosphorylated sites identified in the above study were unknown. To 
establish whether any of the PKA sites involved were Ser63S. Ser636 or Thr494, we 
produced mutant eNOS proteins in which one or more of these residues was negated 
by mutation to an alanine. The incorporation of phosphate was markedly diminished 
by mutation of Ser63s'636(Fig 3.32). Additionally, when all three residues were mutated 
to alanines no PKA-mediated phosphate incorporation could be detected (Fig. 3.33) 
To confirm the identity of Ser63S as one of the PKA phosphorylation sites within 
eNOS, we used the masses of trypsinolysis fragments predicted by in silica digestion 
and utilized selected ion recording electrospray ionization mass spectrometry (SIR-
ESI-MS) to analyze the fragments from actual digests. Analysis of tryptic fragments 
of phosphorylated eNOS showed the presence of a peak of the correct mass predicted 
by phosphorylation at Serm or Ser636 (Fig. 3.34). This peak was not present in the 
digest of unphosphorylated eNOS. However, due to the use of SIR-MS, the presence 
of other undetected phosphorylated peptides cannot discounted. 
3.2.4.4 Effect of in vitro PhosphOlylation on eNOS Activity 
Now it was established that PKA could mediate the phosphorylation of eNOS 
at a site within the ACE, we performed assays to ascertain whether phosphorylation 
altered eNOS-function. 
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We hypothesized a model based upon the regulation of CaM-dependent kinase 
II (Brickey et aI., 1994), in which a sequestered phosphorylation site on the ACE is 
exposed upon Ca2+/CaM binding and that this ACE-phosphorylation would thus 
provide a mechanism to sustain eNOS activity after Ca2+ levels have returned to the 
basal. We therefore looked at the effect of PKA-mediated phosphorylation on the 
observed Ca2+-dependence of eNOS. This was done under the conditions described in 
Part III, whereby pre-formed CaM-eNOS complexes were placed into specific 
EGTAlCa2+-buffered solutions that provide a range of [free Ca2 +], from 
subnanomolar to 1.8 IlM. 
Thus experiments were performed to examine the effect of PKA-mediated 
phosphorylation on the level of free Ca2+ required for activation of eNOS, previously 
treated with ATPIPKA or ATP/inactivated PKA. The extent of phosphorylation in 
each case was assessed using an identical reaction containing 32P-Iabeled ATP (see 
inset). However, the levels of free Ca2+ required for half-maximal activation of eNOS 
were found to be indistinguishable, irrespective of whether PKA-dependent 
phosphorylation of eNOS occurred (Fig. 3.35). 
We also examined the effect of phosphorylation on the maximal catalytic rates 
exhibited by eNOS. Previously treated under the phosphorylating or mock-
phosphorylating conditions described above, eNOS was assayed for its relative rate of 
NO synthesis. None of these treatments were found to cause a significant alteration in 
specific activity of eNOS (Fig. 3.36), although rates of NO synthesis were modestly 
diminished in all cases compared to untreated eNOS. Despite no apparent effect on 
NO synthesis, it is possible that phosphorylation by PKA could mediate an effect 
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exclusively within the reductase domain. Hence, the effect of these PKA treatments 
on reductase function was assessed by eNOS-mediated cytochrome c (Fig. 3.37, panel 
A) and ferricyanide reduction (panel B). No significant effect upon reductase function 
was observed with any of the phosphorylating or mock-phosphorylating treatments. 
3.2.4.5 Mutation of Serill to Mimic PhosphoQ'lation 
Although the mutation/mass spectrometry studies identified Ser63S1636 as a site 
of in vitro PKA-mediated phosphorylation, it was also evident that at least one 
additional residue (Thr494) also underwent phosphorylation. The relative stoichiometry 
of phosphorylation of these two residues in wildtype eNOS was also unclear. 
Additionally, the presence of Mg2+ ions in the kinase reaction mixture complicates the 
interpretation of Ca2+ -dependence curves, due to the ability of Mg2+ to occupy Ca2+_ 
binding sites of CaM. To circumvent these complications, we took advantage of an 
established method to mimic the specific phosphorylation of Ser63S ' Glutamate has a 
similar size and charge pattern to a phosphoserine and accordingly, substitution of a 
Glu for a Ser residue often mimics the effect of phosphorylation. We therefore created 
two mutant eNOS proteins, one expressing the phospho serine-mimic (Glum) and a 
conservative control mutation (Ala63S)' The effect of these mutations on eNOS activity 
were then assessed. 
Expression of these proteins was problematic, yields of Glu63s and Ala63s 
eNOS were much lower than those expected (100 J.1g/liter of culture). This was not 
rectified by the addition of mild detergents, such as CHAPS. Despite the modest 
yields, we attempted to characterize Glu63s and AI~3s eNOS. 
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Specific activity measurements demonstrated the very low level of activity of 
Glu63s and Ala63s mutants (25±5 and 19±2 nmole/min/mg protein), compared to 
wildtype eNOS (135±17 nmole/min/mg protein) (Fig. 3.38). The low yield and 
specific activity of this protein made the assessment of the Ca2+-dependence curve for 
activation by CaM unfeasible. However, Glu63s eNOS did exhibit a reduced rate of 
[ 12SI]_CaM dissociation, compared to the wildtype eNOS (Fig. 3.39). 
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regions of the FMN-insertion (Panel A) and the CaM-binding site (Panel B) of 
eNOS showing conservation of the key residues making up the PKA/PKG 
consensus. 
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Fig. 3.31 32p_Phosphate incorporation into wildtype eNOS by PKA. 
Phosphate incorporation studies were performed as de cribed in Methods . 
P anel A: Autoradiographs of the dried gels showing phosphate 
incorporation into eNOS in a time-dependent manner. Panel B: The same 
gel bands were then excised and phosphate incorporation quantified by 
liquid scintillation counting. 
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Fig. 3.32 32p-Phosphate incorporation into wild type and Ala6351636 eNOS 
by PKA. Phosphate incorporation studies were performed as described in 
Methods . Panel A: Autoradiographs of the dried gel showing pho phate 
incorporation into eNOS in a time-dependent manner. Panel B: The same 
gel bands were then excised and phosphate incorporation quantified by 
liquid scintillation counting. 
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Fig. 3.33 32P-Phosphate incorporation into wildtype and Ala494/63S/636 
eNOS by PKA. Phosphate incorporation studies were performed a 
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Fig. 3.34. Confirmation of Serine635/636 as a site of in vitro PKA-mediated 
phosphorylation by electrospray ionization mass spectrometry using selected ion 
recording. Selected ion recording mass spectrometry (SIR-MS) analysis of trypsin 
digests of native (Panel A) and PKAJATP-exposed eNOS (Panel B), demonstrating 
the appearance of a peak at 842.9 Da (m!z=2), corresponding to phosphorylated 
eNOS633.647 (KESSNTDAGALGTLR). A peak with a similar retention time is not 
present in the unphosphorylated digest. For SIR-MS analysis, both native and 
phosphorylated proteins contained PKA and eNOS (150 pmoles); ATP was present 
only in the latter case. Samples were eluted from a reverse phase (CIS) HPLC column 
feeding directly into the mass spectrometer. 
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Fig, 3.37. Effect of PKA·mediated phosphorylation on the rates of 
ferricyanide and cytochrome c reduction. eNOS was treated as described 
in Fig. 3.36 and assessed for cytochrome c (Panel A) and ferricyanide 
(Panel B) reductase activities. Reactions were performed using 250 nM 
CaM, 100 J.1M Ca2+ and 1 pmole (cytochrome c) or 0.1 pmole (ferricyanide) 
of eNOS. Activity in the absence of CaM was assessed in the presence of 5 
mM EGT A. Values are the mean of triplicate experiments ± SEM. 
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Fig. 3.36. Effect of PKA-mediated phosphorylation on the rate of NO synthesis 
by eNOS. eNOS (8 pmoles) was treated for 20 min with either phosphorylation 
buffer only (control), ATPlheat inactivated PKA (ATP), PKA only or ATP/PKA 
and then incubated in NOS assay buffer containing 250 nM CaM and optimal Ca2+ 
concentrations (100 JlM) .. Values shown are the mean of triplicate experiments ± 
SEM. 
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Fig. 3.37. Effect of PKA-mediated phosphorylation on the rates of 
ferricyanide and cytochrome c reduction. eNOS was treated as described 
in Fig. 3.36 and assessed for cytochrome c (Panel A) and ferricyanide 
(Panel B) reductase activities. Reactions were performed using 250 nM 
CaM, 100 IlM Ca2+ and 1 pmole (cytochrome c) or 0.1 pmole (ferricyanide) 
of eNOS. Activity in the absence of CaM was assessed in the presence of 5 
roM EGT A. Values are the mean of triplicate experiments ± SEM. 
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Fig. 3.38. Rates of NO synthesis of wildtype Glu635 and Ala635 eNOS. All 
experiments were carried out using 10 pmoles of NOS, 250 nM CaM and maximal Ca2+ 
concentrations. CaM-free measurements of activity were obtained in the presence of 5 
mM EGTA and rates are derived from the mean of two separate preparations of each 
enzyme, assayed in triplicate. 
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Fig, 3.39. Rate of [12SIl-CaM dissociation from wildtype and GIU63S eNOS. Panel A: the 
rate of CaM dissociation from CaM-eNOS complexes formed at maximal levels of Ca2+ 
(100 ~M) was assessed by following the time-dependent loss of bound C25Il-CaM 
following the addition of a 3000-fold molar excess of unlabeled CaM. CaM binding is 
expressed as a percentage of the maximum observed prior to the addition of unlabeled 
CaM. Panel B: A semi-log plot of the above data allows the derivation of a dissociation 
rate by linear regression. 
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3.3 Discussion 
3.3.1An Autoinhibitory Control Element Defines Calcium-regulated Isoforms of 
Nitric Oxide Synthase. 
Nitric oxide synthases are classified based upon their mode of regulation by 
Ca2+/CaM (for review see Sessa, 1994). Whereas an extremely high affinity for 
binding of CaM causes iNOS to be active even at resting levels of intracellular Ca2+ 
(Cho et al., 1992), eNOS and nNOS (cNOSs) are classified as Ca2+-dependent 
because they are intermittently activated by Ca2+/CaM binding following transient 
stimulus-evoked increases in intracellular Ca2+. The NOSs are unique among 
Ca2+/CaM-dependent enzyme systems in that CaM-binding/dissociation gates the flow 
of electrons through the enzyme (Abu-Soud & Stuehr, 1993). This was thought to 
occur by facilitating the alignment of the reductase domain FMN with the oxygenase 
domain heme (Abu-Soud & Stuehr, 1993), allowing inter-domain electron flux. 
However, CaM-binding was later shown to up-regulate electron flux by a dual 
mechanism, increasing both the inter-flavin (FAD ~ FMN) and the inter-domain 
(reductase ~ oxygenase) transfer of electrons (Abu-Soud et al., 1994). The 
conformational changes involved in this process are unknown and their elucidation is 
hampered by the lack of structural information concerning a NOS reductase domain 
or its position relative to the cognate oxygenase domain. Moreover, the molecular 
basis for this CaM-binding "switch" to activate cNOSs was completely unknown 
prior to this study. In contrast, the activation of most other Ca2+/CaM-dependent 
enzymes has been shown to rely upon the displacement of an intrinsic autoinhibitory 
control element (Jarrett & Madhavan, 1991). 
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Herein we have shown that cNOSs possess a polypeptide insertion within their 
FMN-binding domains that is: 1) unique to NOS isoforms that are regulated by 
transient Ca2+/CaM binding; 2) positioned adjacent to the CaM-binding domain, as 
assessed by molecular modeling; 3) an impediment to Ca2+ /CaM binding and hence, 
enzyme activation; 4) displaced upon the binding of Ca2+/CaM. We propose that the 
tonic inhibition of cNOSs is reliant upon the occupation of key regulatory sites on 
cNOS by the autoinhibitory insertion. CaM binding causes the displacement of the 
insertion from these sites, thus activating NOS catalysis by "disinhibition". Close 
proximity of the inhibitory insertion would provide for an exceedingly high local 
concentration, forcing the equilibrium to favor the insertion-bound/inhibited state in 
the absence of bound Ca2+-CaM. This provides a possible explanation for the 
detection of basal activity in purified eNOS or nNOS in the absence of bound 
Ca2+/CaM (Moncada et al., 1989; Nathan & Xie, 1994), as it is conceivable that a low 
steady-state of the disinhibited conformation of cNOS may exist in the absence of 
bound- Ca2+/CaM. 
Following up on our identification of a putative ACE in the FMN-binding 
domain of cNOSs, recent reports have confirmed the autoinhibitory function (Chen & 
Wu, 2000; Daff et aI., 1999; Montgomery et al., 2000; Nishida & Ortiz de 
Montellano, 1999). Nishida and coworkers (Nishida & Ortiz de Montellano, 1999) 
engineered a series of cNOS constructs in which the ACE was deleted. For several 
other Ca2+/CaM-dependent enzymes, removal of an autoinhibitory domain eliminated 
tonic inhibition, resulting in an increased level of enzymatic activity in the absence of 
bound CaM. Removal of the ACE from cNOSs, either by deletion of the ACE or by 
substitution with the reductase domain of iNOS, however, did not result in Ca2+/CaM-
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independent NO synthesis (Daff et ai., 1999; Montgomery et ai., 2000; Nishida & 
Ortiz de Montellano, 1999). Nonetheless, maximal Ca2+/CaM-independent reductase 
domain activity was found to increase 2-3-fold, compared to the corresponding wild 
type enzyme. The Ca2+/CaM-independent activities of mutant cNOSs were at least 
equal to the Ca2+/CaM-bound activities exhibited by their respective wild type 
proteins. Additionally, the eNOS ACE deletion mutants (eNOS~) were found to have 
a reduced Ca2+-dependence for activity (ECso = 20 nM) compared to wild type eNOSs 
(ECso = 150 nM) (Nishida & Ortiz de Montellano, 1999). Substitution of either the 
entire reductase domain from eNOS or nNOS, with the homologous sequence of 
iNOS (devoid of an inherent insertion peptide), resulted in a similarly reduced Ca2+-
dependence (EC~o = 10 nM in each case). Essentially identical effects on Ca2+-
dependence were obtained for nNOS constructs expressing a deletion of the ACE 
(Daff et ai., 1999; Montgomery et aI., 2000). 
cNOS proteins without the peptide insertion exhibited enhanced Ca2+/CaM-
independent reductase activities and synthesized NO at reduced levels of Ca2+, 
compared to wild type proteins. These characteristics define the peptide insert as an 
autoinhibitory control element that contributes to the observed physiological Ca2+_ 
dependence of cNOSs. However, as cNOS constructs lacking the autoinhibitory 
peptide still require CaM for NO synthesis, it was also apparent that 
removaVdisplacement of the ACE alone is insufficient to elicit enzyme activation. 
Hence, CaM-induced conformational changes in addition to ACE displacement are 
necessary for activation of NO production. These additional actions of CaM may 
include alignment of FMN and heme regions between companion subunits in cNOS 
dimers, as well as alignment of FAD and FMN domains within subunits; alone or 
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together. these CaM-induced modifications would promote catalytically productive 
electron flux into cNOS oxygenase domains (Abu-Soud & Stuehr. 1993). 
The proposed control mechanism specifies that the binding of Ca2+/CaM 
would elicit the displacement of the ACE: this would predict that the presence of the 
ACE reduces the affinity for Ca2+/CaM binding to cNOSs. Reciprocally. the absence 
of the ACE in the sequence of iNOS would obviate the otherwise expected steric 
hindrance to Ca2+/CaM-binding and contribute to the observed high affinity Ca2+/CaM 
binding exhibited by iNOS at all levels of intracellular Ca2+. Studies of polypeptides 
corresponding to the CaM-binding sites of eNOS and iNOS, and of chimeras. in 
which the CaM-binding sequence of one NOS isoform is substituted for the 
corresponding region of another (Ruan et al.. 1996; Venema et al., 1996), indicate 
that the Ca2+ -dependence and affinity of CaM binding is dictated by elements in 
addition to the recognized CaM-binding sequence. These results have been interpreted 
to imply the existence of auxiliary CaM-binding regions on iNOS. accounting for the 
high-affinity CaM-binding exhibited by iNOS. However, the information provided 
herein recommends an alternative interpretation of these results, that the absence of 
the ACE from the sequence of iNOS contributes to an enhanced CaM affinity at low 
levels of free Ca2+. 
The studies of ACE-deleted cNOSs outlined above provide some insight into 
the underlying mechanism of the Ca2+-independent activity exhibited by iNOS. 
Chimeric cNOSs expressing the reductase domain of iNOS (including the CaM-
binding site), like iNOS itself, exhibited activity even in the presence of 5 rnM EGTA 
(Nishida & Ortiz de Montellano, 1998). If the absence of the ACE is the only reason 
165 
for the Ca2+ -independence of iNOS, then cNOS chimera lacking the ACE would also 
be expected to exhibit Ca2+-independent activity. However, such chimera, although 
requiring a reduced level of free Ca2+ for maximal activity than the respective wild 
type cNOSs, were nonetheless inactive in the presence of a calcium-chelator, EOT A. 
Therefore the Ca2+ -independent activity of iNOS cannot be explained simply by the 
absence of an ACE, but may arise from two scenarios. Either, iNOS possesses regions 
in addition to the canonical CaM-binding site that contribute to the interaction with 
bound CaM, or, as yet unidentified regions of cNOSs contribute to the proposed steric 
hindrance of Ca2+/CaM binding and hence, cNOS activation. 
In support of the former view, it is notable that known proteins which exhibit 
high-affinity CaM-binding at low levels of free Ca2+ often have two regions that 
contribute to the CaM-binding site. If thiswere the case for iNOS, a suitable candidate 
for this auxiliary site must lie immediately adjacent to the acknowledged CaM-
binding site. Coded for by a single exon, analogous to the two exons of cNOSs coding 
for the ACE, a small (17 amino acids in human iNOS), highly acidic (6 Arg/Lys) 
region exists. Close proximity to the conventional CaM-binding site and a charge 
pattern that is complimentary to the exposed acidic region of activated CaM, make 
this a good candidate for additional interactions with bound CaM. The smaller size of 
this region, compared to the ACE, would preclude the spatial hindrance of CaM-
binding that we attribute to the ACE. Deletion or mutation of this region in iNOS or 
replacement with the ACE of a eNOS, would provide a valuable test of wether this 
peptide provides a second CaM binding site in iNOS. Interestingly, an alternative 
alignment of the FMN-binding regions of NOSs (Chen & Wu, 2000) identifies a 
region in iNOS that is analogous to the region eNOS607_613 (KSYKIRF) within the 
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ACE. A modified mutation of the entire ACE of eNOS, in which only the regions of 
the ACE on either side of this motif are deleted (eNOSs94-606 and eNOS61 4-64S) has been 
constructed and investigated for function (Chen & Wu, 2000). This mutant exhibits 
high-affinity CaM binding and maintains 60% of its maximal level of NO synthesis in 
the presence of 5 mM EGTA. This region of iNOS, and regions immediately flanking 
it, are rich in basic residues and therefore could serve as an accessory CaM-binding 
site. This mutant was co-expressed with CaM and. like wild type iNOS was found to 
bind CaM as an intrinsic co-factor. Reciprocally, the absence of this region from the 
previously described ACE-deletions (Daff et at., 1999; Montgomery et at., 2000; 
Nishida & Ortiz de Montellano, 1999) may explain the lack of predicted Ca2+. 
independent activity. 
Our results, considered in the context of subsequent mutational analysis as 
noted above, may also provide an understanding of the intricacies of the Ca2+. 
independent activity exhibited by iNOS in vivo. Although it is known that 
incorporation of CaM into iNOS is a co-translational event, it remains unknown why 
CaM binding to iNOS appears to be Ca2+-independent. One possibility is that iNOS 
binds to, and is activated by, Ca2+-free CaM, nonetheless, this is unlikely given the 
observed decrease in iNOS activity in the presence of high concentrations of EGT A. 
More likely is that Ca2+-saturated CaM is incorporated into iNOS, and once bound 
exhibits a much higher affinity for Ca2+ binding, resulting in residual activity even in 
the presence ofEGTA. Hence, the term "Ca2+-independent" may be a misleading term 
when it comes to iNOS and other high-affinity CaM-binding proteins, such as 
phosphorylase kinase (Cohen et at., 1978; Grand et at., 1981) and myosin light chain 
kinase (Krueger et at., 1998). 
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Given the proposed manner of ACE-mediated inhibition, whereby the ACE 
functions as an impediment to Ca2+/CaM-binding, it is surprising that some ACE-
derived peptides can inhibit iNOS activity, albeit at much higher concentrations than 
required to inhibit cNOS activity. As mentioned previously, iNOS binds CaM with a 
remarkably high affinity, boiling in SDS-containing, calcium-chelating buffers is 
required to uncouple CaM-iNOS complexes (Cho et al., 1992). Inhibition of NOS 
activity by ACE-derived peptides is therefore, extremely unlikely to involve the 
displacement of bound CaM from iNOS. As a direct interaction can be demonstrated 
between CaM and ACE-derived peptides at high concentrations, one possibility is that 
the peptides interact with iNOS-bound CaM in situ, in the process disrupting iNOS 
activity. There is also the possibility that the reductase domain of iNOS, although 
devoid of an ACE, still contains vestigial binding sites required for ACE-mediated 
inhibition. This may provide clues to the evolutionary derivation of the NOS family 
of proteins. It is conceivable that iNOS either evolved from the cNOSs via a deletion 
event or, reciprocally, that the cNOSs were derived from iNOS by an insertional 
event. The presence of vestigial ACE-binding sites in iNOS would favor the former 
scenario. It is notable that phylogenetic trees, created by computer-assisted analysis of 
NOS isoform divergence, indicates that ACE-containing NOS (cNOSs) is ancestral to 
ACE-free NOS (iNOS). 
Although the putative site(s) of ACE/cNOS inhibitory interaction are 
unknown, several inferences as to the general locale and characteristics of such 
regions can be made. Firstly, Ca2+/CaM- dependent regulation remains intact in 
isolated nNOS reductase domain, making it likely that some sites of ACE-interaction 
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reside within this domain (Newton et al., 1998). Secondly, given the highly basic 
nature of the ACE (especially of eNOS), sites of interaction are likely to carry an 
excess of negative charge. Thirdly, by analogy to CaM-dependent kinase II, in which 
the autoinhibitory domain binds with the substrate binding site, the ATP binding site 
and bound-CaM (Brickey et al., 1994), the presence of multiple sites of eNOS/ACE 
interaction may be envisioned. 
Considering the probability that ACE-binding sites would be acidic in nature, 
one obvious candidate would be the surface of bound CaM; Ca2+ -bound CaM has an 
excess of exposed negative charges and also satisfies the criteria of proximity to the 
ACE. Examination of the amino acid sequence of cNOSs shows the presence of 
acidic "patches" located within the oxygenase domain. Other possible sites of 
interaction are the regions of the FMN-binding domain that flank the ACE or are 
directly adjacent to the CaM-binding domain. The location of some ACE-binding 
sites in the oxygenase domain is consistent with two observations. Firstly, chimeric 
NOSs expressing the reductase domain of cNOSs paired with the iNOS oxygenase 
domain exhibit a much-reduced Ca2+-dependence. In such chimera, the substituted 
iNOS oxygenase domain may be devoid of ACE interaction sites, nullifying the 
inhibitory effect that would otherwise be seen with wild type cNOSs. Secondly, the 
pattern of trypsinolysis observed for CaM-free isolated nNOS reductase domain, 
indicates that the ACE is already "free" (liu and Gross, unpublished observation), 
conceivably by removal of sites of ACE interaction within the oxygenase domain. 
Future mutational analysis of these putative binding sites in cNOSs, coupled with 
increased structural studies will be required to definitively identify sites of 
ACE/eNOS interaction. 
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Our initial studies, combined with subsequent mutational approaches. confirm 
the role of the FMN-insertion as an autoinhibitory control element (ACE). The 
absence of this region results in an increased basal-, and Ca2+/CaM-stimulated 
electron flux through the reductase domain of both eNOS and nNOS. Secondly, the 
ACE of the cNOSs appears to be largely. but not solely, responsible for the Ca2+_ 
dependence of activity exhibited by these enzymes. Important questions that remain 
are the autoinhibitory mechanism of the ACE and the location and identity of the key 
ACE-peptide interaction sites. 
Our study of ACE-derived pep tides suggests that binding may involve at least 
two conserved regions within the ACE. One is the basic motif RRKRK of eNOS 
(truncated to RK in nNOS) and the other is located at the well conserved N-terminal 
aspect of the ACE (EERKSYKVRF). ACE-derived peptides that express the N-
terminal region weakly inhibit eNOS activity, while those expressing the RRKRK 
motif are considerably more potent. The possible roles of these regions are considered 
below. 
3.3.2 Deletion of a Pentabasic Sequence Within the Autoinhibitory Control Element 
of eNOS Causes Enhanced Activity of the Reductase Domain and an Increased Rate 
of NO Synthesis. 
From the deletion studies discussed in the previous section, we can now attribute two 
functions to the ACE of cNOSs: (1) govern the rate of electron flux through the 
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reductase domain and (2) increasing the observed Ca2+ concentration required for 
activation by Ca2+/CaM. Whether identical or distinct, structural motifs of the ACE 
mediating (1) and (2) was considered. 
As noted above, alignment of the ACE regions of cNOSs clearly shows two 
distinct regions of conservation. An N-terminal segment, conserved throughout the 
cNOSs and a pentabasic motif (RRKRK) unique to eNOSs, (although a truncated 
dibasic form can be found in nNOSs, RK). To investigate the function of the RRKRK 
motif we expressed and characterized mutant eNOS proteins in which this motif was 
deleted or substituted with five Ala residues. In comparison to wild type eNOS, 
mutants lacking this motif were 2-3 fold more active in terms of NO synthesis, 
stemming directly from an increased rate of electron flux through the reductase 
domain ( as assessed from a concomitant increase in cytochrome c and ferricyanide 
reduction). Both basal (CaM-independent) and CaM-activated reductase activity was 
increased by the mutation, although bound-CaM was still required for the synthesis of 
NO. It is notable that calcium ECso values for activation by CaM were only slightly 
increased in the mutants and Ca2+-dependence for CaM-binding were completely 
unaffected by the mutation. Additionally, eNOS proteins lacking the RRKRK motif 
exhibited a slightly increased rate of CaM dissociation. 
The characteristics of mutant eNOSs that lack the RRKRK motif, combined 
with analyses of NOS mutants by other labs, helps to resolve some of the issues 
concerning cNOS regulation by Ca2+/CaM and the ACE. Deletion of the entire ACE 
from eNOS provided an interesting but unanticipated result, in that the resulting CaM-
bound protein exhibited a greatly increased maximal rate of NO synthesis, compared 
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to CaM-bound wild type eNOS (Nishida & Ortiz de Montellano, 1999). When the 
corresponding mutation was made in nNOS, the maximal catalytic rate of CaM-bound 
enzyme was unaffected by the absence of the ACE (Daff et al., 1999; Montgomery et 
al., 2000). This was unexpected, given our hypothesis that CaM-binding would 
completely relieve the inhibitory effect of the autoinhibitory domain and therefore the 
CaM-bound mutant and wild type eNOS were predicted to exhibit similar catalytic 
rates. However, it was previously shown that the NOS isoforms have fundamentally 
different rates of maximal enzymic activity. Specifically, nNOS (Bredt & Snyder, 
1990; Gerber & Ortiz de Montellano, 1995; Harteneck et al., 1994; Roman et al., 
1995) and iNOS (Fossetta et al., 1996; Gerber et ai., 1997; Hevel et al., 1991~ Stuehr 
et al.; 1991) have been shown to exhibit 5-10 fold higher overall activity than eNOS 
(Chen et al., 1997; List et al., 1997; Martasek et al., 1996; Pollock et al., 1991; 
Rodriguez-Crespo et ai., 1996; Rodriguez-Crespo & Ortiz de Montellano, 1996) (The 
specific activities we observed for wild type NOSs agreed well with published 
reports). The reduced rate of NO synthesis by eNOS was shown to arise specifically 
from a reduced maximal activity of the reductase domain (Nishida & Ortiz de 
Montellano, 1998), although the structural basis for this impaired reductase activity 
was unknown. We now appreciate that the autoinhibitory peptide is responsible for 
the inherently slower rate of reductase domain electron flux in eNOS. 
NOS protein chimera containing the eNOS reductase domain, but with a 
deletion of the ACE, displayed an increase in maximal reductase domain activity 
(assessed by cytochrome C and ferricyanide reduction) compared to wild type eNOS. 
It is notable that for eNOS~, the CaM-free reductase activity actually exceeded that 
observed with CaM-bound wildtype eNOS (Nishida & Ortiz de Montellano, 1999). 
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This implies that the inhibitory effects of the ACE are never fully removed by CaM 
binding to wildtype eNOS, explaining the relatively low level of reductase domain 
activity and hence NO synthesis by eNOS. Accordingly, the structural features which 
impair reductase activity of eNOS reside within the ACE. 
Although present in a truncated form in nNOSs, the pentabasic motif 
(RRKRK) is perfectly conserved throughout all the available mammalian eNOS 
sequences. Our results suggest that the pentabasic motif is the structural feature which 
is responsible for the attenuated reductase function of eNOS. Removal of this motif 
results in an enzyme with maximal CaM-bound rates of NO synthesis, as well as 
cytochrome c and ferricyanide reduction, that are comparable to that of nNOS. 
Support for this view comes from our finding that removal of this motif alleviates the 
residual inhibitory effects exerted on eNOS by the ACE, even in the presence of 
bound Ca2+/CaM. A similar deletion (WRRKRKESS) using the same expression 
system, was reported to result in no significant change in the observed maximal 
activities and a slight decrease in the ECso for Ca2+ (Chen & Wu, 2000). The reason 
for these different findings is assumed to be due to the removal of the extra four 
amino acids. Indeed, we would assume that the length of the residual ACE in mutated 
eNOSs is very important if, as hypothesized, the functioning of the ACE involves 
multiple sites of interaction. 
A role for the RRKRK motif in attenuation of electron flux through the 
reductase domain is supported by the ACE-derived peptide studies described in 
section I. Here, the most potent peptides were derived from the ACE of eNOS and 
contained the pentabasic motif. Potency increased as the pentabasic region was 
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gradually lengthened to include the entire ACE sequence. Peptides derived from the 
ACE of nNOS were much less potent inhibitors of NOS activity. This suggests that, 
due to the presence of the RRKRK motif, the ACE of eNOS is a much better inhibitor 
of NOS activity than the ACE of nNOS. 
We previously proposed the RRKRK motif as a site of interaction between the 
ACE and the surface of eNOS or bound CaM. We suggested a possible 
complementary binding site for this motif to be a "patch" of acidic residues in the 
oxygenase domain of cNOSs. Given the accelerated rate of CaM dissociation, relative 
to wild type eNOS, that we observed in mutants lacking the RRKRK motif, an 
interaction between the RRKRK motif and acidic regions of CaM may be more likely. 
From our ACE-derived peptide studies, mutation of the RRKRK motif would be 
expected to decrease the rate of CaM-dissociation from eNOS. Our results 
demonstrate the reverse situation, the lack of an RRKRK motif accelerates CaM-
dissociation. One possible interpretation is that the RRKRK motif is involved in 
ACE-CaM interactions (or interactions with regions flanking the CaM-binding site) 
that are not required for activation, but rather prevent "optimal" (nNOS-like) CaM-
binding. This may limit the extent of the CaM-induced conformational changes and 
account for the reduced activity of eNOS, compared to nNOS. 
The role of the conserved N-terminal region of the ACE of cNOSs was not 
investigated by us, but was hypothesized to dictate the relative Ca2+ -dependence, 
similar for both eNOS and nNOS. Deletion of a similar region of eNOS 
(QHKSYKIR) (Chen & Wu, 2000), resulted in a decrease in the ECso for Ca2+ 
required for activity without a dramatic effect on rate of NO synthesis, compared to 
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wild type (97±24 and 138±21 nmol/minlmg, respectively) Although a significant 
portion of this activity was Ca2+-independent (18±6 nmollminlmg), iNOS-like, high-
affinity CaM-binding was not observed. Additionally, a much larger shift in Ca2+_ 
dependence was observed when the entire (or entire minus eNOS607_6\3) ACE was 
deleted from eNOS (Chen & Wu, 2000; Nishida & Ortiz de Montellano, 1999). 
The RRKRK motif may also provide a basis for the classification of 
Ca2+/CaM-dependent NOSs of invertebrate origins, such as those expressed by 
Rhodnius prolixus (Yuda et al., 1996) and Drosophila melanogaster (Regulski & 
Tully, 1995). As the RRKRK motif is conserved in all the currently available eNOS 
sequences, we can consider this as criteria for classification at the molecular level. In 
the same way that presence of an ACE within the FMN binding domain defines 
cNOSs, the presence of an RRKRK motif within the ACE defines cNOS classification 
to specify eNOSs. All of the invertebrate cNOS sequences available to date do not 
express this motif within their ACE regions (Fig. 3.6, panel B), classification of these 
proteins as nNOSs would therefore seem appropriate. 
3.3.3 Regulation of eNOS by Phosphorylation of a Conserved cAMP-dependent 
Protein Kinase Site (Serill> Within the AutoinhibitOlY Control Element. 
Although eNOS is classified as Ca2+-dependent, other methods of regulation 
are inherent given the ability of certain stimuli to activate eNOS in a Ca2+_ 
independent manner; such stimuli include estrogen (Caulin-Glaser et ai., 1997), 
insulin (Zeng & Quon, 1996), insulin-like growth factor (Tsukahara et at., 1994) and 
vascular shear-stress (Ayajiki et al., 1996; Kuchan & Frangos, 1994). Given that a 
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large part of the regulation of eNOS activity rests with displacement of the 
auto inhibitory peptide, it is conceivable that reversible, Ca2+-independent mechanisms 
have evolved to relieve the exerted inhibitory effects. To gain insight into the 
mechanisms involved in "Ca2+-independent" eNOS activity, we considered the well 
characterized CaM-dependent protein kinase II (Strack et al., 1997). In this CaM-
dependent system autophosphorylation of the autoinhibitory domain mediates Ca2+_ 
independent activity. For eNOS, an attractive possibility would be that 
phosphorylation of the ACE can modify a site(s) of interaction, and hence 
relieve/reduce its imposed inhibitory actions. 
The ACE of eNOS is very rich in Ser and Thr residues and sequence analysis 
identified a conserved consensus site for cAMP-dependent protein kinase (PKA) 
mediated phosphorylation (R/l/KxS/T) at Ser63S1636 (RKESS). We demonstrated Ser63S ' 
in addition to Ser494 within the CaM-binding domain, to be an in vitro target for PKA-
mediated phosphorylation. However, functional analysis of phosphorylated eNOS 
showed no significant effect on the maximal rate of NO synthesis, maximal reductase 
activities, or the ECso of free Ca2+ required for enzyme activation. These findings are 
challenged by recent evidence suggesting a regulatory role for phosphorylation of this 
residue of eNOS by both PKA and cGMP-dependent kinase (PKG)(Butt et al., 2000). 
This group showed that eNOS was phosphorylated by both PKA and PKG in vitro 
and involved both Ser and Thr residues. Mass spectrometry identified phosphorylated 
residues corresponding to Serll77 (analogous to Ser1l79 in the bovine sequence), at the 
C-terminus and Ser633 (analogous to Ser 63sin the bovine sequence) within the ACE. 
Functional characterization of in vitro phosphorylated eNOS showed a reproducible, 
partial activation (10-20% of maximum), which was independent of Ca2+/CaM. This 
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also correlated with an approximate 4-fold increase in V max in the presence of bound 
Ca2+/CaM. Additionally, PKA stimulation in intact endothelial cells increased both 
Ca2+/CaM-independent and -dependent eNOS activity. However, more recent 
evidence would suggest that phosphorylation of Serl177 in the C-terminus of eNOS 
was the preferred site of phosphorylation by PKA (Chen et ai., 1999), and accounted 
for observed changes in phenotype that had been attributed by Butt et al to Ser63S 
phosphorylation. A mounting body of evidence now exists to support Ser1l79 as the 
major, phosphorylation-dependent site of eNOS regulation from studies involving 
protein kinase B (PKAIAkt) (Dimmeler et ai., 1998; Dimmeler et ai., 2000; Dimmeler 
et ai., 1999; Fisslthaler et ai., 2000; Fulton et aI., 1999; Luo et ai., 2000; McCabe et 
ai., 2000), this will be discussed in detail in chapter 4. 
In order to bypass complications of experimental interpretation owing to 
simultaneous phosphorylation of multiple sites, we assessed the possible regulation of 
eNOS by phosphorylation of Ser63S in a slightly different manner. We produced a 
mutant eNOS in which this Ser residue was exchanged for a Glu residue, the charge 
pattern of which can emulate the effects of a phosphoserine. However, these proteins 
failed to support a role for phosphorylation of the ACE in the regulation of enzyme 
activity. We must conclude that the regulatory effects attributed to phosphorylation of 
this residue (Butt et ai., 2000), were in fact due to the phosphorylation of Ser1l79 
within the C-terminus of eNOS. 
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CHAPTER 4 
THE C-TERMINUS OF ENDOTHELIAL NITRIC OXIDE SYNTHASE 
IMPEDES CALCIUM/CALMODULIN-INDUCED ENZYME ACTIVATION 
AND SERVES AS A SECOND AUTOINHIBITORY CONTROL ELEMENT 
4.1 Introduction 
In chapter 3, we previously demonstrated that the FMN binding subdomain of 
Ca2+-dependent isoforms of nitric oxide synthase (cNOS) contain a 45 amino acid 
insertion that functions as an auto inhibitory control element (ACE)(Salerno et ai., 
1997). Limited proteolysis studies revealed that the ACE is physically displaced upon 
CaM.binding to eNOS and that synthetic ACE·derived peptides inhibit both CaM 
binding and NOS activation. . Homology-based molecular modeling provided 
structural predictions consistent with an interaction between the ACE and bound CaM 
on eNOS. A model was posed whereby the ACE reversibly docks with a site on 
cNOS that impedes CaM binding and hence, enzyme activity. Binding of CaM to 
eNOS was postulated to displace the ACE by virtue of domain overlap, thereby 
eliciting enzyme activation. Support for this prediction was subsequently provided by 
demonstrations that deletion of the entire ACE from eNOS(Chen & Wu, 2000; 
Nishida & Ortiz de Montellano, 1999) or hNOS(Daff et ai., 1999; Montgomery et ai., 
2000) resulted in a marked reduction in the Ca2+ concentration required for activation 
of NO synthesis. Deletion of the ACE from eNOS also caused an increase in the 
maximal rate of NO synthesis, to a level comparable with that of wild type nNOS and 
iNOS(Nishida & Ortiz de Montellano, 1999). The mechanism by which ACE deletion 
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enhances NO production by eNOS must explain a specific acceleration in electron 
flux through the reductase domain. 
Recognition sites on cNOSs that interact with the ACE to modulate activity 
remain to be elucidated. That such sites reside within the reductase domain is 
indicated by the finding that Ca2+/CaM-dependent control of electron flux remains 
intact in isolated eNOS- and nNOS-derived reductase domains (Abu-Soud & Stuehr, 
1993; Abu-Soud et al., 1994). Despite the lack of a solved structure for any NOS 
reductase domain, 3-D homology-based models of NOS reductase subdomains can be 
developed considering many related proteins with defined high-resolution structures 
(Salerno et al., 1997). Only two regions of eNOS can not be reliably modeled in this 
manner due to the lack of suitable structural homologs. These completely unknown 
structural elements are the aforementioned 45 amino acid ACE peptide that resides in 
the FMN-binding subdomain and a C-terminal peptide (27-42 amino acids, depending 
on NOS isoform) that is not found in any related FAD-containing flavoprotein and is 
partially sequence-conserved within NOS isoforms. 
The C-terminal peptide is not needed for enymatic activity, inasmuch as NO 
synthesis is not attenuated by truncation of this region in iNOS (Xie et al., 1994). 
Nonetheless, the C-terminal peptide could conceivably function in regulation of 
enzyme activity. Recent studies have shown that endothelial shear-stress results in 
phosphorylation of a conserved serine within this C-terminal peptide of eNOS (Ser 
1179 in bovine eNOS) that causes attenuated Ca2+-dependence and enhanced catalytic 
activity in vivo (Chen et al., 1999; Dimmeler et al., 1999; Fulton et aI., 1999). We 
describe here the expression and characterization of a truncated bovine eNOS mutant 
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lacking Ser 1179 and the subsequent 26 C-terminal amino acids. Herein we present 
evidence supporting a key functional role for this C-terminal extension in determining 
the Ca2+-dependence for activation by calmodulin and in controlling the rate of eNOS 
catalysis. 
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4.2 Results 
4.2.1 Identification and Characterization of an Autoinhibitory Control 
Element Within the C-terminal Extension of eNOS 
Despite> 40% homology between the C-terminal regions of rat cytochrome 
P450 reductase (CPR) and NOS isoforms, alignments revealed that the C-termini of 
all NOSs extend beyond the site of CPR termination (Fig. 4.1 panel A). The fact that 
CPR is functionally homologous to the NOS reductase domain, including binding 
sites for NADPH, FAD and FMN, implies that the C-terminal extension in NOSs is 
not required for catalytic function. Indeed, it has been demonstrated for murine iNOS 
that all 31 amino acids C-terminal to regions homologous to CPR, can be deleted 
from the C-terminus without loss of activity (Xie et ai., 1994). Any further truncation 
of iNOS results in a loss of activity. Despite being surplus to requirements for NOS 
catalysis, significant identity in the C-termini of each individual isoform, and general 
conservation among all isoforms, suggests functional importance (Fig. 4.1, panel B). 
However, as for the previously described FMN-insertion, the lack of crystal-
structures for the reductase domain of any of the NOS isoforms hampered the 
formation of a structurally-based hypothesis for the function of the C-terminal 
extension. Again, we turned to homology to gain insight into the possible regulatory 
function of the C-terminus of eNOS and we considered the high-resolution crystal 
structure of rat CPR (Wang et ai., 1997). Although this exercise provides no direct 
structural information about the C-terminus of eNOS, the relative positioning of the 
C-terminus in CPR is telling. Notably, the C-terminus of CPR curls back towards the 
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main body of the enzyme and ends in a region proximal to the binding sites for both 
NADPH and FAD (see Fig. 4.2). The penultimate residue of CPR is Trp, which lies at 
the interface between bound NADPH and FAD. In this setting the aromatic ring of 
Trp is coplanar with the isoalloxazine ring of FAD and positioned in a manner in 
which the x-cloud of electrons could reasonably modulate electron transfer between 
NADPH and FAD. All NOSs contain the conservative aromatic substitution of Phe in 
place ofTrp in CPR (see Fig. 4.1). Given this arrangement, one can readily imagine 
that interactions of the C-terminus could cause subtle reorientation of this aromatic 
residue, and hence serve to regulate electron flux through the reductase domain. 
Importance of this Phe in NOS catalysis has already been demonstrated for iNOS; 
while activity is not diminished by removal of all subsequent C-terminai amino acids, 
deletion of this Phe results in 71 % loss in maximal activity (Xie et ai .• 1994). 
To investigate the possible regulatory function for the C-terminal extension of 
eNOS. we expressed and purified a mutant eNOS truncated at the C-terminus. 
Introduction of a stop codon in lieu of Ser1179, a residue that has previously been 
implicated as a site of in vivo regulation by the kinase AktIPKB (Dimmeler et al., 
1999; Fulton et ai .• 1999). results in C~7, a trunc~ted eNOS protein that is lacking 
27 of the 42 C-terminal amino acid residues that extend beyond the termination of 
CPR (see Fig. 4.1). 
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Fig. 4.1. Sequence alignment of various NOS isoforms and cytochrome P450 
reductase (CPR). Alignment was performed by the Clustal method using DNA 
Star Megalign, a program in the Lasergene suite of molecular biology tools. Panel 
A: Comparison of CPR with representative members of the three NO isoforms 
showing the C-termini (shaded regions are conserved between CPR and 0 s). 
Panel B: Conservation of regions of the C-terminal extension between NO 
isoforms (shaded regions are conserved). 
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Fig. 4.2. Structure of cytochrome P450 reductase (Wang, et aL 1997) showing 
only the positioning of the C-terminal residues (yellow) in relation to the bound 
cofactors, FAD, FMN and NADP+. Note that the penultimate Trp residue stacks 
with the FAD isoalloxazine ring at the juncture between the three cofactors. 
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4.2.1.1 Expression and purification. 
A two-step purification involving sequential affinity chromatography steps on 
ADP-sepharose and CaM-sepharose resins resulted in >90% homogeneity for both 
wildtype and C~27 eNOS, as estimated from Coomassie-stained SDSIP AGE (Fig. 
4.3). After several unsuccessful attempts at purification of expressed C~27 eNOS 
using the established protocol for wildtype eNOS, we investigated the reasons for our 
failure. After establishing the validity of expression by comparing the Triton X-100 
lysates of IPTG-induced vs. non-induced BL21 E. coli cells by SDS-PAGE, we next 
investigated the location of the desired protein. Surprisingly, we found the protein 
was localized to the particulate fraction of centrifuged lysates and, as only the soluble 
fraction was used for subsequent steps, was lost during processing. However, 
denaturing methods (Triton X-IOO, organic extraction) did not yield viable eNOS. 
Such methods have been used to purify other proteins, but due to eNOS being a large, 
complex enzyme containing a variety of cofactors, such denaturation/renaturation 
methods are unsuitable. The inclusion of the relatively gentle detergent CHAPS had 
previously been used to remove acylated-wildtype eNOS from anchorage sites in 
mammalian cell membranes (Garvey et al., 1994; Liu & Sessa, 1994; Pollock et al., 
1992). Hence, we tried this approach in our E. coli-based expression system. 
Extraction of CA27 eNOS (but not wildtype eNOS) from bacterial pellets was 
significantly improved by the inclusion of CHAPS (20 mM) in the bacterial lysis 
buffer. We assume this to be due to the predicted exposure of hydrophobic residues in 
the C-terminus of CA27 eNOS, which lead to a membrane associated protein. Overall 
protein yields ranged from 2-10 mg purified protein per liter of bacterial culture. 
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Spectrophotometry demonstrated that the CO-bound spectra of dithionite-
reduced Cfl27 and wt eNOS were indistinguishable (Fig. 4.4), indicating that C-
terminal truncation does not compromise heme-coordination. Accordingly, spectral 
assessment of heme-chromophore was used to quantify eNOS protein mass. 
Additionally, truncation of the C-terminus did not attenuate the ability of Cfl27 eNOS 
to form homodimeric complexes (Fig. 4.5). 
Now that we had expressed and purified functional Cfl27 eNOS, we 
investigated the effects of C-terminal truncation by characterization of the protein 
with relation to eNOS catalytic function and regulation by Ca2+/CaM. 
4.2.1.2 Catalytic activities of Cfl27 and wildtype eNOS 
Three catalytic activities of eNOS were analyzed and contrasted for wildtype 
and CA27 enzymes (Figs. 4.6 and 4.7). These distinct activities were determined in 
the absence and presence of bound-CaM (250 nM) and indicate maximal electron flux 
to heme (NO synthesis, Fig. 4.6), FAD (cytochrome c reduction, Fig. 4.7 panel A) and 
FMN (ferricyanide reduction, Fig. 4.7 panel B) (Adak et al., 1999). 
As shown in Fig 4.6, neither wildtype nor Cfl27 eNOS supported detectable . 
levels of NO synthesis in the absence of added CaM (although our laboratory has 
previously detected CaM-independent basal NO synthesis by eNOS using the much 
more sensitive [3H]-citrulline assay). Truncation of the C-terminus of eNOS resulted 
in a 2-fold increase in maximal CaM-induced NO synthesis, compared to wildtype 
enzyme (from 152±14 to 303±4 nmoVminlmg). 
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Given that the rate-limiting step for NO synthesis by CaM-bound eNOS 
appears to reside in the reductase domain (Nishida & Ortiz de Montellano, 1999; 
Nishida & Ortiz de Montellano, 1998), we monitored the rate that artificial electron 
acceptors could be reduced by electrons derived from reductase domain flavins of 
wildtype and CA27 eNOS. Although significant basal cytochrome c and ferricyanide 
reduction was observed with both CA27 and wildtype eNOS; basal activity was 3-4 
fold greater with CA27 (Fig. 4.7, panels A and B, respectively). In both cases, 
activity was accelerated 2-3 fold over basal after addition of excess CaM. 
Interestingly, the basal reductase activities of CA27 were greater than the CaM-
stimulated activities of wildtype eNOS. These findings reveal that truncation of 
eNOS's C-terminus markedly accelerates both basal and maximal CaM-induced 
electron flux to FAD and FMN. 
4.2.1.3 Effect of a C-terminal extension-derived peptide on eNOS activity 
As the use of synthetic peptides had provided insights into the function of the 
ACE present within the FMN-binding domain, we assessed the effect of a peptide 
(eNOS ll79-,2os) derived from the C-terminal extension on eNOS activity 
(corresponding to the 27 amino acids deleted in CA27 eNOS). However, unlike 
peptides derived from the FMN domain-ACE, eNOSII79_,20S was only weakly 
inhibitory, attenuating NO synthesis, 20% with 100 J.1M of peptide (Fig. 4.8). 
Inhibition of CA27 eNOS by eNOSII79_,20S followed a similar pattern to that observed 
for wildtype eNOS. Due to this lack of inhibition, the effects of this peptide on [1251]_ 
CaM binding were not assessed. 
We also assessed the effect of this peptide on the reductase domain of eNOS; 
a dose-response relationships were established for both CaM-dependent and 
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-independent reductase activities. For wildtype eNOS, both CaM-dependent and 
-independent cytochrome c reduction (FMN-mediated) were unaffected by eNOS 1179_ 
1205 at all concentrations tested (:~100 J.1M, Fig. 4.9, panel A). Truncation of the C-
terminus did not make eNOS more susceptible to inhibition of cytochrome c 
reductase activity (Fig. 4.9, panel B). Similarly, no effect was observed on 
ferricyanide reductase activity for either wildtype or C~27 eNOS (Fig. 4.10, panels A 
and B). 
Peptide studies outlined above would suggest that the C-terminal extension is 
not autoinhibitory, although removal of this region by mutation results in increased 
catalytic rates. Therefore, the phenotype of C~27 eNOS supports the proposed 
auto inhibitory role of the C-terminal extension, hence referred to as autoinhibitory 
control element 2 (ACE-2), in contrast with the established ACE-l within the FMN-
binding domain. However, although truncation of ACE-2 enhanced the basal, CaM-
free reductase activities of eNOS to a level greater than that of CaM-bound wildtype 
eNOS, additional CaM-induced conformational changes were required for this 
increase to manifest as NO production. CaM binding increases both the intra-domain 
(NADPH -+ FAD -+ FMN), and inter-domain (reductase domain -+ oxygenase 
domain, FMN -+ heme) electron flux through cNOSs (Abu-Soud et ai., 1994). We 
assume that these additional CaM-induced conformational changes are required to 
provide the functional FMN-heme alignment required for NO synthesis. We therefore 
investigated the effects of truncation of ACE-2 on the regulation of eNOS by 
Ca2+/CaM. 
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Fig. 4.3. SDS-polyacrylamide gel electrophoresis of purified recombinant 
C!127 eNOS. Recombinant C!127 eNOS eNOS protein was purified to > 90% 
homogeneity and showed approximate molecular weight of 135 kDa. 
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Fig. 4.4. P450 spectra of wildtype and C!127 eNOS. The CO-bound , dithionite 
reduced spectra of wild type (panel A) and C!127 eNOS (panel B) were obtained as 
described in methods. 
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Fig. 4.5. Low-temperature SDS-polyacrylamide gel electrophoresis of 
wild type and C!127 eNOS. Samples were prepared in SDS gel loading buffer a 
normal, but were not boiled. This allows the NOS homodimer to remain intact 
during electrophoresis. The apparent molecular weights of> 200 kDa indicates 
the formation of stable dimers by C!127 eNOS . 
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Fig. 4.6. Rates of NO synthesis by wildtype and CA27 eNOS. All experiments were 
carried out using 10 pmoles of NOS, 250 nM CaM and optimal Ca2+ concentrations 
(100 /lM). CaM-free measurements of activity were obtained in the presence of 5 mM 
EGTA and rates are derived from the mean of two separate preparations of each 
enzyme, assayed in triplicate. 
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4.2.1.4 Ca2+ -dependence of calmodulin binding and activation of eNOS 
One aspect of eNOS regulation is that it is catalytically quiescent at resting 
levels of intracellular Ca2+ (=100 nM), only becoming active once Ca2+/CaM binding 
is facilitated by stimulus-evoked increases in intracellular Ca2+ (::; 1 JlM). We 
wondered if the truncation of ACE-2 would affect the activation of eNOS by 
Ca2+/CaM. Therefore, experiments were performed to compare the Ca2+-dependence 
for activation of wildtype and Cfl27 eNOS (80 nM) by CaM (100 nM). As shown in 
Fig. 4.11 (panel A), truncation of the C-terminus of eNOS resulted in a 5 to 6-fold 
diminution in the concentration of Ca2+ required for half-maximal activation of NO 
synthesis, compared to wildtype eNOS (ECso values for free Ca2+ = 83 nM and 461 
nM, respectively). Notably, Cfl27 eNOS was >90% active at concentrations of Ca2+ 
that support less than 10% maximal activity of wildtype eNOS. This relative "Ca2+-
independence" of Cfl27 eNOS contrasts with the complete Ca2+ -independence of 
IDurine iNOS activity at all concentrations of Ca2+ tested (Fig. 4.11, panel A). 
As the activation of eNOS is dependent upon the conformational changes 
induced by Ca2+/CaM binding, we next compared the Ca2+-dependence for [mIl-CaM 
binding to Cfl27 and wildtype eNOS. Assessment of both [12SI]_CaM binding (Fig. 
4.11, panel B) and eNOS activity (Fig. 4.11, panel A) were performed using an 
identical array of Ca2+ buffer solutions, permitting direct comparison of observed 
Ca2+_dependencies. Despite the substantial difference between ECso values for Ca
2+ 
observed for activity of Cfl27 and wiIdtype eNOS, curves reflecting the Ca2+_ 
dependence for binding of [12sJl-CaM exhibited a much smaller difference between 
wildtype and Cfl27 eNOSs. For obvious reasons, [12sJl_CaM binding experiments 
'mpossible to perform with iNOS. 
were 1 
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These findings are reconciled by a fundamental difference between these 
enzymes: (discussed more fully in Part II) whereas wildtype eNOS binds [mIl-CaM 
at Ca2+ concentrations that are significantly lower than that required for physiological 
enzyme activation (=4-fold difference in ECso values), the Ca2+ -dependence for [mI]_ 
CaM binding and activation of Cl127 eNOS are indistinguishable at Ca2+ 
concentrations above those typically found in resting cells (100 nM)(Persechini & 
Cronk, 1999). It is notable however, that the physiological level of Ca2+ needed for 
eNOS activation is likely to be highly complex, and influenced by numerous factors, 
including the concentration of Mg2+, caveolins, heat shock protein 90 (HSP90), CaM, 
and the ratio of CaM to NOS. 
4.2.1.5 Calmodulin binding affinity. 
As the Ca2+-independent activity of iNOS is due to its remarkably high-
affinity binding of CaM (Cho et ai., 1992), we wondered whether an increased 
affinity for CaM contributes to the reduced Ca2+-dependence for activation of Cl127 
compared to wildtype eNOS. To examine this possibility, we defined the 
concentration-dependence for CaM to both activate and bind to Cl127 and wildtype 
eNOS, in th~ presence of excess Ca2+ (100 J.1M). In contrast to predictions, activity 
assays showed that Cl127 eNOS displayed a slightly reduced affinity for CaM vs. 
wildtype eNOS (ECso = 35 and 23 nM, respectively; see Fig. 4.12, panel A). 
Saturation analysis of [12sI]_CaM revealed similar and essentially identical 
affinities of CaM for Cl127 vs. wildtype eNOS (EC so = 13 nM and 14 nM, 
respectively; see Fig. 4.12, panel B). Based on estimated calculations of free [CaM], 
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correcting for the component of added [J2SI]_CaM that contributes to total binding, we 
calculate Kd values for C~27 and wildtype eNOS of 3 nM and 4 nM, respectively. 
Such calculations were not possible for assays of NOS activity, as a direct 
measurement of bound-CaM was unavailable. 
As a further analysis of the affinity for CaM binding of wild type and C~27 
eNOS, we assessed the rate of dissociation of eNOS-CaM complexes that had been 
formed at maximal levels of Ca2+. Dissociation was initiated using the previously 
described experimental design to prevent the re-association of [J2sI]-CaM-cNOS 
complexes, following addition of a 3000-fold molar excess of unlabelled CaM. The 
rate of dissociation of C~27-CaM complexes was not discernibly different from that 
exhibited by CaM complexes involving wildtype eNOS; indeed fitted curves were 
virtually superimposable (Fig. 4.13, panel A). Linear analysis of this data indicated 
half times for [l12S]-CaM dissociation of 21.4 and 21.0 min for wildtype and C~27 
eNOS, respectively (Fig. 4.13, panel B). 
Binding affinity is determined by two variables, association rate (kon) and 
dissociation rate (koft). As we had found no difference in the rate of CaM dissociation, 
we also looked at the relative rates of CaM association with wildtype and C~27 eNOS 
(Fig. 4.14). Rates of CaM association were indistinguishable for these enzymes, 
although the rapidity of binding precluded the determination of K.xf' Nonetheless, we 
conclude that truncation of ACE-2 does not significantly affect the affinity of eNOS 
for CaM binding and must occur by a different mechanism. This phenomenon will be 
discussed in more detail in part II. 
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4.2.1.6 Does it effect the EC~ for Ca2+ if the CaM-eNOS complexes are pre-formed 
The experiments described in the previous section only looked at the 
formation of eNOS complexes under conditions in which Ca2+ was limited. Under 
physiological conditions CaM-binding to eNOS, and hence activation, would occur 
during a spike in intracellular Ca2+. CaM-eNOS complexes would then dissociate, and 
hence inactivate eNOS, as intracellular Ca2+ returned to resting levels. We therefore 
investigated potential differences (hysterisis) in the Ca2+-dependence curve for 
inactivation vs. activation of eNOS proteins. Activity of wildtype and C!l.27 eNOS 
were assessed under each of two conditions. Firstly, CaM-eNOS complexes were 
allowed to pre-form at maximal levels of Ca2+ ("" 1 JlM) prior to addition of Ca2+_ 
chelating buffers. Thus, this experimental paradigm reflected the achievement of a 
new equilibrium condition for bound CaM after dissociating from eNOS due to Ca2+_ 
chelation (unbinding). Secondly, eNOS (in"" 1 JlM Ca2+) was added to Ca2+-buffered 
solutions already containing CaM. In this setting, the levels of Ca2+ limited the 
equilibrium of association of CaM-eNOS complexes (binding). For both C!l.27 and 
wildtype eNOS, the two different treatments did not demonstrate any significant 
difference in the level of free Ca2+ required for half maximal activity (Fig. 4.15, 
panels A and B). Hence. the observed differences in Ca2+-dependence for activity for 
C!l.27 eNOS. compared to wildtype eNOS, could not be attributed to differences in 
the Ca2+ -dependence for binding to these species. 
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4.2.2 CaM binding and eNOS activation are distinct and temporally separated events 
It is accepted, as written several times in the body of this thesis, that cNOS is 
activated by Ca2+/CaM binding following a stimulus-evoked increase in intracellular 
Ca2+, however, it seems that this may be factually incorrect. This statement would 
suggest that CaM-binding caused cNOS activation. However, the results in part I (Fig. 
4.11. but shown more clearly in Fig 4.16, panel A) indicated that wildtype eNOS 
binds r25I]-CaM at Ca2+ concentrations that are significantly lower than required for 
enzyme activation (=4-fold difference in ECso values). Previously. our laboratory 
observed similar differences between CaM-binding and activation exist for nNOS 
(Weissman. Jones and Gross, unpublished finding). When the same comparison is 
made for C627 eNOS (Fig 4.16, panel B) the Ca2+-dependence for [12sI]_CaM binding 
and activation of C627 eNOS are indistinguishable at Ca2+ concentrations above those 
typically found in resting cells (100 nM)(Persechini & Cronk. 1999). This suggests an 
inherently different mode of regulation between the two enzymes and provides insight 
into the physiological regulation of eNOS. 
From our data. and that of others (Venema et ai .• 1996), it seems that CaM 
binding alone is not always sufficient to fully activate cNOS enzymes and, at low 
levels of intracellular Ca2+, an inactive cNOS-CaM complex can exist. When 
searching for a basis for this phenomenon, we looked at what is known about the 
regulation of cNOSs, and other CaM-dependent enzymes by Ca2+/CaM. 
From the study of CaM itself, we gained an appreciation that CaM can interact 
with target proteins via one or both of its two calcium-binding lobes (see Fig. 4.26). 
CaM is a 17 KD protein composed of an 8-turn central ex-helix, flanked by globular 
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N-terminal and C-terminal Ca2+-binding lobes (Babu et al., 1988). Each lobe consists 
of two EF-hand motifs that possess the capacity for binding a single Ca2+ atom 
(Persechini et ai., 1989). Binding of Ca2+ causes a conformational change, exposing 
hydrophobic and acidic residues which engage in binding to the relevant regulatory 
sites on target proteins (Weinstein & Mehler, 1994). It has been shown that the C-
terminal lobe of CaM binds Ca2+ with a greater affinity (approximately lO-fold) than 
the N-terminallobe (Linse et al., 1991). Hence, at basal levels of Ca2+, one lobe of 
CaM will exist partially in the active binding conformation, while the other remains in 
an inactive non-binding conformation. 
Binding by cNOSs of a CaM species that is only partially Ca2+-saturated is 
supported by the fact that each lobe of CaM can bind to nNOS independently 
(Persechini et al., 1994) and that binding of the N-terminal lobe mediates nNOS 
activation (Persechini et al., 1996). Given this large disparity in Ca2+ affinity between 
the two lobes of CaM, it is not surprising that [12sJ]-CaM-binding studies indicate that 
the C-terminallobe of CaM can be bound to both nNOS (Weissman, Jones and Gross, 
unpublished observation) and eNOS at resting concentrations of intracellular Ca2+ 
(100nM). 
We therefore utilized wildtype CaM, in conjunction with CaM constructs 
which were engineered to express two C-terminal (CC-CaM) or two N-terminal (NN-
CaM) lobes (Persechini et al., 1994), to investigate the activation of eNOS and Cfl.27 
eNOS by Ca2+/CaM. 
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4.2.2.1 Activation of wild type and CA27 eNOS by en~ineered CaM proteins 
Before we assessed the effects of engineered CaM proteins on enzyme 
activation, it was first necessary to establish that these proteins were capable of 
complex formation with wildtype and CA27 eNOS. As 125I-Iabeled CC-CaM and NN-
CaM were unavailable, we compared the ability of these engineered proteins to 
competitively inhibit the binding of [125I]_CaM to eNOS proteins. As shown in Fig. 
4.17 (panel A), at a concentration of 50 nM wildtype (NC-CaM), NN-CaM and CC-
CaM all potently inhibited the binding of [125I]_CaM (1 nM) to wildtype eNOS 
(94.7±O.5, 92.8±0.3 and 86.5±1.5% inhibition, respectively). This indicates that all 
engineered CaMs had the ability to form complexes with wildtype eNOS. A similar 
pattern of competitive inhibition was observed for the various CaM proteins with 
CA27 eNOS (Fig. 4.17, panel B), although with slightly less potency (93.4±2.0, 
85.6±2.0 and 78.o±1.5% inhibition, by CN-, NN- and CC-CaM, respectively). Given 
that binding of eNOS by these engineered CaM proteins was confirmed, we 
investigated their ability to elicit activation of wildtype and CA27 eNOS. 
Like NC-CaM, NN-CaM elicited full activation of eNOS, but CC-CaM failed 
to evoke any detectable NO synthesis (Fig. 4.18). This concurred with the previous 
findings of nNOS by Persechini et ai, showing that although both lobes of CaM are 
capable of interactions with cNOSs, binding of the N-terrninallobe is essential for 
activation (Persechini et al., 1996). Predictably, CA27 eNOS was fully activated by 
NN-CaM, but interestingly was also partially activated by CC-CaM. CC-CaM elicited 
29.8±4.3% of the activity of CA27 eNOS, relative to that observed in the presence of 
NC-CaM (Fig. 4.18). It is possible that higher concentrations of CC-CaM would elicit 
fuller activation of CA27 eNOS, however, we were unable to test this due to limited 
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CC-CaM availability (a one-time gift from Dr. Persechini). The fact that CC-CaM 
I 
was able to elicit partial activation of Cfl.27 eNOS, but not wildtype eNOS, suggests 
that there are distinct differences in the mode of CaM-dependent activation of the two 
enzymes. 
To further investigate this phenomenon, we looked at the ability of NN - and 
CC-CaM to activate the reductase domain of wildtype and Cfl.27 eNOS. For wildtype 
eNOS (Fig. 4.19, panel A), NN-CaM, as expected, elicited full activation of 
cytochrome c reductase activity. Interestingly, CC-CaM was able to elicit a modest 
increase in the rate of cytochrome c reduction (29.6±7.8% of NC-CaM-dependent 
activity). Cfl.27 eNOS (Fig. 4.19, panel B) also exhibited full activity in the presence 
of bound NN-CaM, and exhibited a similar level of increased activity in the presence 
of CC-CaM (25.88±0.5% of NC-CaM-increased activity). When· ferricyanide 
reduction was examined, NN-CaM again elicited near full activation of wildtype 
eNOS (66.3±16.2% of NC-CaM-increased activity) (Fig. 4.20, panel A). However, 
CC-CaM did not elicit any increase in the rate of ferricyanide reduction. Conversely, 
Cfl.27 eNOS-dependent ferricyanide reduction was fully activated by either NN-CaM 
or CC-CaM (145.0±3.3% and 90.5±2.2% of NC-CaM-increased activity, 
respectively). This again suggests fundamental differences in CaM-dependent 
regulation between wildtype and Cfl.27 eNOS. 
From our experiments with CC-CaM, there are two reasonable explanations to 
consider for the activation of Cfl.27 eNOS in the absence of an N-terminal lobe of 
, 
CaM, an apparent prerequisite for activation of wildtype eNOS. One possibility is that 
binding of a single C-Iobe of CaM is sufficient to elicit the partial activation of Cfl.27, 
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but not wildtype eNOS. The second possible scenario is that both lobes of CaM are 
required for activation of CtJ.27 eNOS, but one of the C-Iobes of CC-CaM can 
substitute for the normally present N-Iobe. The latter explanation would require that 
truncation of ACE-2 modifies the critical interactions between eNOS and the N-Iobe 
of CaM that lead to enzyme activation. We hypothesize that the presence of ACE-2, 
directly or indirectly, acts as an obstruction to binding for the N-Iobe of CaM. 
To test this, we compared the Ca2+-dependence curves for activation of 
wildtype and CtJ.27 eNOS by NN-CaM. As expected, due to the low-affinity Ca2+. 
binding exhibited by the N-Iobe of CaM (compared with the C-Iobe), Ca2+-
dependence curves for both enzymes were significantly shifted to the right, vs. NC-
CaM (Fig. 4.21). However, the ECso of Ca2+ for activation of CtJ.27 eNOS was 
significantly different to that for wildtype eNOS (ECso 853.1±3.10 and 1089.0±1O.4). 
This result supports our hypothesis that the presence of ACE-2 primarily affects the 
interactions of eNOS with the N-Iobe of CaM. Ca2+-dependence curves for [125I]_CaM 
binding, dependent on interactions between eNOS and the C-Iobe of CaM, show very 
little difference between wildtype and CtJ.27 eNOS. However, Ca2+-dependence 
curves for CaM-dependent activation, largely dependent on interactions between 
eNOS and the N-Iobe of CaM, demonstrate a 5-fold reduction in ECso of Ca2+ of 
CtJ.27 eNOS. The above· experiment, using NN-CaM demonstrates that the 
interactions between the N-Iobe of CaM and eNOS are indeed different between wild 
type and CtJ.27 eNOS. 
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4.2.3 RegulatoI)' interactions of ACE-2 
4.2.3.1 Interactions between ACE-l and ACE-2 
Mutant eNOS lacking ACE-2 exhibited a 2 to 3-fold increase in specific 
activity and a 5 to 6-fold decrease in the observed ECso for Ca2+ for eNOS activation 
by Ca2+/CaM. This was very similar to the observed. phenotype of eNOS mutants 
lacking the aforementioned ACE-I, within the FMN-binding domain (Chen & Wu, 
2000; Nishida & Ortiz de Montellano, 1999). Due to this similarity, we wondered if 
this could be explained by an interaction between ACE-l and ACE-2. If ACE-2 
contained a binding site for ACE-I, which was required to exert its inhibitory effects, 
or vice versa, then removal of one would negate effects of the other. Hence, deletion 
of ACE-l or ACE-2 could have similar effects because they are affecting the same 
inhibitory machinery. 
To test this theory we utilized the ACE-I-derived peptides described in 
chapter 3, specifically eNOS617_639' This peptide forms an inhibitory complex with 
wildtype eNOS, displacing bound CaM and preventing enzyme activation. The 
location of the ACE-l binding site on eNOS is unknown; we hypothesized that if this 
peptide exerts its effects by an interaction with a binding site within ACE-2, Ct:.27 
eNOS would be less susceptible to inhibition by the peptide. We compared the 
potency of eNOS617-639 to inhibit both activity of, and [125IJ-CaM binding to, wildtype 
and Ct:.27 eNOS. Consistent with our hypothesis, C~27 eNOS was significantly less 
susceptible to inhibition of both activity (ICso > 1 00 JlM) and [12sIJ-CaM binding (ICso 
=50 JlM), compared to wildtype eNOS (ICso =30 JlM and =15 JlM, for activity and 
[12SI]_CaM binding, respectively) (Fig 4.22, panel A and B). Although these results 
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are supportive of a regulatory interaction between ACE-l and ACE-2, further 
biochemical and/or structural evidence is required to confirm this interaction. 
4.2.3.2 Interaction between ACE-2 and heat shock protein 90 
The phenotype of ACE-2 truncated eNOS is also similar to that exhibited by 
eNOS when in a functional complex with heat shock protein 90 (HSP90). We 
wondered whether the binding of HSP90 involves interactions with ACE-2, that may 
disable the tonic inhibition of eNOS imposed by this region. Thus, we compared the 
ability of HSP90 to evoke increases in activity of wildtype and C~27 eNOS (Fig. 
4.23). HSP90 caused a similar dose-dependent increase in the activity of both 
wildtype and C~27 eNOS. However, the maximum increase in either case was only 
30-50% above control levels, a much smaller increase than the reported 2 to 3-fold 
increase in activity (Garcia-Cardena et al., 1998). These results fail to support the 
view that eNOS activation by HSP90 complex formation does not involves ACE-2. 
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4.3 Discussion 
From the cloned sequences it was apparent that the reductase domain of all the 
NOS isoforms shows striking homology to mammalian CPRs (Bredt et al., 1991; 
Griffith & Stuehr, 1995). Despite this overt resemblance. reductase domains of 
cNOSs are distinguished from CPR in that their inter-flavin electron flux is controlled 
by binding of Ca2+/CaM (Abu-Soud & Stuehr. 1993; Abu-Soud et al .• 1994) - the 
structural basis for this mode of regulation is unknown. The present findings suggest 
a pivotal role of the C-terminus of eNOS in controlling reductase domain activity by 
CaM . 
. There are three segments of cNOSs for which CPR displays no homologue. 
the CaM binding peptide. the ACE peptide in the FMN subdomain, and a C-terminal 
peptide extension. The regulatory role of CaM and the ACE peptide are now well 
established, we therefore considered that the C-terminal extension might also serve a 
regulatory function in cNOSs. This view is in accord with recent demonstration that 
phosphorylation of a C-terminal Ser residue modulates eNOS activity in vivo (Chen 
et al., 1999; Dimmeler et al., 1999; Fulton et al., 1999). 
Here we have shown that truncated eNOS, lacking 27 amino acids from the C-
terminus, displays activity at dramatically reduced levels of free Ca2+ in comparison 
to wildtype eNOS. Truncation of the C-terminus also results in a 2-3 fold acceleration 
in maximum CaM-induced NO synthesis. associated with to an enhanced activity of 
the reductase domain, as measured by rates of cytochrome c and ferricyanide 
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reduction. The truncation also imparts a diminished sensitivity to inhibition by a 
synthetic FMN domain ACE-derived peptide (ACE-I). 
Independent investigations from the laboratory of Dr. Masters, simultaneously 
described a regulatory role for the C-termini of all three isoforms of NOS (Roman et 
al., 2000; Roman et al., 2000). For iNOS (Roman et al., 2000), mutants lacking a1121 
amino acids of ACE-2, a 7 to to-fold increase in reductase activities was described, 
however, NO synthesis was decreased 55-70%. Using stopped-flow 
spectrophotometry, electron transfer into and between the two flavins, and from the 
flavins to the heme, was assessed to be 2 to 5-fold faster in the absence of ACE-2. 
Similar mutants, lacking the entire ACE-2, were made for both of the eNOS isoforms 
with interesting results (Roman et al., 2000). Removal of the entire ACE-2 of rat 
nNOS (33 amino acids) or bovine eNOS (42 amino acids) resulted in an enzyme 
which exhibited CaM-free cytochrome c reductase activities that were 7 to 21-fold 
higher than the corresponding wildtype cNOS. Unexpectedly, the addition of CaM 
resulted in a decrease in these rates, whereas CaM-bound wildtype and truncated 
NOSs reduced cytochrome c at roughly similar rates. When the FAD-dependent 
reduction of ferricyanide was assessed, the results were slightly different. For nNOS, 
the truncated form exhibited CaM-free rates of ferricyanide reduction that were 
markedly higher than the wildtype, but unchanged by CaM-binding. Similarly, in the 
absence of CaM, the truncated form of eNOS exhibited a 2-fold greater rate of 
ferricyanide reduction than wildtype eNOS. However, while the addition of CaM 
caused an increase in activity of wildtype eNOS, ferricyanide reduction by the 
truncated forms was attenuated upon CaM binding. Thus, CaM enhanced the 
reductase functions of wildtype cNOSs, but acted as a partial, non-competitive 
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inhibitor of the reductase functions of truncated mutants. When the ability of these 
proteins to synthesize NO was assessed, it was found that truncated forms of cNOS 
exhibit a significant increase in the rate of NO synthesis, compared to their cognate 
wildtype forms (45 and 33% increase for truncated nNOS and eNOS, respectively). 
Notably, the truncated proteins also exhibited CaM-independent synthesis of NO, 
albeit at low levels (14 and 20% of CaM-dependent NO synthesis for truncated nNOS 
and eNOS, respectively). 
Combined with our own studies, the evidence from C-terminal truncation 
confirm the important regulatory function of the C-terminal extension (ACE-2) for all 
NOS isoforms (Roman et al., 2000; Roman et al., 2000). However, the mechanism by 
which ACE-2 exerts these inhibitory effects remains to be elucidated. Additionally, 
given that AktIPKA-mediated phosphorylation of a Ser residue within ACE-2 of 
eNOS has been shown to be an in vivo form of regulation (Chen et al., 1999; 
Dimmeler et al., 2000; Dimmeler et al., 1999; Fulton et al., 1999; McCabe et al., 
2000), our studies provide a possible mechanism for the regulation of eNOS by 
AktlPKA. 
4.3.1 How does ACE-2 exert its autoinhibitOlY effects? 
As the reductase domain of NOSs exhibits a good degree of homology to 
cytochrome P450 reductase (CPR), we used the solved crystal structure of CPR 
(Wang et al., 1997) to gain insight into the possible regulatory functions of ACE-2. 
Obviously, as CPR lacks this region, this exercise provides no direct structural 
information about the C-terminus of eNOS. However, the relative positioning of the 
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C-terminus in CPR is highly informative. Notably, the C-terminus of CPR curls back 
towards the main body of the enzyme and ends in a region proximal to the binding 
sites for both NADPH and FAD. As shown in Fig. 4.2, the penultimate residue of 
CPR, a Trp residue, lies at the interface between bound NADPH and FAD. The 
distance between bound NADPH and the isoalloxazine ring is at least 9 AO, a distance 
too great for efficient electron tunneling. This structure was derived using bound 
NADP+, and hence the distance may actually be reduced by a conformational shift 
when NADPH is bound to CPR, allowing efficient electron transfer. 
In any event, the structure of CPR raise the possibility that the C-terminal 
residues playa role in electron transfer. The aromatic ring of the penultimate Trp of 
CPR is coplanar with the isoalloxazine ring of FAD and is positioned in a manner in 
which the 1t-cloud of electrons could reasonably modulate electron transfer between 
NADPH and FAD. It is possible that this 1t-cloud of electrons provides a route for 
electron flow, directly mediating the transfer of electrons from NADPH to FAD. It is 
equally possible that this 1t-cloud of electrons serves as an impediment to electron 
transfer, which must be displaced in order to facilitate electron transfer. As can be 
seen in Fig. 4.1, all NOSs contain a Phe residue, which is homologous to the C-
terminal Trp of CPR. Given this arrangement, one can readily imagine that 
interactions of the C-terminus could cause subtle reorientation of this aromatic 
residue, and hence serve to regulate electron flux through the reductase domain. 
Importance of this Phe in NOS catalysis has already been demonstrated for iNOS; 
while activity is not diminished by removal of all subsequent C-terminal amino acids, 
deletion of this Phe results in 71 % loss in maximal activity (Xie et al., 1994). 
Conceivably, ACE-2 could extend to a point where it can modulate the transfer of 
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electrons from FAD to FMN. The two flavin rings of FAD and FMN form contacts 
via their dimethyl benzene rings; it is possible that ACE-2 could modulate both the 
angle and distance between these two rings. This could in tum regulate the flow of 
electrons between the two moieties. An interaction between ACE-2 and the reductase 
domain flavins is supported by evidence from truncation of the entire ACE-2. Firstly, 
removal of this region increases the rate of electron flow, both into (NADPH -7 FAD) 
and between (FAD -7 FMN) the flavins (Roman et al., 2000; Roman et al., 2000). 
Secondly, the presence of ACE-2 also stabilizes the one electron-reduced 
semiquinone form exhibited in intact iNOS, the semiquinone form could not be 
detected in truncated iNOS. Stabilization of the semiquinone may occur by ACE-2 
limiting molecular oxygen's access to the "opening" of the FAD-FMN interface. This 
possibility may extend to artificial electron acceptors, cytochrome c and ferricyanide, 
providing an explanation for the enhanced reductase activities observed with C-
terminal-truncated NOSs. 
Further consideration of CPR structure suggests an additional mechanism by 
which the C-terminal extension could serve to inhibit eNOS activity - obstruction of 
the trans-flow of electrons from the reductase domain of one monomer to the 
oxygenase domain of the other monomer. The structure of CPR is consistent with the 
possibility that C-terminal residues of NOS extend into the region of the dimer 
interface. If so, interactions with the FMN-domain auto inhibitory peptide may serve 
to modulate FMN-heme contacts required for NO synthesis. In one model, we 
envision that the C-terminal extension might impose a "wedge" that impedes electron 
transfer between the FMN of one monomer and the heme of its counterpart. A role for 
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the ACE-2 in the control of inter-domain (FMN ~ heme) electron flow is supported 
by stopped-flow analyses of ACE-2 deleted NOSs. In truncated iNOS the rate limiting 
step for NO synthesis was no longer the supply of electrons from the reductase 
domain (heme reduction), as for wildtype iNOS, but was now limited by the rate of 
dissociation of the heme-nitrosyl complex. This would imply that ACE-2 interferes 
with the flow of electrons between reductase and oxygenase domains. 
An intriguing possibility is that ACE-l and ACE-2 function in concert, i.e. the 
auto inhibitory peptide in the FMN-binding domain confers inhibition by interacting 
with residues in the C-terminal peptide extension. If so, phosphorylation of Serl179 
(or removal of the C-terminal extension) may activate eNOS by preventing this 
interaction. Several findings provide evidence consistent with an interaction between 
the C-terminus and the autoinhibitory domain. First, deletion of the autoinhibitory 
domain results in an enzyme with a decreased Ca2+-dependence for activation and a 2-
3 fold increase in the rate of NO synthesis (Nishida & Ortiz de Montellano, 1999), a 
near-identical phenotype to that observed for CtJ.27 eNOS. If the C-terminus contains 
the binding site for the auto inhibitory 'domain, this would explain the similar 
phenotypes; inhibition can be equivalently relieved by removal of either 
auto inhibitory domain in toto, or by selective modification of key sites of interaction. 
Second, we found that truncation of the C-terminus of eNOS imparts a diminished 
sensitivity to inhibition by a synthetic autoinhibitory domain-derived peptide. The 
efficacy of such peptides for inhibiting CaM binding and activation of cNOSs was 
considered to result from binding to residues that dock with the endogenous 
autoinhibitory peptide (Salerno et al., 1997). The CPR crystal structure does not 
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provide clear support for this interaction. Indeed, ACE-! and ACE-2 would appear to 
originate from opposing sides of the reductase domain flavins, at too greater a 
distance to infer their interaction. However, given the lack of structural information 
for either ACE, the relative extension and positioning of the two is unknown and an 
interaction between the two remains possible. 
Lastly, an interaction between ACE-2 and bound CaM is a possibility; 
consideration of the relative positioning of the two may be telling. Since CaM-binds 
at the N-terminal side of the reductase domain, it would likely be situated on the re-
face of the FAD isoalloxazine ring, with ACE-2 covering the other side of the flavins. 
Therefore, CaM and ACE-2 could modulate electron flow by adjusting the relative 
distance and/or orientation of the two isoalloxazine rings and bound NADPH. This 
may additionally involve the alignment of FMN-heme contacts required for the 
synthesis of NO. By this model, the effects of CaM would be opposed to those of 
ACE-2; while CaM induces positive effects, aligning the moieties for efficient 
electron transfer, ACE-2 may exert negative effects that disrupt this alignment. 
The system outlined above provides a basis to interpret the ACE-I/ACE-2-
derived peptide studies described in results section. Nonetheless, a conundrum exists, 
although both regions obviously serve an auto inhibitory function, ACE-derived 
peptides are potent inhibitors of eNOS activity (and CaM binding), while ACE-2-
derived peptides are weakly inhibitory only at very high concentrations (> 100 J.lM). 
This may be reconciled as a simple issue of peptide access. By analogy to the CPR 
structure, ACE-! should be located on the external faces of the homodimer and 
binding sites would be expected to be freely accessible, whereas, ACE-2 is located at 
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the dimer interface, ACE-2-derived peptides which may limit access to the interior 
face of the flavins where they may exert an inhibitory effect. 
Structural infonnation regarding the C-tenninus and the autoinhibitory domain 
will be essential to define the actual mode(s) of regulation carried out by these 
domains. However, this infonnation may not be forthcoming given the highly mobile 
nature predicted for the elements involved. 
4.3.2 ACE-2 and "capping" of reductase activity 
The low rate of NO synthesis of eNOS (=130 nmole/minlmg) compared to 
nNOS (=500 nmole/minlmg) or iNOS (=600 nmole/minlmg), has been demonstrated 
to be due to an attenuated activity of the eNOS reductase domain. Deletion of ACE-! 
from eNOS restores activity to a level comparable to that of nNOS or iNOS, whereas, 
deletion of ACE-! from nNOS does not influence catalytic rate. Hence, it was 
assumed that while the reductase domain of eNOS was "handicapped", those of 
nNOS and iNOS represented the maximum catalytic rates possible. However, deletion 
of ACE-2 in its entirety (21-42 amino acids, depending on isoform) caused an 
increase in the maximal rates of cytochrome c reduction in all isoforms. This 
observation suggests that even for iNOS and nNOS, the rate of electron flow is 
"capped", even in the "maximally active" CaM-bound fonn. Why would evolutionary 
forces act to "cap" the reductase activity of NOSs? The answer to this question for 
cNOSs would seem to be for regulation by Ca2+ ICaM. The reductase activities of 
wildtype cNOSs are greatly potentiated by CaM binding, whereas, in the absence of 
ACE-2 reductase activities are already at or near maximal. For iNOS, the capping of 
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electron flux does not provide for regulation by Ca2+/CaM , but may instead provide a 
critical means to limit the production of superoxide from the reductase flavins (Xia et 
al., 1998). The rate-limiting step for NO synthesis of iNOS lacking the entirety of 
ACE-2 is in the oxygenase domain. Indeed, evolutionary pressure to prevent the 
simultaneous cellular generation of high-output NO and superoxide. and the resulting 
reactive products, would presumably be great. Thus, in the absence of ACE-2, the 
situation would favor the production of flavin-derived superoxide, due to a "backlog" 
of electron transport by the reductase domain. ACE-2 may act as a built in mechanism 
to stop this situation from arising, by limiting the maximal flux of electrons through 
the reductase domain to ensure the production of NO. 
4.3.3 ACE-2 and reductase -+ oxygenase electron transfer 
Although we have been discussing ACE-2 from an autoinhibitory point of 
view, certain aspects of the truncation mutant phenotype suggest that the presence of 
ACE-2 (or regions of it) is a requirement for efficient NO synthesis. Although, 
truncated cNOSs, lacking the entirety of ACE-2, exhibit a similar CaM-bound rate of 
electron flux through the reductase domain, compared to the relevant wildtype, this 
does not translate to NO synthesis. Indeed, truncated mutants exhibit only a 33-45% 
of the increase in activity observed in the cognate wildtype eNOS. This would 
indicate that ACE-2 is required for an efficient transfer of electrons from the 
reductase domain to the oxygenase domain. In effect, the presence of ACE-2 may 
serve to stabilize the FMN-heme contacts required for effective electron transfer. In 
the case of our mutant, lacking only the 27 amino acids at the C-terminal end of ACE-
2, increased reductase activity is mirrored by an increased rate of NO synthesis. This 
would imply that the stability of FMN-heme contacts is maintained in this mutant , 
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suggesting that regions of ACE-2, N-terminal to Ser1l79, are specifically required to 
stabilize the contacts for efficient reductase -+ oxygenase electron transfer, and hence 
efficient NO synthesis. Indeed, there is a high degree of conservation in this region 
between eNOS (bovine eNOS1l63-1178) and nNOS (rat nNOS1397-1429), suggesting an 
important functional role. For iNOS, truncation of ACE-2 did not compromise the 
ability of the mutant to synthesize NO, probably due to the tight "coupling" of FMN-
heme electron transfer contributed by additional structural features that are unique by 
this isoform. 
4.3.4 Binding of CaM and activation of eNOS are related, yet distinct processes 
It is commonly assumed that CaM binding to eNOS and enzyme activation 
are obligately linked events. On the contrary, with wildtype eNOS, we observe a 
large disparity between the Ca2+-dependence curves for CaM-binding and activation 
(see Fig. 4.16), a phenomenon previously observed for nNOS (B.A. Weissman, C.L. 
Jones, B.S. Masters, P. Martasek and S.S. Gross, submitted). Binding of CaM to 
eNOS is over 50% saturated at Ca2+ concentrations that support less than 5% of 
maximal NO synthesis. This would suggest that CaM could be bound to eNOS 
without eliciting activation of the enzyme. 
A reasonable explanation for this disparity can be obtained from considering 
the structure of CaM itself (see Fig. 4.24). CaM consists of two lobes held together 
by a flexible linker domain. Upon binding of Ca2+, the lobes of CaM undergo a 
conformational change, which reveals sites required for interaction with target 
proteins. Notably, the two lobes of CaM are activated at very different levels of free 
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Ca2+, the C-terminal lobe at -100nM and the N-terminal lobe at -700nM free Ca2+ 
(Persechini et al .• 1996). It has previously been shown that binding of the N-terminal 
lobe of CaM is responsible for the activation of nNOS (Persechini et al., 1996). 
The large difference in Ca2+-affinity between the C- and N-Iobes of CaM 
suggests that at low levels of Ca2+ (100-200 nM), only the high-affinity C-Iobe EF 
hand pairs (1<cJ <100nM) will bind Ca2+. Hence, a CaM species will exist with an 
activated C-Iobe and an inactive N-Iobe, a species that could potentially bind to eNOS 
without eliciting activation. The N-Iobe EF hand pairs, having a 6-fold lower affinity 
for Ca2+, would not become active until much higher levels of intracellular Ca2+ were 
attained. Thus, when a stimulus-evoked Ca2+ spike is initiated, it is the C-Iobe that 
first undergoes the compaction process, exposing the acidic regions required for 
interaction with eNOS. As binding of the C-Iobe is insufficient to elicit eNOS 
activation, an inactive eNOS-CaM complex could be formed, in which CaM is 
tethered to eNOS via the C-Iobe. A further increase in the level of free Ca2+ would 
result in the compaction of the N-Iobe, binding of the N-Iobe to CaM, and enzyme 
activation. 
From a physiological point of view, this mechanism would offer two desirable 
features: rapid response to a stimulus and prompt termination following cessation of 
the stimulus. Several properties of the CaM-cNOS interaction may contribute to the 
rapid on/off response. The inactive eNOS-CaM complex, with CaM bound solely via 
the C-Iobe, would hold the N-Iobe in close proximity to the CaM binding site, 
creating a very high local concentration of the N-Iobe. This would shift the 
equilibrium towards the activation of eNOS. Additionally, once CaM is tethered to 
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eNOS via the C-Iobe, this may induce a conformational change in the N-Iobe to 
increase the apparent affinity for Ca2+. Together, these factors would increase the 
efficiency of CaM-dependent activation during a transient increase in intracellular 
Ca2+ levels. The rapid activation of cNOS is enhanced by the fact that Ca2+ -binding to 
the N-Iobe EF hands of CaM occurs 70 times faster (1.6 x 108 M-1s·1) than binding to 
the C-Iobe EF hands (2.3 x 106 M·1s·1)_ This would provide for exceedingly rapid 
binding of the N-Iobe of tethered CaM, and hence cNOS activation, in response to a 
calcium-elevating stimulus. There is also evidence that Ca2+ dissociates much more 
quickly from the N-Iobe of CaM, compared to the C-Iobe (5 to 29-fold faster, for 
Ca2+/CaM complexes with myosin light chain kinase or CaM kinase (Johnson et al., 
1996). Hence, as intracellular Ca2+ returns to resting levels, binding ofthe N-Iobe of 
CaM would be lost rapidly, resulting in acute shut-down of NO synthesis. 
4.3.5 A physiological model of eNOS activation 
From consideration of the range of intracellular Ca2+ levels incurred during a 
stimulus-evoked Ca2+ -spike, a physiological model can be constructed. Resting levels 
of intracellular Ca2+ are approximately 100 oM, which can be increased to as high as 
1-2 JlM upon stimulation. The C-Iobe of CaM, with an apparent I«J of less than 1 00 
nM Ca2+, would be expected to have a high degree of Ca2+ -occupancy even at resting 
levels of intracellular Ca2+. Thus, it may be erroneous to think of CaM as "free 
floating" in the endothelial or neuronal cell where it awaits cNOS interaction upon 
transient stimulation-evoked increases in intracellular Ca2+ levels. Instead, it is likely 
that CaM is to a significant extent pre-bound through its C-Iobe to cNOSs at resting 
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levels of intracellular Ca2+, in a conformation that does not elicit enzyme activation. 
Subsequent stimulation-evoked increases in intracellular Ca2+ would then cause the 
N-terminallobe of CaM to compact and assume the conformation required for cNOS 
binding and activation. Thus, a two-stage model for Ca2+/CaM activation of cNOSs is 
suggested wherein CaM-binding occurs at one Ca2+ concentration and activation of 
eNOS only occurs at a higher Ca2+ concentration. This would be similar to the 
proposed mode of activation of phosphorylase kinase, a Ca2+ /CaM-dependent protein 
kinase in which CaM is present as a tightly bound subunit regardless of activation 
state (Cohen et al., 1978; Grand et al., 1981). The resulting interaction of the N-Iobe 
of CaM with the C-terminal aspect of the CaM binding site on cNOSs would 
potentially displace the adjacent ACE-lor the C-terminal ACE-2, and contribute to 
activation, as discussed later. 
The activation of myosin light chain kinase (MLCK), a Ca2+/CaM-dependent 
kinase, was the subject of a recent small angle scattering study (Krueger et al., 1998) 
that is particularly relevant to the model we propose for the activation of eNOS. The 
author demonstrated that CaM binding to MLCK begins at sub stoichiometric Ca2+ 
concentrations, i.e. when only C-terminal EF hands have bound Ca2+. Once bound via 
the C-Iobe, a further increase in Ca2+ levels resulted in Ca2+ binding at the N-Iobe EF 
hands of CaM, eliciting MLCK activation. Binding of CaM to MLCK solely via the 
C-Iobe was confirmed by the use of a mutant CaM, in which the N-terminal EF ands 
were incapable of binding Ca2+. This study also concluded that, at resting levels of 
intracellular Ca2+, CaM would likely be tethered to MLCK via the C-Iobe in an 
inactive complex. This complex is then "primed" for rapid response to a stimulus-
evoked increase in intracellular Ca2+. This model for MLCK activation by Ca2+/CaM 
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is essentially identical to the one we propose for the activation of eNOS in vivo, 
although our conclusion derives from a completely different line of investigation. 
We acknowledge that the model for the physiological activation of eNOS 
proposed above, is presented in its simplest form and does not take into account 
additional cellular variables that may be important, such as concentration of Mg2+ 
ions, caveolins or HSP90. 
The model is summarized below and shown in Fig. 4.25. 
A three-stage modelfor the activation of eNOS by Ccl+/CaM 
The following information suggests a sequential multi-step model for the 
Ca2+/CaM-dependent regulation of eNOS (in accord with our previous model for 
nNDS activation): 
a) CaM binds to eNOS at subsaturating levels of Ca2+ 
b) CC-CaM binds to eNOS at sub saturating levels of Ca2+, but elicits no activation 
c) Binding of the N-tenninallobe of CaM is essential for wildtype eNOS activation, 
but not CA27 eNOS activation. 
Using these facts, we propose this three-stage model for eNOS activation: 
1) In a resting cell (100 nM Ca2+), CaM exists predominantly with two Ca2+ ions 
bound to the C-Iobe EF-hand pairs. The C-Iobe is therefore compacted and primed 
for binding to eNOS. The compacted C-Iobe interacts with the CaM-binding site 
of eNOS, but the enzyme remains inactive. 
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2) A stimulus-evoked increase in intracellular Ca2+ (approaching or exceeding 1 
JlM) triggers the binding of Ca2+ to the two remaining EF-hands of CaM-causing 
compaction of the N-Iobe, however, eNOS still remains inactive. 
3) The compacted N-Iobe of eNOS-bound CaM binds to its cognate binding site, 
triggering full activation of eNOS. 
4.3.6 ACE-2 and Ca2+/CaM-dependence of eNOS activation 
Truncation of ACE-2 resulted in a 5 to 6-fold reduction in ECso for Ca2+ 
required for the activation of eNOS by CaM, compared to wildtype. Since removal of 
ACE-2 did not directly affect the Ca2+-dependence or affinity of CaM for binding, 
these effects must be due to differences exhibited by the inactive CaM-eNOS 
complex. Given the model outlined in the previous section, at low levels offree-Ca2+, 
CaM would be bound to eNOS via the C-Iobe only. For C!J.27 eNOS to exhibit 
activity at low concentrations of free Ca2+, either the interactions between the C-Iobe 
of CaM and eNOS are sufficient to elicit activation or once tethered to C!J.27 eNOS 
by the C-Iobe, the affinity of the N-Iobe for Ca2+ becomes increased. 
From our experiments with CC-CaM it seems that there are subtle differences 
in the mechanism of CaM-dependent regulation between wildtype and C!J.27 eNOS. 
Although CC-CaM binds to wildtype eNOS, it does not initiate NO synthesis. 
Furthermore, binding of CC-CaM does not evoke any significant increase in either of 
the measured reductase activities of wildtype eNOS. However, CC-CaM does elicit 
partial activation ofC!J.27 eNOS, to approximately 30% of that elicited by wildtype 
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Fig. 4.24. Structure of CaM based on X-ray diffraction studies. Taken from 
"Molecular Biology ofthe Cell", 2nd Edition, p711, by B. Alberts, et al. 
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Fig. 4.25.Four-Step model of eNOS activation by Ca2+/CaM. (1) In a resting cell 
(100 nM Ca2+), CaM exists with two Ca2+ ions bound to the C-lobe, the C-lobe is 
therefore compacted and primed for binding to eNOS. (2) The compacted C-lobe 
interacts with the CaM-binding site of eNOS, but the enzyme remains inactive. (3) 
A stimulus-evoked increase in intracellular Ca2+ (sl f!M) causes the binding of 
Ca2+ to the two remaining EF-hands of CaM-causing compaction of the N-lobe. 
However, eNOS remains inactive. (4) Binding of the compacted N-lobe of CaM to 
eNOS elicits full activation. 
CaM (NC-CaM). Studies of the ability ofCC-CaM to activate the reductase functions 
of CAl7 eNOS provided the surprising result that CC-CaM elicited ferricyanide 
reduction to a comparable extent to that elicited by NC-CaM. Cytochrome c 
reduction by Cd27 eNOS was also partially activated by CC-CaM, =20% of that 
elicited by NC-CaM. Therefore, in the absence of 27 amino acids of ACE-2, CC-
CaM is capable of inducing at least some of the conformational changes required for 
the synthesis of NO. Whether the observed level of activity (30% of maximal) is due 
to a submaximal activation of all the Cd27 eNOS dimers present or maximal 
activation of a small percentage is unresolved. What is clear is that truncation of 
ACE-2 removes some of the negative factors, which prevent the proper alignment of 
co-factors required for NO synthesis, and hence, activation by CC-CaM becomes 
feasible. Indeed, When the complete length of ACE-2 is removed (Roman et ai., 
2000), both nNOS and eNOS exhibit a small amount of CaM-independent NO 
synthesis. Such truncated cNOSs also exhibit CaM-independent reductase functions 
in excess of those exhibited by the cognate CaM-bound wildtype enzymes. NN-CaM, 
which is capable of eliciting full activation of both wildtype and Cd27 eNOS, 
activates Cd27 eNOS at a slightly lower level of free Ca2+ than wildtype eNOS (ECso 
values of 853 and 1089 nM, respectively). This would imply that truncation of ACE-
2, removes an obstacle to the binding of the N-Iobe of CaM, allowing activation at 
lower levels offree Ca2+. 
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4.3.6 Insights into eNOS regulation by AktlPKA-mediated phosphorylation of Serl179 
ACE-2 (eNOS1163-120S) has previously been implicated in eNOS regulation, but 
in another context. Indeed, phosphorylation of Ser1l79 (bovine sequence, see Fig.4.26) 
by Akt or PKA, has been demonstrated to be a factor in the in vivo activation of 
eNOS by physiological stimuli (Dimmeler et aI., 2000; Dimmeler et al., 1999; 
Fisslthaler et 01., 2000; Fulton et 01., 1999; Luo et 01., 2000). Once phosphorylated at 
this residue, eNOS exhibits a 2 to 3-fold increase in catalytic rate and demonstrates 
activity even at resting levels of intracellular Ca2+. Analysis of our truncated protein 
provides some insights into the underlying mechanism of eNOS regulation by 
phosphorylation of Serl179. CD.27 eNOS, lacks Serl179, and all amino acids C-terminal 
to it,. and exhibits a similar increase in catalytic rates to that observed for 
phosphorylated wildtype eNOS. Thus, removal of 27 amino acids from the C-
terminus (including Ser1179) mimics the effects of phosphorylation of Ser1l79. This 
would imply that phosphorylation of this residue represents a "loss of function" rather 
than a "gain of function", Given the regulatory function assigned to the C-terminus 
(ACE-2) in limiting maximal activity of the enzyme, phosphorylation of Serll79 
probably removes/diminishes the auto inhibitory effects of ACE-2. The manner by 
which phosphorylation of Ser1l79 diminishes the inhibitory effects of ACE-2 is also 
unknown. However, it is conceivable that the incorporation of a phosphate at this 
position may cause a conformational change by repulsion/attraction of neighboring 
residues that offsets the interactions which sustain tonic inhibition. 
Phosphorylation of Serl179 also allows "Ca2+ -independent" activation of eNOS 
when transfected into cultured ECV304 cells (Fulton et al., 1999). However, in cell-
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free assays. neither phosphorylated eNOS nor eNOS mutants mimicking this 
phosphorylation (Ser1l79 ~ ASP1l79). exhibit a significant reduction in the ECso for 
Ca2+ required for NO synthesis. Interestingly, Cd27 eNOS exhibits a 5 to 6-fold 
decrease in the ECso for Ca2+ required for activity and eNOS lacking ACE-2 in its 
entirety, exhibit a degree of activity even in the absence of bound CaM. This disparity 
in relative Ca2+-dependence between in vitro and in vivo situations suggests that other 
modifications, in addition to phosphorylation of Serl179, are required for eNOS to 
exhibit "Ca2+ -independent" activity in cells. The complete removal of this region of 
eNOS, as in Cd27 eNOS or similar truncations, mimics the effects of these additional 
interactions. As eNOS activation has been shown to involve an interaction with 
HSP90, an attractive possibility is that HSP90 st~bilizes a conformation in 
phosphorylated eNOS, which entirely.negates the effects of ACE-2 and allows "Ca2+_ 
independent activation". 
Although their can be little doubt that eNOS is regulated in vivo by Akt-
mediated phosphorylation, it seems that this site is also conserved within ACE-2 
regions of the nNOS isoforms (Ser1412 in the rat sequence, see Fig. 4.25). Although no 
functional significance has been demonstrated for this site, it would be an attractive 
mechanism for "Ca2+-independent" activation ofnNOS. However, stimuli that evoke 
such a "Ca2+-independent" activation of nNOS, have yet to be identified. However, 
evidence now points to a role for Akt-mediated phosphorylation in the Ca2+. 
dependent activation of eNOS, a similar mode of activation is not unlikely for nNOS. 
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Fig. 4.26. Conservation of the Akt phosphorylation site throughout the 
cNOSs. The Akt site is perfectly conserved throughout the eNOS family of 
proteins. Additionally, although no functional significance has been 
demonstrated, the Akt site is also present in members of the nNOS family 
of proteins. 
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Chapter 5 
Summary 
Nitric oxide synthases are a family of proteins that perform some of the most 
complex chemistry known to biology; the regulation of these proteins, it seems, is 
equally complex. Herein, we have identified two novel regions of NOSs (ACE-I and 
ACE-2), that function as autoinhibitory control elements. ACE-I, located within the 
FMN-binding domain, correlates with Ca2+-dependence and is only found in eNOS 
and nNOS. The presence of ACE-I, largely accounts for the observed Ca2+. 
dependence of the cNOSs and serves to govern the reductase activities of eNOS. 
ACE-2, located within an extension of the C-terminus, is present in all the isoforms of 
NOS. However, regions of ACE-2 are unique to, and conserved in, cNOSs. Removal 
of 27 amino acids of ACE-2 causes an increased catalytic rate and reduces the Ca2+ 
requirement for maximal activity. Removal of ACE-2 in its entirety causes a shift to a 
CaM-independent NO synthesis, albeit much less efficiently than that of the CaM-
bound. The molecular basis for the function of these regions in the regulation of NOS 
is unknown. Structural information pertaining to the reductase domain of cNOSs will 
be required to elucidate their function, however, due to the highly mobile status of the 
ACEs, acquisition of such structural information may not be forthcoming. 
~.l ACE-I. ACE-2 and the CaM-bindin~ Site: A tripartate system for re~ulation of 
~NOS. 
From my work, it seems that there are three major regions responsible for the 
regulation of eNOS, the CaM-binding site, ACE-I and ACE-2. F~om the work of 
others, it is evident that this is also the case for nNOS. Indeed, iNOS, may also have 
this trifecta of regulatory regions, although it lacks ACE-2, its high affinity CaM-
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binding can only be explained by the presence of auxiliary CaM-binding regions 
(which may reside in a position analogous to ACE-I, see discussion Chapter 3). 
This trifecta of regulatory regions works in concert to facilitate the Ca2+/CaM-
dependent activation/inactivation of eNOS, in response to physiological stimuli. The 
CaM-binding site, quite obviously, binds to Ca2+/CaM. ACE-l acts as a steric 
impediment to Ca2+/CaM-binding and is displaced during the CaM-binding process. 
ACE-2 acts as a gate to electron flow between the NOS co-factors (NADPH -+ FAD 
~ FMN ~ Heme), the negative modulatory effects of ACE-2 are alleviated by 
Ca2+/CaM-induced conformational changes. 
The following scheme of eNOS regulation, derived from interpretation of our 
data, and that of others (Daff et al .• 1999; Dimmeler et al.. 1999; Fulton et al., 1999; 
Montgomery et al., 2000; Nishida & Ortiz de Montellano, 1999; Nishida & Ortiz de 
Montellano, 1998; Roman et al., 2000; Roman et al., 2000), offers a possible 
mechanism for the tripartate regulation mentioned previously. Regulation of eNOS is 
accomplished by a conspiracy between Ca2+/CaM, ACE-l and ACE-2. The ACEs 
exert negative effects which must be alleviated in order to elicit eNOS activation. In 
the absence of bound CaM, ACE-l occupies as yet unknown regulatory binding sites. 
ACE-2, we propose to exert effects which push the NADPHIFADIFMN alignment 
out of alignment, thereby limiting the flow of electrons through the reductase domain. 
Following a stimulus-evoked increase in intracellular Ca2+. the C-terminal lobe of 
CaM becomes compacted and binds to eNOS, however, eNOS does not become 
activated. A further increase in intracellular Ca2+ causes the compaction of the N-
terminal lobe of CaM. The subsequent interaction between the N-Iobe of CaM and the 
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C-terminal portion of the CaM-binding site of eNOS, displaces ACE-I from its 
regulatory sites. N-Iobe binding, displacement of ACE-I, or more likely a 
combination of the two, overcome the tonic inhibitory effects exerted by ACE-2. This 
allows proper alignment of the flavins for efficient electron transfer. The yin/yang 
relationship between ACE-2, which is envisioned to push the flavins out of alignment 
and Ca2+/CaM, which serves to push the flavins into alignment, may provide the 
"molecular toggle" by which Ca2+/CaM elicits activation. ACE-I may serve simply as 
a hindrance to the binding of Ca2+/CaM, thus prolonging the effects of ACE-2. Thus 
deletion of ACE-I may simply remove this obstacle, providing Ca2+/CaM binding at 
lower levels of free Ca2+ and favoring the alleviation of the inhibition exerted by 
ACE-2. Another explanation would be a direct interaction between the two ACEs, 
however, by analogy to the CPR structure, ACE-I and ACE-2 would appear to reside 
on opposite sides of the NOS monomer, diminishing the likelihood for direct 
interaction. 
Ca2+-independent activation of eNOS is explained by Akt-mediated 
phosphorylation of Ser1l79; our results indicate that this posttranslational modification 
of eNOS removes/reduces the inhibitory effects exerted by ACE-2. This would then 
allow eNOS to be active at resting levels of intracellular Ca2+. Activation of 
phosphorylated eNOS at resting levels of intracellular Ca2+ may only require binding 
of the C-Iobe of CaM. Our Ct1.27 eNOS truncation was partially activated by an 
engineered CaM, which expressed two C-Iobes. This process may not require the 
displacement of ACE-I, which we predict to interfere with binding of the N-Iobe of 
CaM. From the study of mutants mimicking the phosphorylation of Ser1\79' it is likely 
that "Ca2+-independent" activation of eNOS requires an association with protein(s) 
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other than CaM. Given its established role in the regulation of eNOS, a good 
candidate for such an "other" interacting protein would be HSP90 (Garcia-Cardena et 
al., 1998). 
Obviously, the regulation of eNOS is multifactorial in its complexity. In the 
above model, we have not accounted for the various regulatory modifications eNOS 
undergoes in vivo. The regulation of eNOS, much more so than other NOS isoforms, 
involves reversible palmitoylation in addition to multiple protein-protein interactions. 
Inhibitory complexes of eNOS with members of the caveolin family of proteins 
(Garcia-Cardena et al., 1996; Garcia-Cardena et al., 1997; Ju et al., 1997; Michel et 
al., 1997; Venema et al., 1997) and members of the transmembrane receptors (Ju et 
al., 1998) have been reported. In addition, activated eNOS has been found to form a 
complex with HSP90 that enhances maximal NO production (Garcia-Carden a et al., 
1998). These factors all contribute to multifactorial regulation of eNOS, that is 
superimposed on the simple model we present. 
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6.1 ACE-lIACE-2 interplay 
Chapter 6 
Future Work 
Given the similar phenotypes of eNOS mutants lacking ACE-lor ACE-2, and 
that a mutant lacking a region of ACE-2 is a resistant to inhibition by ACE-l derived 
peptides, we proposed an interaction between the two ACE regions. If ACE-2 
contained the binding site for ACE-I, then removal of either one would negate the 
effect of the other. We propose to investigate this in two ways. Firstly, using a 
fluorescein-tagged ACE-I derived peptide (eNOS628_634)' we would investigate the 
interaction of this peptide with wildtype (eNOSI_12os), Cll.27 (eNOS I_I 178) and a 
truncation mutant of eNOS lacking the entirety of ACE-2 (eNOS I_1I63). If the binding 
site of ACE-I is contained within ACE-2, then the truncated proteins would be 
expected to exhibit a lower affinity for binding of the fluorescently tagged protein. 
Relative affinity would be assessed in a 96-well based assay using a microplate 
fluorometer. Secondly, additional mutagenesis would be performed to express eNOS 
mutants lacking the entirety of ACE-I, the entirety of ACE-2, the entirety of ACE-I 
and ACE-2, and Cll.27 lacking the entirety of ACE-I. By comparison of the 
phenotypes of these various mutants, the possibility of an interaction between the two 
could be ascertained. If the effects of ACE-I and ACE-2 are mediated by distinct 
mechanisms, then the double deletion would be expected to exhibit a much higher 
level of activity than ether of the single deletions. If ACE-2 is the binding site of 
ACE-I, then deletion of either one would be equivalent to deletion of both. 
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6.2 Caveolin and Ca2+/CaM 
One of the possibilities we put forward is that CaM may be tethered to eNOS 
at resting levels of intracellular Ca2+, by interactions between eNOS and the C-Iobe of 
CaM. The basis for this was the high affinity of the C-Iobe for Ca2+ (Kd<lOO nM) 
(Persechini et at., 1996; Persechini et at., 1996) combined with the established values 
for resting levels of intracellular Ca2+ (Nathan & Xie, 1994). However, the interaction 
of eNOS with caveolin was not considered in this hypothesis. Caveolin and CaM 
seem to bind to eNOS in a competitive manner; inactive eNOS exists as a membrane-
bound complex with caveolin-l (Cav-l) (Garcia-Cardena et at., 1996; Garcia-Cardena 
et at., 1997; Ju et at., 1997; Michel et al., 1997; Venema et al., 1997) which 
dissociates upon activation by Ca2+/CaM the eNOS-Cav-l. However, from the 
numerous experiments carried out thus far, it is unclear whether it is possible for the 
C-Iobe of CaM and Cav-l to simultaneously bind to eNOS. Most in vitro experiments 
have considered the interaction between eNOS and Cav-I (or derived peptides) solely 
for its effect on eNOS activity. CaV-l mediated inhibition of eNOS activation was 
fully reversible by excess CaM, but his does not preclude the existence of a three part, 
eNOS-Cav-I-CaM (bound only by the C-Iobe) interaction. To investigate this 
possibility, we would use the engineered mutant CaM protein expressing two C-Iobes 
(CC-CaM) in conjunction with Cav-I-glutathione-s-transferase (GST) fusion protein. 
By using Cav-I-GST fusion protein bound to glutathione-agarose beads, the relative 
effects of wildtype and CC-CaM on Cav-I-eNOS complex dissociation could be 
assessed using the established "pull-down" method. 
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6.3 HSP90 and phosphoorlation of ACE-2 
Mutants eNOSs mimicking the phosphorylation of Ser1179, exhibit "Ca2+_ 
independent" activity when transfected into cells. However, when the Ca2+-
dependence is assessed in vitro, activity at such low levels of Ca2+ (100 nM) are not 
observed (McCabe et al., 2000). This suggests that phosphorylation of eNOS, by 
itself, is insufficient to elicit activation of eNOS at resting levels of intracellular Ca2+. 
This indicated that an intracellular factor, perhaps HSP90, may be crucial t<:> facilitate 
the apparent "Ca2+-independent" activity of eNOS. We propose that HSP90 might 
stabilize a conformation of phosphorylated eNOS, which fully alleviates the 
inhibitory effects of ACE-2 and allows "Ca2+-independent" activation of eNOS. To 
test this we propose an in vitro reconstitution experiment using recombinant HSP90. 
The ability of Akt-mediated phosphorylation to elicit "Ca2+-independent" activation 
of eNOS shall be addressed in two ways. Firstly, in vitro phosphorylation of eNOS 
using recombinant Akt (Upstate Biotech, Lake Placid, NY) will be used. Secondly, 
mutation of Ser1l79 to mimic phosphorylation of this residue (McCabe et al., 2000) 
will be carried out. The Ca2+ -dependence curves of these enzymes shall then be 
compared to wildtype eNOS, in the absence or presence of an equal amount of 
HSP90. If HSP90 is the intracellular factor facilitating in vivo eNOS activity at resting 
levels of intracellular Ca2+, then phosphorylated/phosphorylation mimic eNOSs would 
be expected to exhibit activity at reduced levels of Ca2+ in the presence of HSP90. The 
techniques used here are described in Methods section. 
tt.4 HSP90 and Ca2+/CaM bindin~ 
Although HSP90 elicits the activation of eNOS at resting levels of 
intracellular Ca2+, the underlying mechanism of this process is not well understood. 
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One possibility is that once complexed with HSP90, the interaction between CaM and 
eNOS is stabilized, even at low levels of Ca2+. The effects of HSP90-eNOS complex 
formation on the stability of eNOS-[12sI]-CaM-eNOS complexes will be assessed 
using the pre-incubation protocol outlined in Methods. Wildtype eNOS-[12sI]-CaM 
complexes will be allowed to form in the presence or absence of recombinant HSP90. 
The complexes will then be transferred to EGT AlCa2+ buffered solutions representing 
a range of Ca2+ concentrations. The level of [12sI]_CaM binding after a defined time 
period will then be assessed by scintillation counting. Additionally the rate of CaM 
dissociation of [12SI]-CaM-eNOS complexes, compared to HSP90-[12sI]-CaM-eNOS 
complexes will be assessed as described in Methods. If the HSP90-eNOS-CaM 
complex is significantly more stable than the eNOS-CaM complex, then this 
"complex stabilization" may provide a mechanism for the in vivo effects of HSP90 
on the regulation of eNOS. 
6.5 Evaluation of Mutant eNOSs in Cultured Cells 
Although we have thoroughly characterized the various eNOS mutants in an in 
vitro setting, the behavior of such proteins in a cellular environment may provide 
insights into physiological eNOS regulation. This work is already underway, mutant 
protein cDNA (CA27, RRKRK sub, RRKRK del, GlUm and wildtype eNOS) have 
been generated in a mammalian expression vector (pCDNA3, Invitrogen, Carlsbad, 
CA) for future transfection into cultured cells. Mammalian transfections would use 
tWO eNOS forms. Firstly, eNOSs incorporating a mutation of the myristoylation site 
(GIY2 ~ AIa2), to allow cytosolic expression (Liu & Sessa, 1994), will be transfected 
into a human embryonic kidney cell line (HEK 293). This will allow assessment of 
the mutants in the absence of complicating factors such as caveolin that would only 
apply to membrane-bound eNOS. Additionally, the effects of CaveolinlAktIPKA etc 
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could be assessed by co-transfection. Secondly, myristoylation-intact eNOSs, will be 
transfected into immortalized human bone endothelial cells (HBECs). This will 
permit the study of mutant eNOSs in their native cell type and presumably subcellular 
setting, effects of these mutations on regulation/interactions of eNOS could be studied 
in a more physiological setting. 
, ' 
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